|
Monash IVF Group Limited is a provider of human fertility services and specialised women’s imaging and diagnostic services. The company offers Assisted Reproductive Services (ARS), including in vitro fertilisation (IVF), reproductive genetic services, and tertiary-level prenatal diagnostics. It also delivers specialist diagnostic obstetric and gynaecological ultrasound services. The group operates throughout Australia and Southeast Asia, serving patients experiencing infertility and those requiring advanced diagnostic care. The company’s origins trace back to the work of pioneers who achieved the first IVF pregnancy in the world in 1973. It supports research and development in reproductive medicine and ultrasound through its Research and Education Foundation. Summarised from the company's own disclosures, fiscal year ended Jun 2026 |
Industry Health Care Equipment & Services | Homepage monashivfgroup.com.au |
| Sector Healthcare | IR page monashivfgroup.com.au/investor-centre | |
|
Tags
assisted reproductive services, in vitro fertilisation, reproductive genetics, prenatal diagnostics, obstetric ultrasound, gynaecological ultrasound, fertility treatments, reproductive medicine, Monash IVF Group Research and Education Foundation
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | A$ 294.174M |
| Market cap (USD) | $ 199.608M |
| P/E | 39.21 |
| PEG | — |
| P/BV | 1.15 |
| P/S | 1.09 |
| P/OCF | 8.02 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 3.3% |
| ROI | 2.3% |
| ROIC | 5.6% |
| Profit margin | 3.1% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | -27.6% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | 43.2% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -11.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 269.459M | 271.917M | 254.96M | 213.59M | 192.294M | 183.605M | 145.417M | 151.98M | 150.638M | 155.182M | 156.561M | 124.955M | 114.012M | 96.598M |
| Net profit | 8.326M | 25.676M | -5.949M | 21.966M | 18.406M | 25.33M | 11.726M | 19.852M | 21.353M | 29.619M | 28.775M | 21.373M | 2.581M | -14.856M |
Podcast Mentions
Announcements lodged with ASX, newest first, routine forms (director and substantial-holding notices, daily buy-back and quotation notices) included. The link opens the announcement on ASX. Press releases from the company's own website, newest first.
Final Director’s Interest Notice
Appendix 3Z
Rule 3.19A.3
Final Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.
Name of entity Monash IVF Group Limited ABN 90 169 302 309 We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of director
Richard Hugh Davis
Date of last notice
1 June 2020
Date that director ceased to be director
28 October 2026
Part 1 – Director’s relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Number & class of securities
182,067 ordinary shares
- See chapter 19 for defined terms. 11/3/2002
Appendix 3Z Page 1
Appendix 3Z Final Director’s Interest Notice Part 2 – Director’s relevant interests in securities of which the director is not the registered holder Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Name of holder & nature of interest
Note: Provide details of the circumstances giving rise to the relevant interest
Number & class of securities
Nil
Part 3 – Director’s interests in contracts Detail of contract
n/a
Nature of interest
n/a
Name of registered holder (if issued securities)
n/a
No. and class of securities to which n/a interest relates
- See chapter 19 for defined terms. Appendix 3Z Page 2
11/3/2002
Final Director’s Interest Notice Rule 3.19A.3
Appendix 3Z Final Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.
Name of entity Monash IVF Group Limited ABN 90 169 302 309 We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of director
Richard Charles Henshaw
Date of last notice
1 June 2020
Date that director ceased to be director
28 October 2026
Part 1 – Director’s relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Number & class of securities
Nil
- See chapter 19 for defined terms. 11/3/2002
Appendix 3Z Page 1
Appendix 3Z Final Director’s Interest Notice Part 2 – Director’s relevant interests in securities of which the director is not the registered holder Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Name of holder & nature of interest
Note: Provide details of the circumstances giving rise to the relevant interest
Number & class of securities
Richard Charles Henshaw (Richgill 1,358,842 ordinary shares Family Trust A/C) – indirect interest
Part 3 – Director’s interests in contracts Detail of contract
n/a
Nature of interest
n/a
Name of registered holder (if issued securities)
n/a
No. and class of securities to which n/a interest relates
- See chapter 19 for defined terms. Appendix 3Z Page 2
11/3/2002
1
ASX Announcement
Monash IVF Group Limited (ASX:MVF) 26 October 2026
Director resignation and withdrawal of AGM resolution 3c Monash IVF Group Limited (ASX: MVF) advises that Mr Gerd Schenkel has resigned as a Director for personal reasons with effect from 26 October 2026 and has withdrawn his nomination for election at the Company’s Annual General Meeting (AGM). Resolution 3c (Election of Director – Mr Gerd Schenkel) set out in the Notice of Annual General Meeting dated 23 October 2026 is therefore withdrawn and will not be put to shareholders at the AGM. Any votes already submitted in respect of that resolution will be disregarded. The withdrawal of Resolution 3c does not affect the validity of the proxy form accompanying the Notice of Annual General Meeting or any proxy votes already submitted in respect of the remaining resolutions. All other items of business set out in the Notice of Annual General Meeting are unchanged. The Board remains focused on its ongoing renewal process and will continue its search for additional non-executive directors, having regard to the skills, experience and independence required to support Monash IVF Group’s next phase. Further appointments will be announced as appropriate. Authorised by the Board of Directors.
Final Director’s Interest Notice
Appendix 3Z
Rule 3.19A.3
Final Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.
Name of entity Monash IVF Group Limited ABN 90 169 302 309 We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of director
Gerd Schenkel
Date of last notice
3 September 2026
Date that director ceased to be director
26 October 2026
Part 1 – Director’s relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Number & class of securities
Nil
- See chapter 19 for defined terms. 11/3/2002
Appendix 3Z Page 1
Appendix 3Z Final Director’s Interest Notice Part 2 – Director’s relevant interests in securities of which the director is not the registered holder Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Name of holder & nature of interest
Note: Provide details of the circumstances giving rise to the relevant interest
Number & class of securities
Nil
Part 3 – Director’s interests in contracts Detail of contract
n/a
Nature of interest
n/a
Name of registered holder (if issued securities)
n/a
No. and class of securities to which n/a interest relates
- See chapter 19 for defined terms. Appendix 3Z Page 2
11/3/2002
1
ASX Announcement
23 October 2026
The Manager ASX Market Announcements Office Australian Securities Exchange Dear Manager Monash IVF Group Limited – Notice of 2026 Annual General Meeting In accordance with the Listing Rules, attached are the following documents in relation to Monash IVF Group Limited’s Annual General Meeting (AGM): • • •
Notice of 2026 AGM; Sample Proxy Form; and Notice and Access Letter.
Yours faithfully,
Rebecca Dean General Counsel & Company Secretary Monash IVF Group Limited T: +61 3 9420 8235 Authorised by the Board of Directors
23 OCTOBER 2026
Notice of 2026
Annual General Meeting
23 OCTOBER 2026 1
23 OCTOBER 2026
Dear Shareholder On behalf of the Monash IVF Group Limited (MVF or the Company) Board, I am pleased to invite you to attend our 2026 Annual General Meeting (AGM) to be held on Thursday 26 November 2026 at 2.00pm (AEDT). Shareholders will be able to attend our AGM both in person and online through our virtual meeting platform. Details of how to attend and participate in the AGM are set out in the accompanying Notice of Meeting. The Notice of Meeting also includes information in relation to voting; the items of business to be considered at the AGM; Explanatory Notes and the Board’s recommendations on each item. Board renewal and succession The Board has continued its renewal and succession program to ensure that MVF maintains an appropriate mix of skills, experience and perspectives to support the Company’s strategy and long-term success. As part of that process, shareholders will be asked to re-elect Ms Catherine West and elect Dr Dwayne Crombie and Mr Gerd Schenkel as Directors of the Company. Together, these Directors bring significant listed company, healthcare, governance, strategy, technology, digital transformation and customer experience expertise, which the Board considers will support MVF’s refreshed Nurture 2030 strategy, continued investment in innovation, strengthened patient experience and the delivery of sustainable long-term value. Executive Remuneration The AGM items of business include the adoption of MVF’s FY2026 Remuneration Report and approval of FY2026 and FY2027 Long Term Incentive (LTI) grants to Dr Victoria Atkinson, Managing Director and Chief Executive Officer. The FY2026 and FY2027 LTI grants to Dr Atkinson are presented to shareholders for approval in Item 4 of this Notice of Meeting and will form part of Dr Atkinson’s Total Remuneration Opportunity. Voting recommendations The Board considers that resolutions 2, 3 and 4 in the Notice of Meeting are in the best interests of shareholders as a whole and recommends that shareholders vote in favour of them, subject to the voting exclusions and the interests of the relevant Directors described in the Notice of Meeting. The Company’s 2026 Annual Report is available on the Company’s website and I encourage shareholders to review it before the Meeting. On behalf of the Board, I thank you for your continued support and look forward to your participation at the 2026 AGM. Yours sincerely
Richard Davis Chair Monash IVF Group Limited
2
23 OCTOBER 2026
Notice of 2026 Annual General Meeting Notice is hereby given that the Annual General Meeting (AGM or Meeting) of shareholders of Monash IVF Group Limited (the Company or Monash IVF Group) will be held in person and available online on Thursday 26 November 2026 at 2.00pm (AEDT). Shareholders may choose to attend the meeting in person or virtually.
In person: KPMG Tower Two Level 36, Meeting Room 36.17-18 Collins Square 727 Collins Street Melbourne VIC 3008 Virtually: To access the Meeting, please enter the following link into your web browser on your computer or online device: https://meetings.openbriefing.com/MVF26
3
23 OCTOBER 2026
Business of the AGM Item 1 - Consideration of Monash IVF Group Financial Reports To receive and consider the Financial Report, the Directors’ Report and the Auditor’s Report for the year ended 30 June 2026. Item 2 - Adoption of the Remuneration Report (non-binding advisory vote) To consider and, if thought fit, to pass the following resolution as an ordinary resolution of the Company: “To adopt the Remuneration Report, which forms part of the Directors’ Report for the year ended 30 June 2026.” Note: As per section 250R of the Corporations Act 2001 (Cth), the vote on this resolution will be advisory only and will not bind the Directors or the Company. A voting exclusion statement applies to this resolution as per the Explanatory Notes in this document. Item 3 - Election and Re-election of Directors To consider and, if thought fit, to pass each of the following resolutions as an ordinary resolution of the Company: Item 3a - Re-election of Ms Catherine West as a Director “That Ms Catherine West, an Independent Non-Executive Director of the Company, and being eligible, be reelected as a Director of the Company.” Item 3b - Election of Dr Dwayne Crombie as a Director “That Dr Dwayne Crombie, an Independent Non-Executive Director of the Company, and being eligible, be elected as a Director of the Company.” Item 3c - Election of Mr Gerd Schenkel as a Director “That Mr Gerd Schenkel, an Independent Non-Executive Director of the Company, and being eligible, be elected as a Director of the Company.” A summary of each Director’s background and experience is set out in the Explanatory Notes of this document. Item 4 - Approval of grant of performance rights to the Chief Executive Officer (CEO) and Managing Director under the Long-Term Incentive Plan To consider and, if thought fit, to pass each of the following resolutions as an ordinary resolution of the Company: Item 4a - Grant of FY2026 LTI Performance Rights to the CEO and Managing Director “That approval be given for all purposes, including ASX Listing Rule 10.14, for the grant of 279,383 performance rights to Dr Victoria Atkinson, Chief Executive Officer and Managing Director, as her Long-Term Incentive grant for FY2026 on the terms described in the Explanatory Notes accompanying this Notice of Meeting.” Item 4b - Grant of FY2027 LTI Performance Rights to the CEO and Managing Director “That approval be given for all purposes, including ASX Listing Rule 10.14, for the grant of 504,070 performance rights to Dr Victoria Atkinson, Chief Executive Officer and Managing Director, as her Long-Term Incentive grant for FY2027 on the terms described in the Explanatory Notes accompanying this Notice of Meeting.” Note: A voting exclusion statement applies to each of the resolutions in Item 4 as set out in the Explanatory Notes in this document. By order of the Board
Rebecca Dean Company Secretary 4
23 OCTOBER 2026
Notice of Annual General Meeting Annual Report Monash IVF Group Annual Report is accessible via the website https://www.monashivfgroup.com.au/ investor-centre/annual-reports/ Eligibility to Vote For the purpose of determining entitlement to vote at the Meeting, shares will be taken to be held by the persons who are registered holders at 7:00pm (AEDT) Monday, 23 November 2026. Accordingly, share transfers registered after that time will be disregarded in determining entitlements to vote at the Meeting. Participating at the Meeting Shareholders are requested to participate in the AGM in person or virtually via our virtual AGM platform at https://meetings.openbriefing.com/MVF26 or via a Direct Voting Form or the appointment of a proxy. We recommend logging in to our online platform at least 15 minutes prior to the scheduled start time for the Meeting using the instructions below: Enter https://meetings.openbriefing.com/MVF26 into a web browser on your computer or online device: • shareholders will need their Securityholder Reference Number (SRN) or Holder Identification Number (HIN); and • proxyholders will need their proxy code which MUFG Corporate Markets will provide via email within 24 hours prior to the Meeting. Alternatively, the proxy code can be obtained by calling the Share Registry on 1300 554 474 the day of the Meeting. Shareholders can also ask questions and make comments verbally during the AGM. Shareholders will need to contact MUFG Corporate Markets on 1800 990 363 or +61 1800 990 363 before 5:00pm (AEDT) by Monday, 23 November 2026 to obtain a personalised PIN number to ask a question or make a comment via the telephone. If your holding cannot be verified by the moderator, you will attend the Meeting as a visitor and will not be able to ask a question or make a comment verbally – however, you can still submit questions or make comments in the other ways described below.
To ask a question or make a comment via telephone please dial 1800 870 861 or +61 2 9189 8866 after 1:45pm (AEDT) on the day of the Meeting. You will receive instructions on how to ask a question or make a comment during the Meeting from the phone moderator. More information about how to participate in the Meeting by telephone is available in the Virtual Meeting Guide available at AGMs | Monash IVF Group. Further information on how to participate virtually is set out in this Notice of Meeting and the Online Platform Guide. The Virtual Meeting platform will enable shareholders to: • See the Meeting presentation material and listen to the Meeting live; • Vote online during the Meeting; • Participate, ask questions and make comments online (orally and electronically) during the Meeting. Voting on all resolutions will be conducted by a poll. Shareholders may also cast their votes at the Meeting by appointing a proxy (preferably the Chair of the Meeting) by 2:00pm (AEDT) on 24 November 2026 or voting online during the Meeting. In the event of a technological failure that prevents shareholders from having a reasonable opportunity to participate in the Meeting, the Company will provide an update on its website and the ASX platform to communicate the details of the postponed or adjourned Meeting to shareholders. If it becomes necessary to make further alternative arrangements for holding the Meeting, the Company will provide shareholders with as much notice as practicable. Further information will be made available on the Company’s website and the ASX platform. All shareholders will have a reasonable opportunity to ask or submit questions or make comments during the AGM via the virtual AGM platform at the appropriate time while the Meeting is in progress, including an opportunity to ask questions of the Company’s external auditor. 5
23 OCTOBER 2026
To ensure that as many shareholders as possible have the opportunity to ask and submit questions and make comments, shareholders are requested to observe the following:
or number of votes each proxy is entitled to exercise may be specified. If no proportion or vote number is specified, each proxy may exercise half the number of votes.
• all shareholder questions and comments should be articulated or stated clearly and should be relevant to the business of the Meeting, including matters arising from the Financial Report, Directors’ Report (including the Remuneration Report) and Auditor’s Report, and general questions and comments about the performance, business or management of the Company;
A proxy does not need to be a shareholder. A body corporate appointed as a member’s proxy may appoint a representative to exercise any of the powers the body may exercise as a proxy at the AGM.
• if a shareholder has more than one question or comment on an item, all questions and comments should be asked or submitted at the one time; and • shareholders should not ask questions or make comments at the Meeting regarding personal matters or those that are commercial in confidence. Shareholders who prefer to register questions in advance of the Meeting are invited to do so. A Shareholder Question Form has been included with this Notice of Meeting and is also available on the Company’s website: AGMs | Monash IVF Group. We will attempt to address the more frequently asked questions during the Chair and Managing Director’s presentations to the Meeting. Voting by Proxy To provide shareholders with ease and convenience, whilst the Meeting can be attended in person, the Meeting will also be available virtually. Shareholders may participate in the Meeting online via the Virtual Meeting platform provided by MUFG Corporate Markets – https://meetings.openbriefing.com/ MVF26. You may still participate by lodging a proxy vote prior to the Meeting or vote in person at the Meeting or online during the Meeting (described in further detail below). In accordance with sections 249L and 249X of the Corporations Act 2001 (Cth), a shareholder may attend the AGM and vote, or may appoint a proxy to vote on the shareholder’s behalf. A member who is entitled to cast 2 or more votes but prefers to use a proxy vote may appoint no more than 2 proxies. If 2 proxies are appointed, the proportion
If a shareholder has not directed the proxy on how to vote, the proxy may vote as the proxy deems fit, and similarly if the shareholder appoints the Chair of the AGM as proxy but does not direct the Chair on how to vote on an item, the Chair will vote in accordance with her voting intention as stated, namely in favour of each of the proposed resolutions set out in the Notice of Meeting. Lodging your Proxy Form Proxy Forms should be lodged online at MUFG Corporate Markets in accordance with the instructions provided on the website. To use this facility, you will need your Holder Identification Number (HIN) or Securityholder Reference Number (SRN). This is located on the front of your Shareholder letter and you will be deemed to have signed your Proxy Form if you lodge it in accordance with the instructions on the website. Alternatively, you can lodge your completed and signed Proxy Form (together with any power of attorney or other authority under which the appointment was signed, or a certified copy of the authority, letter of representation, or power of attorney) to be received by 2:00pm on Tuesday, 24 November 2026. This can be returned by: a. Post using the reply-paid envelope provided or posted to: Monash IVF Group Ltd c/ MUFG Corporate Markets (AU) Limited Locked Bag A14, Sydney South NSW 1235 b. By Hand: MUFG Corporate Markets (AU) Limited Parramatta Square Level 22, Tower 6, 10 Darcy Street, Parramatta NSW 2150 c. Fax to MUFG Corporate Markets on +61 2 9287 0309
6
23 OCTOBER 2026
Proxy voting by the Chair The Chair intends to vote undirected proxies in favour of all proposed resolutions. In the event that there is a change to the Chair’s intention to vote it will be announced on the Monash IVF Group website before the AGM. The Chair’s decision on how to vote on all occasions is conclusive. Where the Chair is appointed as a shareholder’s proxy on Item 2 or Item 4, (or she becomes your proxy by default) and the shareholder has not specified the way in which the Chair is to vote on Item 2 or Item 4, the shareholder is directing the Chair to vote in accordance with the Chair’s voting intentions for these items of business. Corporate Representatives A corporation may elect to appoint an individual to act as its representative in accordance with section 250D of the Corporations Act 2001 (Cth) in which case the Company will require a Certificate of Appointment of Corporate Representative executed in accordance with the Corporations Act 2001 (Cth). The Certificate must be lodged with the Company before the AGM. The Company will retain the certificate. Voting at the Meeting In accordance with section 250JA(1)(a) of the Corporations Act 2001 (Cth), voting on all items of business will be conducted on a poll. You may vote at the Meeting in one of 3 ways: • In person; • Using the online platform. We recommend logging into the online platform at least 15 minutes prior to the scheduled start time by entering – https://meetings. openbriefing.com/MVF26 into a web browser on your computer or online device. Securityholders will need their SRN or HIN; • Proxyholders will need their proxy code which MUFG Corporate Markets will provide via email within 24 hours prior to the Meeting. Alternatively, the proxy code can be obtained by calling the Share Registry on 1300 554 474 the day of the Meeting. Online voting will be open between the commencement of the Meeting at 2:00pm (AEDT) on 26 November 2026 and the time at which the Chair announces voting closure. More information about online participation in the Meeting is available on the Online Platform Guide. 7
23 OCTOBER 2026
Explanatory Notes Item 1 - Consideration of Monash IVF Group Financial Reports The Financial Reports including the Directors’ Report and Auditor’s Report (the Reports) for the year ended 30 June 2026 will be laid before the AGM. There is no requirement for a formal resolution on this item. However, the Chair will allow shareholders a reasonable opportunity to ask questions and make comments on the operations and management of the Company with regard to the Reports. Shareholders may submit written questions in advance of the AGM to the Company’s external auditor regarding the content of the Auditor’s Report and the conduct of the audit via the Shareholder Question Form available on the Company’s website and accompanying this Notice of Meeting. Questions for the auditor must be received by the Share Registry by 5:00pm (AEDT) on Thursday, 19 November 2026. The auditor is not obliged to provide written answers. The Company’s external auditor will attend the AGM and the Chair will provide a reasonable opportunity for shareholders to ask questions relevant to: • the conduct of the audit; • the preparation and content of the Auditor’s Report; • the accounting policies adopted by the Company in relation to the preparation of the financial statements; • the policies adopted by the Company in relation to the preparation of any sustainability reports the Company is required to prepare; and • the independence of the auditor in relation to the conduct of the audit. Item 2 – Adoption of the Remuneration Report (nonbinding advisory vote) Section 250R of the Corporations Act 2001 (Cth) requires a listed company to put a resolution to shareholders to adopt its remuneration report for the relevant financial year. The Remuneration Report for the year ended 30 June 2026 outlines the remuneration arrangements of Monash IVF Group in accordance with the requirements of the Corporations Act 2001 (Cth) and
its regulations. The information has been audited as required by section 308 of the Corporations Act 2001 (Cth). The Remuneration Report addresses the following issues:
- Remuneration governance
- Principles used to determine the nature and amount of remuneration
- Executive remuneration including fixed remuneration and at-risk remuneration
- Independent Non-Executive Director remuneration
- Details of remuneration for key management personnel
- Loans to key management personnel
- Key management personnel shareholdings
- Group performance. Following consideration of the Remuneration Report, the Chair will give shareholders reasonable opportunity to ask questions or to comment on the report before the resolution that the Remuneration Report be adopted be put to the vote. The resolution of this item is advisory only and non-binding on the Company or Board. Voting exclusions As required by the Corporations Act 2001 (Cth), the Company will disregard any votes cast on Item 2: • by or on behalf of any member of the Company’s key management personnel (KMP), whose remuneration details are included in the Remuneration Report or any of their closely related parties, regardless of the capacity in which the vote is cast; or • as proxy by a person who is a member of the Company’s KMP at the date of the Meeting, or a closely related party of such a member, unless the vote is cast as a proxy appointed by a shareholder in writing that specifies how the shareholder wishes to vote. In addition, the Chair of the AGM will be able to vote as a proxy appointed in writing that does not specify the way the proxy is to vote on the resolution and expressly authorises her to vote on the resolution even though that resolution is connected directly or indirectly with the remuneration of a member of the Company’s KMP. Recommendation The Directors recommend that shareholders vote in favour of Item 2. 8
23 OCTOBER 2026
Item 3 - Election and Re-election of Directors
3a Re-election of Ms Catherine West as a Director Ms Catherine West was appointed as an Independent Non-Executive Director in September 2020 and was most recently elected as a Director at the Company’s 2023 Annual General Meeting. Ms West is an experienced ASX-listed Independent Non-Executive Director and has over 25 years of legal, business affairs and strategy experience in customerfocused businesses in the media, entertainment, telecommunications and medical sectors in Australia, the United Kingdom and Europe. Ms West is an Independent Non-Executive Director of Peter Warren Automotive Group. In addition, she is Chair of NIDA, Independent Non-Executive Director of the NIDA Foundation Trust and Chair of the Board of Governors of Wenona School. Ms West was Chair of Nine Entertainment until November 2025 and a Director of the Sydney Breast Cancer Foundation Limited until 30 June 2024. Ms West holds a Bachelor of Laws (Hons) and a Bachelor of Economics from the University of Sydney. She is also a Graduate Member of the Australian Institute of Company Directors. Ms West is a member of the Remuneration and Nomination Committee. The Board considers Ms West to be an independent Director. Recommendation The Board, with Ms West abstaining, recommends that shareholders vote in favour of Ms West’s re-election. In making this recommendation, the Board has considered Ms West’s extensive listed company, governance, legal, business affairs, strategy, customer experience and healthcare sector experience, her independence, and the contribution she is expected to continue making to the Board’s oversight of the Company’s strategy, governance, succession planning, remuneration framework and long-term performance.
3b Election of Dr Dwayne Crombie as a Director Dr Dwayne Crombie (MB ChB, D Com H, FAFPHM, NZCPHM) was appointed by the Board as an Independent Non-Executive Director on 24 November 2025. In accordance with Article 47(d) of the Company’s Constitution, a Director appointed by the Board must retire at the next Annual General Meeting following appointment. Dr Crombie, being eligible, has offered himself for election. Dr Crombie’s experience spans public hospital provision, community-based, mental health and disability services, as well as the funding of public health and disability services, aged care, private health insurance and private healthcare. Dr Crombie originally trained in medicine and specialised in public health before moving into senior management roles. He worked for global healthcare organisation Bupa for more than 15 years in several Managing Director roles, most recently leading Bupa Australia’s health services and insurance businesses before retiring in 2022. His current governance roles include Southern Cross Healthcare, Southern Cross Travel, Repromed New Zealand and InLife Independent Living. Dr Crombie is a member of the Audit and Risk Committee. Recommendation The Board, with Dr Crombie abstaining, recommends that shareholders vote in favour of Dr Crombie’s election. In making this recommendation, the Board has considered Dr Crombie’s extensive experience across public hospitals, community-based health services, mental health and disability services, aged care, private health insurance and private healthcare, and his independence.
9
23 OCTOBER 2026
Item 4 - Approval of grant of performance rights to the CEO and Managing Director under the Long-Term Incentive (LTI) Plan 4a Grant of FY2026 LTI Performance Rights to the CEO and Managing Director 4b Grant of FY2027 LTI Performance Rights to the CEO and Managing Director 3c Election of Mr Gerd Schenkel as a Director Mr Gerd Schenkel was appointed by the Board as an Independent Non-Executive Director effective 1 September 2026. In accordance with Article 47(d) of the Company’s Constitution, a Director appointed by the Board must retire at the next Annual General Meeting following appointment. Mr Schenkel, being eligible, has offered himself for election. Mr Schenkel is an experienced ASX-listed company director and senior executive with more than 25 years’ experience in strategy, digital transformation, technology, customer experience and governance across regulated, consumer-facing businesses. Mr Schenkel has held senior executive roles with Tyro Payments, Telstra and National Australia Bank, including as Chief Executive Officer of Tyro Payments, Executive Director of Telstra Digital and founder of UBank. His previous Board experience includes serving as an Independent Non-Executive Director of Helia Group Limited and as Chair of Credit Clear Limited. He has also served on the Australian Government’s Small Business Digital Taskforce. Mr Schenkel is currently advising organisations in the financial services, telecommunications and technology sectors on their digital and operational strategies. He holds a Master of Business Administration from Columbia Business School and a Master of Engineering (Robotics) from the University of Stuttgart. Recommendation The Board, with Mr Schenkel abstaining, recommends that shareholders vote in favour of Mr Schenkel’s election. In making this recommendation, the Board considers Mr Schenkel’s extensive senior executive and listed company director experience, together with his expertise in strategy, digital transformation, technology, customer experience and governance across regulated, consumerfacing businesses, strengthens the Board’s capability in digital and technology strategy, customer experience, operational transformation and governance as the Company continues to execute its strategic priorities.
Pursuant to ASX Listing Rule 10.14, the Company is seeking shareholder approval for the grant of performance rights to Dr Victoria Atkinson, CEO and Managing Director, as part of her LTI awards for FY2026 and FY2027. If shareholder approval is obtained, Dr Atkinson will be granted: • 279,383 performance rights1 under the FY2026 LTI (Item 4a). Dr Atkinson commenced employment as CEO and Managing Director on 5 January 2026. The Board approved a pro-rated FY2026 LTI opportunity equal to 50% of total fixed remuneration (TFR), calculated from her commencement date and subject to shareholder approval. Under the FY2026 LTI, Dr Atkinson will be granted a total of 279,383 performance rights, which has been determined by dividing Dr Atkinson’s LTI maximum opportunity of $193,973 (equivalent to 50% of Dr Atkinson’s TFR, pro-rated from her commencement on 5 January 2026) by the volume weighted share price of the Company’s shares traded on the ASX on the 10 trading days (VWAP) following the announcement of the FY2025 financial results (being $0.69429). • 504,070 performance rights under the FY2027 LTI (Item 4b). Dr Atkinson will be granted a total of 504,070 performance rights under the FY2027 LTI, which has been determined by dividing Dr Atkinson’s LTI maximum opportunity of $400,000 (equivalent to 50% of Dr Atkinson’s (TFR) by the VWAP following the announcement of the FY2026 financial results (being $0.79354).
10
23 OCTOBER 2026
Key terms of the FY2026 LTI grant The Company’s LTI Plan is designed to align the interests of the CEO with those of shareholders by providing the opportunity to receive an equity interest in the Company through the grant of performance rights. The Company has chosen to grant performance rights to link the CEO’s reward to measures that are important to shareholder value. If approved by shareholders, the performance rights will be granted under the Company’s Equity Incentive Plan. Dr Atkinson’s annual remuneration package includes the following: • Total Fixed Remuneration (base salary and packaged benefits) of $800,000 per annum; • A maximum short-term incentive (STI) opportunity of 50% of her TFR (i.e. $400,000), subject to the achievement of certain performance criteria measures approved by the Board. The STI criteria is subject to both financial and non-financial outcomes and is payable in cash; • An LTI award comprising the granting of performance rights up to 50% of her TFR (i.e. $400,000) (subject to shareholder approval, as described further below). As the performance rights form part of Dr Atkinson’s remuneration:
Prior to vesting, the performance rights do not confer on Dr Atkinson any voting rights or an entitlement to dividends. Performance conditions The performance rights are intended to vest subject to the achievement of performance conditions over a three-year performance period. Consistent with the Company’s existing executive remuneration framework, the performance rights will be tested against: • Tranche 1: Basic Earnings Per Share (EPS) growth (weighted to 70%); and • Tranche 2: Relative Total Shareholder Return (TSR) performance (weighted to 30%). Details of the FY2026 and FY2027 performance hurdles are set out in the following table: Tranche 1: Earnings per share (70% weighting)
Tranche 2: Relative TSR (30% weighting)
Portion of performance rights that will vest against the relevant target
Less than 10% per annum
Less than Index return
0%
10% per annum
Equal to Index return
30%
Between 10% to 12% per annum
Between Index return and Index 30% - 100% pro rata return +5%
At or above 12% per annum
Equal to or greater than Index return +5%2
• the performance rights will be granted at no cost; • no amount is payable on vesting or exercise; and • each performance right entitles Dr Atkinson to one fully paid ordinary share in the Company upon vesting plus an additional number of shares calculated on the basis of the dividends which would have been paid on that one share had it been issued at the time of grant of the performance right and assuming that those dividends were reinvested at the closing price of shares on the distribution date of those dividends.
100%
- Section 4.0 of the Company’s Remuneration Report expressed Dr Atkinson’s proposed total number of performance rights under FY2026 LTI to be a total of 576,128, representing an annualised figure. The 279,383 performance rights in respect of which shareholder approval will be sought under Item 4a has been calculated on a pro rata basis based on Dr Atkinson’s employment between 5 January 2026 to 30 June 2026. Section 3.1 of the remuneration report also contained a typographical error stating that Dr Atkinson would be issued with a total of 134,671 performance rights under the FY2026 LTI. If shareholders approve Item 4a, Dr Atkinson will receive a total of 279,383 performance rights under the FY2026 LTI, with 195,568 performance rights subject to the EPS hurdle and 83,815 performance rights subject to the TSR hurdle. 11
23 OCTOBER 2026
Testing of the performance conditions
• the circumstances of cessation of employment;
Tranche 1: Basic EPS
• the proportion of the performance period completed; and
The performance period will run from 1 July 2025 to 30 June 2028 for FY2026 and 1 July 2026 to 30 June 2029 for FY2027. The hurdle for 70% of the rights is based on an earnings per share hurdle which measures the compound growth of the Company’s basic earnings per share (EPS) over a 3-year period. No vesting occurs at below a threshold level of EPS growth of 10% per annum. 30% will vest at threshold performance, 100% will vest at maximum performance of EPS growth of 12% or above, with pro rata vesting between threshold and maximum.
• the extent to which performance conditions have been satisfied. Change of control Where a Change of Control Event occurs, the Board may determine that unvested performance rights: • vest; • lapse; • remain subject to existing vesting conditions; or
Tranche 2: Relative TSR
• become subject to substitute vesting conditions.
The hurdle for the other 30% of the rights is based on the Company’s total shareholder return relative to the ASX300 Healthcare Accumulation Index (Index) excluding CSL Limited from the 11th trading day after the FY2026 and FY2028 (for the FY2026 LTI grant) and FY2027 and FY2029 (for the FY2027 LTI grant) results announcements. In respect of this tranche, no performance rights will vest if the TSR performance is less than the Index returns. 30% will vest at threshold performance when TSR equals Index returns, 100% will vest at maximum performance if TSR equals Index returns +5% on an annualised basis, with pro rata vesting between threshold and maximum.
Malus and clawback
Key terms of the FY2027 LTI grant For the FY2027 grant, the material terms of the performance rights will be the same as the terms disclosed above in respect of the FY2026 LTI. The outcomes will be determined during the current financial year and will be disclosed in the Company’s FY2027 Remuneration Report. Cessation of employment If Dr Atkinson’s employment with the Company terminates before an award has vested, the unvested performance rights will automatically lapse unless the Board determines otherwise. Subject to the discretion of the Board, the treatment of unvested performance rights upon cessation of employment will be determined having regard to:
Performance rights are subject to the Company’s malus and clawback framework. The Board may determine that performance rights lapse or that benefits derived from performance rights are forfeited or repaid in circumstances including fraud, misconduct, material breach of obligations or material misstatement of financial results. Restrictions on dealing Dr Victoria Atkinson must not sell, transfer, hedge or otherwise deal with performance rights. Any shares acquired following vesting remain subject to the Company’s Securities Trading Policy. Other required information • Dr Atkinson falls within ASX Listing Rule 10.14.1 because she is a Director of the Company. • Dr Atkinson is the only Director eligible to participate and receive performance rights under the LTI Plan. No associate of any Director is entitled to participate. No additional person covered by ASX Listing Rule 10.14 (including any director) who becomes entitled to participate in an issue of securities under the LTI Plan will participate until approval is obtained under ASX Listing Rule 10.14. • ASX Listing Rule 10.14 provides that listed companies must not permit a director or their associates to acquire equity securities by way
- Section 4.0 of the Company’s remuneration report contained a typographical error which stated that this TSR hurdle is “Equal to or less than Index return +5%”. 12
23 OCTOBER 2026
of issue under an employee incentive scheme unless it obtains the approval of its shareholders. Resolutions 4a and 4b seek the required shareholder approval for the purpose of ASX Listing Rule 10.14 and, if shareholder approval is obtained, the Company will proceed to grant the performance rights to Dr Atkinson. • If shareholder approval is not obtained for the grant to Dr Atkinson of the proposed grant of performance rights will not proceed. In that circumstance, the Board would then need to consider alternative arrangements to appropriately remunerate Dr Atkinson.
Voting exclusion statement As required by the Corporations Act 2001 (Cth), the Company will disregard any votes cast on Item 4 as a proxy by a person who is a member of the Company’s KMP at the date of the Meeting or their closely related parties where the proxy appointment does not specify the way the proxy is to vote on Item 4. However, the Chair of the AGM will be able to vote as a proxy appointed in writing that expressly authorises her to vote on the resolution even though that resolution is connected directly or indirectly with the remuneration of a member of the Company’s KMP.
• No loan will be provided in connection with the grant of performance rights.
As required by ASX Listing Rule 10.15, the Company will disregard any vote cast in favour of Item 4 by or on behalf of a person referred to in ASX Listing Rule 10.14 and any associate of such a person.
• As at the date of this notice, Dr Atkinson has not received any securities under the LTI Plan.
However, the Company need not disregard a vote cast on Item 4 if it is cast:
• ASX Listing Rule 7.1 provides that a company must not, subject to specified exceptions, issue or agree to issue more equity securities during any 12-month period than that amount which represents 15% of the number of fully paid ordinary securities on issue at the commencement of that 12-month period. Pursuant to Listing Rule 7.2 Exception 14, if item 4 is approved, approval under ASX Listing Rule 7.1 is not required for any issue of shares resulting from the vesting and exercise of the performance rights. Those shares would not be included in the Company’s 15% limit and would enable that proportion of the 15% limit to be used for a future issue of equity securities.
a. by a person as proxy or attorney for a person entitled to vote on the resolution, in accordance with directions given to the proxy or attorney;
• The acquisition price for the performance rights is nil.
• If shareholder approval is obtained, the performance rights will be granted as soon as practicable following the AGM and in any event within the period required by the ASX Listing Rules, being not later than three years. • Details of any securities issued under the LTI Plan will be published in the Company’s Annual Report for the relevant period, along with a statement that approval for the issue was obtained under ASX Listing Rule 10.14.
b. by the Chair of the Meeting as proxy or attorney for a person entitled to vote on the resolution in accordance with a direction given to the Chair to vote on Item 4 as the Chair decides; or c. by a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided that: i. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on Item 4; and ii. the holder votes on Item 4 in accordance with the directions given by the beneficiary to the holder to vote in that way. Recommendation The Board, with Dr Victoria Atkinson abstaining, recommends that shareholders vote in favour of Items 4a and 4b.
• If shareholder approval is not obtained, the Board will consider alternative arrangements to appropriately remunerate and incentivise Dr Atkinson.
13
23 OCTOBER 2026
Corporate Directory Directors3 Ms Catherine West Chair Dr Victoria Atkinson Managing Director and Chief Executive Officer Ms Catherine Aston Independent Non-Executive Director Dr Dwayne Crombie Independent Non-Executive Director Mr Gerd Schenkel Independent Non-Executive Director Ms Zita Peach Independent Non-Executive Director Ms Rebecca Dean Company Secretary
Registered Office and Principal Place of Business Level 1, 510 Church Street, Cremorne VIC 3121 Share register MUFG Corporate Markets (formerly Link Market Services) Auditor KPMG Stock exchange listing Monash IVF shares are listed on the Australian Securities Exchange (Listing code: MVF) Website https://www.monashivfgroup.com.au/ ABN 90 169 302 309
- Please note that as at the date of this notice of meeting and explanatory statement, Mr Richard Davis and Dr Richard Henshaw are directors of Monash IVF. Mr Davis and Dr Henshaw will retire from their roles on 28 October 2026 and will not be directors of Monash IVF at the AGM. 14
LODGE YOUR VOTE ONLINE https://au.investorcentre.mpms.mufg.com
Monash IVF Group Limited
BY MAIL
ABN 90 169 302 309
Monash IVF Group Limited C/- MUFG Corporate Markets (AU) Limited Locked Bag A14 Sydney South NSW 1235 Australia
FAX BY +61 2 9287 0309 HAND BY MUFG Corporate Markets (AU) Limited
Parramatta Square, Level 22, Tower 6, 10 Darcy Street, Parramatta NSW 2150
ENQUIRIES TO ALL Telephone: +61 1300 554 474
X99999999999 X99999999999
PROXY FORM
I/We being a member(s) of Monash IVF Group Limited (the Company) and entitled to attend and vote hereby appoint:
APPOINT A PROXY
OR if you are NOT appointing the Chairman of the Meeting as your Name proxy, please write the name and email of the person or body corporate you are appointing as your proxy. An email will be sent to your Email appointed proxy with details on how to access the virtual meeting. or failing the person or body corporate named, or if no person or body corporate is named, the Chairman of the Meeting, as my/our proxy to act on my/our behalf (including to vote in accordance with the following directions or, if no directions have been given and to the extent permitted by the law, as the proxy sees fit) at the Annual General Meeting of the Company to be held at 2:00pm (AEDT) on Thursday, 26 November 2026 (the Meeting) and at any postponement or adjournment of the Meeting. The Meeting will be conducted as a hybrid event. You can participate by attending in person at KPMG, Tower Two, Level 36, Meeting Room 36.17-18, Collins Square, 727 Collins Street, Melbourne VIC 3008, or logging in online at https://meetings.openbriefing.com/MVF26 (refer to details in the Virtual Annual General Meeting Online Guide). Important for Resolutions 2, 4(a) & 4(b): If the Chairman of the Meeting is your proxy, either by appointment or by default, and you have not indicated your voting intention below, you expressly authorise the Chairman of the Meeting to exercise the proxy in respect of Resolutions 2, 4(a) & 4(b), even though the Resolutions are connected directly or indirectly with the remuneration of a member of the Company’s Key Management Personnel (KMP). The Chairman of the Meeting intends to vote undirected proxies in favour of each item of business.
STEP 1
the Chairman of the Meeting (mark box)
VOTING DIRECTIONS Proxies will only be valid and accepted by the Company if they are signed and received no later than 48 hours before the Meeting. Please read the voting instructions overleaf before marking any boxes with an T
Resolutions
STEP 2
2
Adoption of the Remuneration Report (non-binding advisory vote)
3(a) Re-election of Ms Catherine West as a Director
For Against Abstain*
For Against Abstain* 4(a) Grant of FY2026 LTI Performance Rights to the CEO and Managing Director 4(b) Grant of FY2027 LTI Performance Rights to the CEO and Managing Director
3(b) Election of Dr Dwayne Crombie as a Director
f you mark the Abstain box for a particular Item, you are directing your proxy not to vote on your behalf on a poll and your votes will not be counted in computing the * Irequired majority on a poll.
STEP 3
SIGNATURE OF SHAREHOLDERS – THIS MUST BE COMPLETED Shareholder 1 (Individual)
Joint Shareholder 2 (Individual)
Joint Shareholder 3 (Individual)
Sole Director and Sole Company Secretary
Director/Company Secretary (Delete one)
Director
This form should be signed by the shareholder. If a joint holding, either shareholder may sign. If signed by the shareholder’s attorney, the power of attorney must have been previously noted by the registry or a certified copy attached to this form. If executed by a company, the form must be executed in accordance with the company’s constitution and the Corporations Act 2001 (Cth).
MVF PRX2601N
MVF PRX2601N
3(c) Election of Mr Gerd Schenkel as a Director
HOW TO COMPLETE THIS SHAREHOLDER PROXY FORM YOUR NAME AND ADDRESS This is your name and address as it appears on the Company’s share register. If this information is incorrect, please make the correction on the form. Shareholders sponsored by a broker should advise their broker of any changes. Please note: you cannot change ownership of your shares using this form.
APPOINTMENT OF PROXY If you wish to appoint the Chairman of the Meeting as your proxy, mark the box in Step 1. If you wish to appoint someone other than the Chairman of the Meeting as your proxy, please write the name and email address of that individual or body corporate in Step 1. A proxy need not be a shareholder of the Company.
LODGEMENT OF A PROXY FORM This Proxy Form (and any Power of Attorney under which it is signed) must be received at an address given below by 2:00pm (AEDT) on Tuesday, 24 November 2026, being not later than 48 hours before the commencement of the Meeting. Any Proxy Form received after that time will not be valid for the scheduled Meeting. Proxy Forms may be lodged using the reply paid envelope or:
DEFAULT TO CHAIRMAN OF THE MEETING Any directed proxies that are not voted on a poll at the Meeting will default to the Chairman of the Meeting, who is required to vote those proxies as directed. Any undirected proxies that default to the Chairman of the Meeting will be voted according to the instructions set out in this Proxy Form, including where the Resolutions are connected directly or indirectly with the remuneration of KMP.
BY MOBILE DEVICE Our voting website is designed specifically for voting online. You can now lodge your vote by scanning the QR code adjacent or enter the voting link https://au.investorcentre.mpms.mufg. com into your mobile device. Log in using the Holder Identifier and postcode for your shareholding.
VOTES ON ITEMS OF BUSINESS – PROXY APPOINTMENT You may direct your proxy how to vote by placing a mark in one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as they choose. If you mark more than one box on an item your vote on that item will be invalid.
BY MAIL
Monash IVF Group Limited C/- MUFG Corporate Markets (AU) Limited Locked Bag A14 Sydney South NSW 1235 Australia
You are entitled to appoint up to two persons as proxies to attend the Meeting and vote on a poll. If you wish to appoint a second proxy, an additional Proxy Form may be obtained by telephoning the Company’s share registry or you may copy this form and return them both together.
SIGNING INSTRUCTIONS You must sign this form as follows in the spaces provided: Individual: where the holding is in one name, the holder must sign. Joint Holding: where the holding is in more than one name, either shareholder may sign. Power of Attorney: to sign under Power of Attorney, you must lodge the Power of Attorney with the registry. If you have not previously lodged this document for notation, please attach a certified photocopy of the Power of Attorney to this form when you return it. Companies: where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the Corporations Act 2001) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please indicate the office held by signing in the appropriate place.
CORPORATE REPRESENTATIVES If a representative of the corporation is to attend the Meeting virtually the appropriate “Certificate of Appointment of Corporate Representative” must be received at [email protected] prior to admission in accordance with the Notice of Annual General Meeting. A form of the certificate may be obtained from the Company’s share registry or online at www.mpms.mufg.com/en/mufg-corporate-markets.
QR Code
To scan the code you will need a QR code reader application which can be downloaded for free on your mobile device.
APPOINTMENT OF A SECOND PROXY
To appoint a second proxy you must: (a) on each of the first Proxy Form and the second Proxy Form state the percentage of your voting rights or number of shares applicable to that form. If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes. Fractions of votes will be disregarded; and (b) return both forms together.
ONLINE https://au.investorcentre.mpms.mufg.com Login to the Investor Centre using the holding details as shown on the Voting/Proxy Form. Select ‘Voting’ and follow the prompts to lodge your vote. To use the online lodgement facility, shareholders will need their “Holder Identifier” - Securityholder Reference Number (SRN) or Holder Identification Number (HIN).
BY FAX +61 2 9287 0309
BY HAND delivering it to MUFG Corporate Markets (AU) Limited* Parramatta Square Level 22, Tower 6 10 Darcy Street Parramatta NSW 2150
- in business hours (Monday to Friday, 9:00am–5:00pm)
23 October 2026
Dear Shareholders 2026 Annual General Meeting On behalf of the Board of Monash IVF Group Limited (MVF), I am pleased to invite you to our 2026 Annual General Meeting (AGM) commencing at 2:00pm (AEDT) on Thursday, 26 November 2026. This year’s AGM will be conducted as a hybrid meeting where shareholders and appointed proxyholders will be able to attend and participate in person or virtually via an online platform. In person:
KPMG, Tower Two, Level 36, Meeting room 36.17-18 Collins Square, 727 Collins Street Melbourne VIC 3008
Virtually:
To access the meeting, please enter the following link into your web browser on your computer or online device –https://meetings.openbriefing.com/MVF26
The following AGM documents accompany this letter – • •
Proxy Form Shareholder Questions Form
Copies of the AGM documents including the Notice of Meeting and the Virtual Meeting Online Guide are also available on the Monash IVF Group website - https://www.monashivfgroup.com.au/investorcentre/agms/ Details regarding the opportunities for shareholders to ask questions at the meeting are contained in the Notice of Meeting. For shareholders that elect to attend the AGM virtually via the online platform, instructions on how to vote and ask questions through the online platform, as well as verbally, are set out in the Virtual Online Guide. I encourage you to submit any questions for the AGM ahead of the meeting so we can address as many of the more frequently asked questions as possible on the day. Monash IVF Group’s 2026 Annual Report was also released today. Should you wish to read this document online, it is available to view and download at: https://www.monashivfgroup.com.au/investorcentre/annual-reports/ Shareholders should monitor the ASX announcements platform and Monash IVF Group website where updates will be provided if it becomes necessary or appropriate to make alternative arrangements for the holding or conduct of the AGM. I look forward to your attendance and participation at the AGM. Yours sincerely
Richard Davis Chairman Monash IVF Group Limited
1
ASX Announcement 9 October 2026
Monash IVF Group Limited (ASX:MVF, the “Company” or “Monash IVF”) Appointment of Chief Financial Officer Monash IVF Group is pleased to announce the appointment of Matt Harrington as Chief Financial Officer. Mr Harrington will commence with the Company by 4 January 2027 following the completion of his current commitments and an agreed transition process. Mr Harrington brings more than 20 years’ senior finance and commercial leadership experience across listed, large, complex and highly regulated organisations in Australia and internationally. He joins Monash IVF Group Limited from Australian Unity, where he has served as Chief Financial Officer of Wealth and Capital Markets. He previously served as Chief Financial Officer of AustralianSuper. He is a Chartered Accountant with CA Australia and New Zealand and is a graduate member of the GAICD. Monash IVF Chief Executive Officer and Managing Director, Dr Victoria Atkinson, said: "We are pleased to welcome Matt to Monash IVF. He brings strong finance, commercial and transformation experience, and a proven track record leading finance functions in large and complex organisations. His experience will be valuable as we continue to execute our strategy and strengthen performance across the Group.” Interim Chief Financial Officer Birol Akdogan will remain with the Company to support an orderly and smooth transition. The Board and Management thank Mr Akdogan for his leadership and contribution as Interim Chief Financial Officer and for his continued support during the transition. Authorised by the Board of Directors.
Important dates for shareholders for the remainder of 2026 are set out below. Dates may change should circumstances require. Any change in dates will be advised to the Australian Securities Exchange (ASX). Event
Date
Closing date for receipt of director nominations
Thursday, 8 October 2026
FY2026 Final Dividend Payment Date
Thursday, 15 October 2026
Notice of Meeting and Annual General Meeting information will be released to the ASX and available by:
Tuesday, 27 October 2026
Annual General Meeting 2026
Thursday, 26 November 2026
5pm AEDT
2pm AEDT Approved by the Board of Directors
Rebecca Dean General Counsel and Company Secretary Monash IVF Group +61 3 9420 8235
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Announcement Summary
Entity name MONASH IVF GROUP LIMITED Date of this announcement Thursday September 03, 2026 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securities to be issued/transferred
ASX +security code
Security description
MVFAA
PERFORMANCE RIGHTS
Total number of +securities to be issued/transferred
Issue date
112,921
21/07/2026
Refer to next page for full details of the announcement
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
1/6
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Part 1 - Entity and announcement details
1.1 Name of entity MONASH IVF GROUP LIMITED We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities. 1.2 Registered number type
Registration number
ABN
90169302309
1.3 ASX issuer code MVF 1.4 The announcement is New announcement 1.5 Date of this announcement 3/9/2026
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
2/6
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Part 2 - Issue details
2.1 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX 2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which: has an existing ASX security code ("existing class")
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
3/6
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B
ASX +security code and description MVFAA : PERFORMANCE RIGHTS Date the +securities the subject of this notification were issued 21/7/2026 Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes
Were any of the +securities issued to +key management personnel (KMP) or an +associate? No Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms Performance Rights granted under the Monash IVF Group Limited Equity Incentive Plan (EIP). The EIP was approved by shareholders at the 2017 annual general meeting. https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2995-01910978-2A1044469&v=undefine Any other information the entity wishes to provide about the +securities the subject of this notification
Issue details
Number of +securities 112,921
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
4/6
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Part 4 - +Securities on issue
Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise: The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing. 4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX) ASX +security code and description
Total number of +securities on issue
MVF : ORDINARY FULLY PAID
389,634,840
4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX) ASX +security code and description MVFAA : PERFORMANCE RIGHTS
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Total number of +securities on issue 1,271,068
5/6
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Part 5 - Other Listing Rule requirements
5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? Yes 5.1a Select the number of the applicable exception in Listing Rule 7.2 13
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
6/6
Appendix 3X Initial Director’s Interest Notice Rule 3.19A.1
Appendix 3X Initial Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.
Name of entity Monash IVF Group Limited ABN 90 169 302 309 We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director
Date of appointment
Gerd Schenkel
1 September 2026
Part 1 - Director’s relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Number & class of securities
- See chapter 19 for defined terms. 11/3/2002
Appendix 3X Page 1
Appendix 3X Initial Director’s Interest Notice
Part 2 – Director’s relevant interests in securities of which the director is not the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Name of holder & nature of Number & class of Securities interest Note: Provide details of the circumstances giving rise to the relevant interest.
Part 3 – Director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
Detail of contract
Nature of interest Name of registered holder (if issued securities)
n/a n/a n/a
No. and class of securities to which n/a interest relates
- See chapter 19 for defined terms. Appendix 3X Page 2
11/3/2002
ASX Announcement Monash IVF Group Limited (ASX: MVF) 3 September 2026
Notification of Release of Restricted Shares in Escrow
In accordance with Listing Rule 3.10A, Monash IVF Group Limited (“Company”) advises that 65,273 fully paid ordinary shares currently held under voluntary escrow will be released on 10 September 2026. The release of escrow shares does not change the issued capital of the Company and 9,423,322 fully paid ordinary shares remain held under voluntary escrow. Approved by the Chief Executive Officer
Rebecca Dean General Counsel and Company Secretary Monash IVF Group +61 3 9420 8235
Monash IVF Group Limited Appendix 4E Preliminary final report
- Company details Name of entity: ABN: Reporting period: Previous period:
Monash IVF Group Limited 90 169 302 309 For the year ended 30 June 2026 For the year ended 30 June 2025
- Results for announcement to the market Underlying net profit after tax (NPAT) amounted to $16.1m which is below the guidance provided in June 2026 of between $17m to $18m. The result includes impact of the write-off of $1.4m (after tax) of prepaid assets. % Revenue from ordinary activities Underlying Earnings before interest, tax, depreciation, amortisation (EBITDA)(1)(2) Earnings before interest and tax (EBIT) Underlying Earnings before interest and tax (EBIT)(2) Underlying Net profit from ordinary activities after tax attributable to members and minority interest(2) Net profit from ordinary activities after tax attributable to members (1)
$'000
down
(0.9%) to
269,459
down down down
(19.5%) to (53.6%) to (34.0%) to
53,419 20,162 28,363
down down
(41.2%) to (67.6%) to
16,111 8,326
The Directors consider EBITDA to be one of the key financial measures of the underlying performance of Monash IVF Group Limited. EBITDA is earnings before interest, tax, depreciation and amortisation. EBITDA is a non-IFRS measure which is used by the Group as a key indicator of performance. This non-IFRS measure is not subject to audit or review. Refer to the reconciliation below.
(2)
Underlying EBITDA, EBIT and NPAT are non-IFRS measures, not subject to audit or review. Refer to reconciliation below.
The profit for the Group after providing for income tax and non-controlling interest amounted to $7.4m (30 June 2025: $25.0m). Refer to the commentary in the Directors' Report in the Operational and Financial Review section. The following table summarises key reconciling items between statutory profit and Underlying EBIT, Underlying EBITDA and Underlying NPAT: 2026 2025 EBITDA EBIT NPAT EBITDA EBIT NPAT $'000 $'000 $'000 $'000 $'000 $'000 Statutory profit after income tax Add: Interest expense Less: Interest income Add: Income tax expense Add: Depreciation Add: Amortisation Reported result Commissioning costs Class action and acquisition costs Impairment of investment SaaS expenses and other costs Professional service costs and additional measures in response to incidents Business restructuring Adjusted Leases Non-cash interest Underlying
8,326 9,202 (425) 3,059 20,830 2,518 43,510 1,623
8,326 9,202 (425) 3,059 20,162 1,623
8,326 8,326 1,136
25,676 7,390 (101) 10,447 19,936 2,083 65,431 503
25,676 7,390 (101) 10,447 43,412 503
25,676 25,676 352
191 2,414
191 2,414
134 1,690
(3,752) 761 1,562
(3,752) 761 1,562
(2,626) 761 1,093
4,485 1,196 53,419 53,419
4,485 1,196 30,071 (1,708) 28,363
3,140 837 15,263 (1,196) 2,044 16,111
1,314 516 66,335 66,335
1,314 516 44,316 (1,350) 42,966
920 361 26,537 (945) 1,827 27,419
Monash IVF Group Limited Appendix 4E Preliminary final report 3. Net tangible assets Reporting period Cents Net tangible assets per ordinary security
Previous period Cents
(8.57)
(10.71)
Amount per security Cents
Franked amount per security Cents
1.3 1.2
1.3 1.2
- Control gained over entities Not applicable.
- Loss of control over entities Not applicable.
- Dividends Current period
Final dividend for the year ended 30 June 2026 per ordinary share to be paid on 15 October 2026 Interim dividend for the year ended 30 June 2026 per ordinary share paid on 10 April 2026
Monash IVF Group’s dividend policy is to target a payout ratio of between 60% and 70% of Underlying NPAT(1). The level of payout ratio is expected to vary between periods depending on general operating conditions, operating cashflow and profit, funding, strategic growth opportunities and availability of franking credits. The record date for the final dividend is 4 September 2026 and the expected dividend payment date is 15 October 2026. (1)
Non-IFRS measure.
Previous period
Final dividend for the year ended 30 June 2024 per ordinary share paid on 11 October 2024 Interim dividend for the year ended 30 June 2025 per ordinary share paid on 11 April 2025 7. Dividend reinvestment plans Not applicable.
Amount per security Cents
Franked amount per security Cents
2.5 2.6
2.5 2.6
Monash IVF Group Limited Appendix 4E Preliminary final report 8. Details of associate entities Reporting entity's percentage holding Reporting period %
Name of associate Compass Fertility Trust (trading as 'Compass Fertility')
30%
- Foreign entities Details of origin of accounting standards used in compiling the report: International Financial Reporting Standards.
- Audit qualification or review Details of audit/review dispute or qualification (if any): The financial statements have been audited and an unmodified opinion has been issued.
- Attachments Details of attachments (if any): The Financial Report of Monash IVF Group Limited for the year ended 30 June 2026 is attached.
- Signed
Signed ___________________________ Mr Richard Davis Chair Melbourne
Date: 31 August 2026
Previous period % 30%
Monash IVF Group Limited ABN 90 169 302 309
Financial Report For the year ended 30 June 2026
Monash IVF Group Limited Contents 30 June 2026 Directors' Report Auditor's independence declaration Corporate Governance Statement Consolidated statement of profit or loss and other comprehensive income Consolidated statement of financial position Consolidated statement of changes in equity Consolidated statement of cash flows Notes to the consolidated financial statements Consolidated entity disclosure statement Directors' declaration Independent auditor's report to the members of Monash IVF Group Limited
2 29 30 42 43 44 45 46 87 89 90
General information The financial statements cover Monash IVF Group Limited as a Group consisting of Monash IVF Group Limited and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Monash IVF Group Limited's functional and presentation currency. Monash IVF Group Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is: Level 1, 510 Church Street Cremorne, Victoria 3121 Australia Monash IVF Group Limited was incorporated on 30 April 2014. A description of the nature of the Group's operations and its principal activities is included in the Directors' report, which is not part of the financial statements. The financial statements were authorised for issue, in accordance with a resolution of Directors, on 31 August 2026.
1
Monash IVF Group Limited Directors' Report 30 June 2026 The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of Monash IVF Group Limited (referred to hereafter as 'Monash IVF Group', 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2026. Directors The following persons were Directors of Monash IVF Group Limited during the whole of the financial year and up to the date of this report, unless otherwise stated: Mr Richard Davis Ms Catherine West Ms Zita Peach Ms Catherine Aston Mr Neil Broekhuizen Dr Richard Henshaw Dr Dwayne Crombie Dr Victoria Atkinson
appointed on 24 November 2025 appointed on 5 January 2026
Principal activities The Group is a leader in the field of human fertility services and is one of the leading providers of Assisted Reproductive Services (ARS), which is the most significant component of fertility care in Australia and Southeast Asia. ARS encompasses a range of techniques used to assist patients experiencing infertility to achieve a clinical pregnancy, including reproductive genetic services. In addition, the Group is a significant provider of specialised women’s imaging and diagnostic services. Operational and financial review The statutory profit for the Group after providing for income tax amounted to $8.3m (30 June 2025: $25.7m). The Group reported Underlying Net Profit After Tax (Underlying NPAT)(1)(2)(6) of $16.1m as compared to $27.4m in 2025.
Group Revenue Underlying EBITDA(1)(2) Underlying EBIT(1)(2) Underlying NPAT(1)(2)(6) Reported EBITDA(1)(2) Reported EBIT Reported NPAT(6)
2026 $'000
2025 $'000
269,459 53,419 28,363 16,111 43,510 20,162 8,326
271,917 66,335 42,966 27,419 65,431 43,412 25,676
(2,458) (12,916) (14,603) (11,308) (21,921) (23,250) (17,350)
(1%) (19%) (34%) (41%) (34%) (54%) (68%)
1.9 2.5
6.4 5.1
(4.5) (2.6)
(70%) (51%)
Earnings Per Share (cents) Dividends Paid/Payable Per Share (cents) 2026 Net debt ('000)(3) Net debt to equity ratio(4) Return on equity (pa.)(5)
$101,158 40% 6%
Change $'000
Change %
2025 $89,573 36% 11%
(1)
Refer to earnings reconciliation on page 4 for Underlying vs Reported EBITDA, EBIT and NPAT.
(2) (3)
EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation), EBIT (Earnings Before Interest and Tax) and Underlying NPAT (Net Profit After Tax) are non-IFRS measures. Debt less cash balances.
(4)
Net debt to equity is net debt divided by equity.
(5)
Return on equity is Underlying NPAT for the twelve-month period to 30 June 2026 and 30 June 2025 divided by closing equity.
(6)
Attributable to ordinary shareholders and non-controlling interest.
2
Monash IVF Group Limited Directors' Report 30 June 2026 Group results commentary Monash IVF Group reported Underlying NPAT of $16.1m, which is 41% below 2025. Underlying EBITDA was $53.4m, a decrease of 19% on 2025. The Group revenue reduced by 1% compared to 2025, reflecting ongoing softness in the Domestic ARS market and the change in market share partly offset by growth in International and ancillary revenue streams. The Group's market share improved to 20.2% up from 19.0% in the first half on a rolling six-month average. FY26 price increases were deferred in our East Coast markets, which impacted EBITDA by approximately $6.1m. The change in Revenue in FY26 was driven by a combination of factors below: ● The rolling twelve months Domestic market share as at 30 June 2026 for stimulated cycles was 19.5% (from 21.0% in 2025). Our market share improved in several key states, with improvement evident in Victoria and New South Wales compared to the first half; ● Ultrasound revenues increased by 2% following pricing changes and the commencement of ultrasound clinics in WA; ● International revenues increased 15% driven primarily by strong growth in Malaysia; and ● Genetics and Ancillary income grew $4.6m, largely driven by increased PGT activity and higher storage fee income. The Group achieved 5,753 clinical pregnancies and continued to deliver strong clinical outcomes, with clinical pregnancy rate per embryo of 42.1% for women aged under 43 years, up 1.8% on 2025, and 44% for women aged under 40 years, up 1.1% on 2025 and well above the ANZARD benchmark. Throughout the year, we provided more than 3,000 patient care episodes per month across IVF, day surgery and scan procedures. Day surgery volumes also continued to grow, with 7,980 procedures performed. The Group's recent investments in strategic infrastructure programs has meant that the majority of surgical procedures are expected to be performed in-house during FY27, increasing revenue capture. Depreciation and amortisation increased by $1.3m to $23.3m or 6% reflecting the AASB 16 impacts of new lease commitments of $15.0m. Net finance costs increased by $1.5m largely driven by an increase in average borrowing levels compared to 2025, driven by capital expenditures coinciding with a period of lower cash generation. The effective tax rate decreased to 26.9% from 28.9% in 2025, reflecting a higher proportion of profit generated by the lowertax international segment relative to Australia. Segment analysis 2026 $'000 Revenue Underlying EBIT Underlying NPAT Reported NPAT
248,237 24,821 13,212 5,617
Australia 2025 $'000
% Change
253,434 39,980 25,342 24,387
(2%) (38%) (48%) (77%)
2026 $'000 21,222 3,542 2,899 2,709
International 2025 $'000
% Change
18,483 2,985 2,077 1,289
15% 19% 40% 110%
Australia Australian Revenue decreased by $5.2m or 2% due to the following: ● $9.7m decrease due mainly to market share losses in the Australian ARS sector in a softer market although some market share gains were recorded in our smaller operations; ● $0.7m increase in Ultrasound revenues was driven by a combination of our WA Ultrasound expansion and improved case mix in Melbourne. Scan volumes reduced slightly in Sydney, with reduced availability of sonographer talent continuing to constrain our business, however various pathways are being explored to alleviate this issue including training and recruitment; ● Day Surgery revenue declined by $0.9m due to reduced IVF activity; and ● Genetics and other revenue streams grew $4.6m, largely driven by increased PGT activity and storage fee income.
3
Monash IVF Group Limited Directors' Report 30 June 2026 Segment analysis (continued) The Australian Segment delivered 2026 Underlying EBIT of $24.8m, down 38% on 2025. The decline reflected lower revenue and higher operating costs, including inflationary pressures. Occupancy and insurance costs increased as expected, while variable clinical and nursing costs did not reduce in line with lower volumes, increasing as a proportion of revenue. Cost efficiency programs started in FY26 are anticipated to gain momentum in FY27. Reported NPAT declined by 77% compared to 2025 driven by lower EBIT including one-off items, being primarily professional service costs and additional measures in response to incidents. The result also includes higher depreciation and amortisation expenses, in addition to higher borrowing costs. International The International segment comprises clinics in Malaysia (Kuala Lumpur and Johor Bahru), Singapore and Indonesia (Bali). Our revenues grew strongly (up 15% on 2025) driven by International and Domestic demand for IVF services in the region. Our targeted marketing efforts aimed at emerging economies within nearby regions, have yielded positive results. More importantly, the new leadership team has provided a more focused strategy aimed at improved patient outcomes and standardised operating procedures. Earnings reconciliation The table below provides a reconciliation of FY2026 and FY2025 Underlying EBITDA, Underlying EBIT and Underlying NPAT to the reported statutory metrics: EBITDA $'000 Statutory profit after income tax Add: Interest expense Less: Interest income Add: Income tax benefit Add: Depreciation Add: Amortisation Reported result Commissioning costs Class action and acquisition costs Impairment of investment SaaS expenses and other costs Professional service costs and additional measures in response to incidents Business restructuring Adjusted Leases Non-cash interest Underlying(1) (1)
2026 EBIT $'000
NPAT $'000
EBITDA $'000
2025 EBIT $'000
NPAT $'000
8,326 9,202 (425) 3,059 20,830 2,518 43,510 1,623
8,326 9,202 (425) 3,059 20,162 1,623
8,326 8,326 1,136
25,676 7,390 (101) 10,447 19,936 2,083 65,431 503
25,676 7,390 (101) 10,447 43,412 503
25,676 25,676 352
191 2,414
191 2,414
134 1,690
(3,752) 761 1,562
(3,752) 761 1,562
(2,626) 761 1,093
4,485 1,196 53,419 53,419
4,485 1,196 30,071 (1,708) 28,363
3,140 837 15,263 (1,196) 2,044 16,111
1,314 516 66,335 66,335
1,314 516 44,316 (1,350) 42,966
920 361 26,537 (945) 1,827 27,419
Non-IFRS measures.
4
Monash IVF Group Limited Directors' Report 30 June 2026 Earnings reconciliation (continued) A total of $6.9m in post-tax items are included in the reconciliation of Profit after Income Tax (Reported NPAT) to the Adjusted NPAT figure. A further $0.8m (post tax) in non-cash AASB 16 lease expenses and right of use asset depreciation is also excluded to arrive at the Underlying NPAT results as reported in prior periods. The major adjustments to derive the Adjusted NPAT include: ● $1.1m commissioning costs related to pre-opening expenditure for new fertility clinics and day hospitals including Brisbane. Our Brisbane facility commenced operations in July 2026, and is expected to increase revenue and capacity during 2027; ● $0.1m of legal costs, including class action and costs primarily relating to the acquisition of WA Ultrasound Pty Ltd; ● $1.7m Software-as-a-Service (SaaS) and other related costs in relation to an enhanced patient management solution. The Group is reviewing the timelines of the business case including the availability of new technologies impacting the sector; ● $3.1m expenses for professional service costs and additional measures arising from clinic‑specific incidents. The amounts exclude insurance recoveries estimated to be up to $2.0m post tax (up to $2.8m pre-tax) which are considered a contingent asset and therefore not recognised as an asset as at 30 June 2026; and ● $0.8m of business restructuring costs relating to leadership changes in Australia and Internationally. Consolidated statement of financial position and capital metrics Balance sheet 30 June 2026 30 June 2025 $'000 $'000
Change $'000
Change %
Cash and cash equivalents Other current assets Lease liabilities (current) Other current liabilities Net working capital
8,842 35,283 (11,166) (54,573) (21,614)
9,427 32,256 (9,722) (51,692) (19,731)
(585) 3,027 (1,444) (2,881) (1,883)
(6%) 9% 15% 6% 10%
Borrowings Goodwill and intangible assets Right-of-use assets Lease liabilities (non-current) Plant and equipment Other net assets/(liabilities)
(109,400) 295,551 81,508 (79,052) 84,245 2,231
(98,529) 297,235 76,423 (71,780) 69,614 (2,814)
(10,871) (1,684) 5,085 (7,272) 14,631 5,045
11% (1%) 7% 10% 21% (179%)
Net assets
253,469
250,418
3,051
1%
Capital metrics
30 June 2026 30 June 2025
Net debt ($'000)(1) Leverage ratio (Net debt / EBITDA(2)) Interest cover (EBITDA(2) / Interest) Net debt to Equity ratio(3) Return on equity(4) Return on assets(5) (1) (2) (3)
$101,158 1.9x 9.1x 40% 6% 3%
$89,573 1.7x 11.3x 36% 11% 6%
Net debt is debt less cash and cash equivalents (excluding capitalised bank fees). EBITDA is based on normalised EBITDA excluding AASB16 lease impact and other items for covenant purposes as defined in the Syndicated Debt Facility Agreement. EBITDA is not an IFRS measure. Net debt divided by equity at the balance date.
(4)
Underlying NPAT for the previous 12-month period divided by closing equity at the balance date.
(5)
Underlying NPAT for the previous 12-month period divided by closing assets at the balance date.
Net debt increased by $11.6m to $101.2m and the carrying value of borrowings was $110.0m as at 30 June 2026. The higher Net debt in the second half was driven by lower than anticipated profits and associated cashflows. The key Net Leverage Ratio is at 1.9x, whilst the Interest Cover Ratio is at 9.1x with both metrics being well within our banking covenants. Given this headroom in covenants, the Board approved a 3-year extension to the banking facility with an increased limit of a further $20m.
5
Monash IVF Group Limited Directors' Report 30 June 2026 Consolidated statement of financial position and capital metrics (continued) Plant and equipment increased by $14.6m driven by higher capex less applicable depreciation expense. Lease liabilities increased by $8.7m primarily due to the present value of future cash rent payments on new, long-term leased facilities in Brisbane. Consolidated statement of cash flows
2026 $'000
EBITDA(1) Movement in working capital Income taxes paid Net operating cash flows (post-tax) Capital expenditure Payments for businesses Proceeds from sale of business Cash flows used in investing activities Free cash flow(1) Dividends paid Dividends paid to non-controlling interest Interest on borrowings Lease incentives received Payments of lease liabilities Net proceeds from borrowings Cash flows (used)/from financing activities Net cash flow movement Effects of exchange rates Closing cash balance (1)
43,510 (4,816) (1,994) 36,700 (23,769) (23,769) 12,931 (4,676) (732) (6,495) 1,789 (14,234) 11,000 (13,348) (417) (168) 8,842
2025 $'000 65,431 (49,645) (2,884) 12,902 (14,427) (3,039) 35 (17,431) (4,529) (19,871) (4,017) (12,446) 39,000 2,666 (1,863) (43) 9,427
Change $'000 (21,921) 44,829 890 23,798 (9,342) 3,039 (35) (6,338) 17,460 15,195 (732) (2,478) 1,789 (1,788) (28,000) (16,014) 1,446 (125) (585)
Change % (34%) (90%) (31%) 184% 65% (100%) (100%) 36% (386%) (76%) 62% 14% (72%) (601%) (78%) 291% (6%)
EBITDA and free cash flow are non-IFRS measures.
Free cash flow above was impacted by reduced EBITDA which was down 34% on last year, which is explained earlier in this report. Working capital for 2026 increased by $4.8m during the year, primarily due to the timing of GST receivables and higher inventories, which increased by $1.4m to mitigate potential supply chain disruptions. The business continued to invest substantial capital expenditure to upgrade our facilities and systems, which are outlined below. The $23.8m of capital expenditure (PPE and Intangibles) included: ● $10.9m spent towards Brisbane fertility clinic and day hospital; ● $7.9m spent towards laboratory (clinical) and medical equipment; and ● $5.0m spent towards IT hardware and associated systems. Interest payments increased by $2.5m, reflecting higher borrowings and brought forward timing of interest coupon upon facility extension. Dividends Dividends paid during the financial year were as follows: Consolidated 2026 2025 $'000 $'000 Fully franked final dividend for the year ended 30 June 2026 of 1.3 cents (2025: 2.5 cents) per ordinary share Fully franked interim dividend for the year ended 30 June 2026 of 1.2 cents (2025: 2.6 cents) per ordinary share
6
5,065
9,742
4,676
10,129
9,741
19,871
Monash IVF Group Limited Directors' Report 30 June 2026 Dividends (continued) Monash IVF Group’s dividend policy is to target a payout ratio of between 60% and 70% of Underlying NPAT(1). The level of payout ratio is expected to vary between periods depending on general operating conditions, operating cashflow and profit, funding, strategic growth opportunities and availability of franking credits. Subsequent to 30 June 2026, the Board elected to declare a final fully franked dividend for the year of 1.3 cents per share, reflecting the improved outlook and stabilised FY2026 earnings. The record date for the final dividend is 4 September 2026 and the expected dividend payment date is 15 October 2026. (1)
Non-IFRS measure.
Commitments and contingencies Other than what is disclosed below, the Group may be involved in legal claims, administrative actions, and proceedings related to the normal conduct of its business including, among other things, medical malpractice, general liability, commercial, employment, and intellectual property matters. Based upon existing information, it is not always possible to predict with certainty the outcome or cost of current legal claims, actions, and proceedings. The Group establishes accruals for estimated costs associated with such matters in a manner that complies with applicable accounting standards. The Directors believe that current matters of which they are aware, should not significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in subsequent financial periods. Contingent asset The Board has considered the recoverability of professional and ancillary costs incurred in relation to claims that have been lodged and settled by the Group. The Board considers that these items are recoverable against our policy on a more likely than not that basis. The Group currently estimates that the potential insurance recoverable is up to $2.8 million. Pursuant to AASB 137 Provisions, Contingent Liabilities and Contingent Assets, the potential insurance recoveries have not been recognised as an asset as receipt of the recoveries is not considered virtually certain at the reporting date. The recoveries will be recognised when receipt becomes virtually certain. Outlook The Company enters FY27 with improved performance and the benefits of strategic initiatives expected to build through the year. The Company’s largely completed infrastructure investment program, refreshed leadership structure and Nurture 2030 strategy are intended to support improved volume growth, margin recovery and returns over the medium term. Structural IVF demand remains compelling over the short to medium term. Monash IVF also welcomes forthcoming national ARS regulatory reform to support higher standards across the sector and the Company has established strong clinical governance, systems, scale and demonstrated patient outcomes. The Company is engaged with governments and regulators and is preparing for the implementation of national ARS standards. Liquidity As at 30 June 2026, the consolidated statement of financial position reflects a net current liability position of $21.6m (30 June 2025: $19.7m) and a net total asset position of $253.5m (30 June 2025: $250.4m). The Directors have assessed that based on the Group’s position it is appropriate to prepare the financial report on a going concern basis. For further information, refer to note 1 of the financial statements. Business strategies and prospects for future financial years The Company’s strategy is expected to deliver sustainable growth through improved patient and doctor value proposition and clinic utilisation. The strategy revolves around organic growth, improving operating leverage for future opportunities, with a FY27 focus on Victoria and NSW. Business risks The macro economic environment remains challenging with global geopolitical instability, economic uncertainty, inflationary pressures continuing to place pressure on supply chains and influence consumer spending habits.
7
Monash IVF Group Limited Directors' Report 30 June 2026 Business risks (continued) Monash IVF Group’s integrated enterprise risk management processes support the identification, management and oversight of clinical, operational and financial risks through appropriate governance forums. Each enterprise risk is assigned to an Executive Leadership Team owner and is subject to regular review, control monitoring, assessment and reporting against the Group’s risk appetite. Principal risks include: Patient Safety and Clinical Quality Patient safety, including the safe handling and storage of biological material, is fundamental to Monash IVF Group’s ART services. The Group maintains clinical governance, quality systems, training, monitoring and incident management processes to support safe, high-quality care and protect the interests of patients and future families. Regulatory and Compliance The regulatory environment for assisted reproductive technology and diagnostic imaging continues to evolve across the jurisdictions in which Monash IVF Group operates. Monash IVF Group actively monitors regulatory developments, engages with industry and regulators, and maintains governance and compliance frameworks to support readiness for new and emerging obligations, including the development of ARTspecific National Safety and Quality Health Service Standards. Cyber Security and Privacy Cyber security and privacy remain critical risks for healthcare organisations due to the sensitive personal and clinical information held and the increasing reliance on digital systems. Monash IVF Group continues to invest in cyber security capability, privacy controls and system safeguards. These activities support the protection of patient information, service continuity and organisational resilience. Digital Health and Artificial Digital health and artificial intelligence present opportunities to improve care, efficiency Intelligence and decision-making, while also creating risks relating to clinical safety, privacy, data governance, cyber security and ethical use. As these technologies are embedded into ways of working, Monash IVF Group will continue to assess their safe and effective use within appropriate governance and risk controls. Supply Chain Resilience Supply chain resilience remains an ongoing area of focus in the current global environment. Geopolitical tensions, economic uncertainty, inflationary pressures, energy market volatility and disruption to key trade routes may affect the availability and cost of critical goods and services. Monash IVF Group continues to monitor critical suppliers, procurement dependencies, inventory risks and contingency arrangements to support service continuity. Business Continuity and Business continuity and operational resilience are important to maintaining patient Operational Resilience services, clinical operations and organisational performance during periods of disruption. Monash IVF Group maintains business continuity and disaster recovery planning processes to support preparedness, response and recovery in the event of cyber incidents, supplier disruption, infrastructure impacts, workforce constraints or external emergencies. Workforce Sustainability and Monash IVF Group’s workforce is central to delivering safe care and sustaining the Wellbeing organisation. The complexity of healthcare, including high levels of attention, task switching and workload demands, can increase the risk of error if not effectively managed. Supporting workforce wellbeing, capability and safe systems of work remains essential to maintaining patient safety, service quality and organisational resilience. Clinician Engagement and The attraction, retention and engagement of clinicians, senior leaders and people in key Leadership Capability roles is important to service quality, growth and organisational continuity. Monash IVF Group supports leadership capability, succession planning, professional development, engagement strategies and a patient-centred culture to help attract and retain critical talent. The Group remains focused on strengthening its risk management maturity and organisational resilience while continuing to deliver safe, high-quality care for patients.
8
Monash IVF Group Limited Directors' Report 30 June 2026 Significant changes in the state of affairs During the financial year, the Group continued its Board renewal and succession planning process. As part of this process, Dr Dwayne Crombie was appointed as a Non-Executive Director on 24 November 2025 and Dr Victoria Atkinson was appointed as Managing Director and Chief Executive Officer on 5 January 2026. The Group also refreshed its executive leadership team, with changes to a number of senior leadership roles to support the execution of the Group’s strategic priorities. Other than these Board and leadership changes, and as otherwise disclosed in this report, there were no significant changes in the state of affairs of the Group during the financial year. Matters subsequent to the end of the financial year No matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years. Likely developments and expected results of operations Likely developments in the operations of the Group and the expected results of those operations in subsequent financial years have been discussed where appropriate in the operating and financial review. Information on Directors Name: Title: Qualifications: Experience and expertise:
Mr Richard Davis Independent Chair Bachelor of Economics from the University of Sydney Mr. Richard Davis joined Monash IVF Group in June 2014. Up until recently, Richard served as a non-executive director of ASX listed companies, InvoCare Limited and Australian Vintage Limited (Chairman) having resigned from these directorships in 2023 and 2024 respectively. Richard worked for InvoCare for 20 years until 2008.
Other current directorships: Former directorships (last 3 years): Special responsibilities: Interests in shares: Name: Title: Qualifications: Experience and expertise:
Other current directorships: Former directorships (last 3 years): Special responsibilities: Interests in shares:
For the majority of that time he held the position of CEO and managed the growth of that business through a number of ownership changes and over 20 acquisitions, including offshore in Singapore. Prior to InvoCare Limited, Richard worked as an accounting partner of Bird Cameron. None InvoCare Limited, Australian Vintage Limited Member of Remuneration and Nomination Committee Member of Audit and Risk Committee 182,067 ordinary shares Ms Catherine West Independent Non-Executive Director Bachelor of Laws (Hons) and a Bachelor of Economics from the University of Sydney Ms Catherine West is an experienced ASX listed non-executive director and has over 25 years of legal, business affairs and strategy experience in customer focused businesses in the media, entertainment, telecommunications and medical sectors in Australia, the UK and Europe. Catherine is a Non-Executive Director of Peter Warren Automotive Group. In addition, she is Chair of NIDA, Non-Executive Director of the NIDA Foundation Trust and Chair of the Board of Governors of Wenona School. Catherine was Chair of Nine Entertainment until November 2025 and a Director of the Sydney Breast Cancer Foundation Limited until her resignation on 30 June 2024. Peter Warren Automotive Group, NIDA Foundation Nine Entertainment Member of Remuneration and Nomination Committee 37,100 ordinary shares
9
Monash IVF Group Limited Directors' Report 30 June 2026 Information on Directors (continued) Name: Title: Qualifications: Experience and expertise:
Other current directorships: Former directorships (last 3 years): Special responsibilities: Interests in shares: Name: Title: Qualifications: Experience and expertise:
Ms Zita Peach Independent Non-Executive Director Bachelor of Science, FAICD, FAMI Ms Zita Peach has more than 35 years of commercial experience in the pharmaceutical, biotechnology, medical devices and health services industries, and has worked for major industry players such as CSL Limited, Fresenius Kabi and Merck Sharp & Dohme, the Australian subsidiary of Merck Inc. Zita is a Non-Executive Director of Icon Group Pty Ltd, Vet Partners Pty Ltd and Nucleus Network Pty Ltd. Zita is also the Chair of the Olivia Newton John Cancer Research Institute. None Pacific Smiles Group Limited Chair of Remuneration and Nomination Committee 92,803 ordinary shares Ms Catherine Aston Independent Non-Executive Director Bachelor of Economics (Macquarie University) and Master of Commerce, Accounting & Law (University of NSW) Ms Catherine Aston is an experienced Non-Executive Director / Chair of listed and unlisted entities covering technology, financial services, marketing services, health and government sectors across Australia and Asia. Catherine has a broad commercial background with executive roles in finance, marketing and strategy, including as CFO for Telstra International and Chief Executive Officer of a mobiles joint venture in Sri Lanka. Catherine is currently a Non-Executive Director of IVE Group Ltd (Chair of the Audit and Risk Committee) and IMB Bank Ltd (Chair of Capital and Securitisation Committee). Catherine is Chair of Macquarie Investment Management Ltd and was a Director of Integrated Research Limited until March 2024.
Other current directorships: Former directorships (last 3 years): Special responsibilities: Interests in shares: Name: Title: Qualifications:
Catherine is a Graduate of the Australian Institute of Company Directors and a Senior Fellow of the Financial Services Institute of Australasia (FINSIA). IVE Group Limited, IMB Bank Ltd Macquarie Investment Management Limited, Integrated Research Limited Chair of Audit and Risk Committee Member of Remuneration and Nomination Committee 2,000 ordinary shares
Experience and expertise:
Mr Neil Broekhuizen Independent Non-Executive Director Chartered Accountant and holds a Bachelor of Science (Eng) Honours degree from Imperial College, University of London Mr. Neil Broekhuizen is the Joint Chief Executive Officer of Ironbridge.
Other current directorships: Former directorships (last 3 years): Special responsibilities: Interests in shares:
Neil has over 35 years' experience in the finance industry including 29 years in private equity with Investcorp and Bridgepoint in Europe and Ironbridge in Australia. He has sat on the Ironbridge Investment Committee since inception. None Bravura Solutions Limited Member of Audit and Risk Committee 350,000 ordinary shares
10
Monash IVF Group Limited Directors' Report 30 June 2026 Information on Directors (continued) Name: Title: Qualifications: Experience and expertise:
Other current directorships: Former directorships (last 3 years): Interests in shares: Name: Title: Qualifications: Experience and expertise:
Dr Richard Henshaw Executive Director MD FRANZCOG FRCOG Dr Richard Henshaw, MD FRANZCOG FRCOG, has practiced in the field of reproductive medicine since 1995. Richard worked as a Fertility Specialist for the Group and retired from clinical practice in July 2025. Richard has served on many national bodies, including RANZCOG Council, the IVF Medical Directors Group of Australia and New Zealand, and the Reproductive Technology Accreditation Committee. None None 1,358,842 ordinary shares Dr Dwayne Crombie Independent Non-Executive Director (appointed on 24 November 2025) MB ChB, D Com H, FAFPHM, NZCPHM Dr Dwayne Crombie's experience has spanned in public hospital provision, community-based, mental health and disability services. It has also included funding of public health and disability services, aged care, private health insurance and private healthcare. Dwayne originally trained in medicine and specialised in public health before moving on to senior management roles. He worked for global healthcare organisation Bupa for more than 15 years in several Managing Director roles. He most recently led Bupa Australia's health services and insurance businesses before retiring in 2022.
Other current directorships: Former directorships (last 3 years): Interests in shares: Name: Title: Qualifications: Experience and expertise:
Dwayne's current governance roles include Southern Cross Healthcare, Southern Cross Travel, Repromed New Zealand and InLife Independent Living. None None Nil Dr Victoria Atkinson Managing Director & Chief Executive Officer (appointed on 5 January 2026) MBBS, FRACS, RMHM AFRACMA, GAICD Dr Victoria Atkinson is a distinguished healthcare executive with over 30 years' experience spanning clinical, operational, and governance leadership across Australia's public, private and not-for-profit health sectors. Victoria's previous role was Chief Medical Officer at Healthscope, where she oversaw clinical strategy, governance, risk, medical affairs and medico-legal nationwide. Prior to Healthscope, Victoria was the national Chief Medical Officer and Group General Manager of Clinical Governance at St Vincent's Health Australia and previously, was the Director Medical Governance at Melbourne Health, combining this with an active clinical role.
Other current directorships: Former directorships (last 3 years): Special responsibilities: Interests in shares:
Victoria is a cardiothoracic surgeon by training, with a Masters in Health Management. Victoria is currently a Non-Executive Director of the McGrath Foundation Board and Medical Indemnity Protection Society Ltd (MIPS). Victoria retired from Opal Aged Care in May 2026. None None None Nil
11
Monash IVF Group Limited Directors' Report 30 June 2026 Information on Directors (continued) 'Other current directorships' quoted above are current directorships for listed entities only and excludes directorships of all other types of entities, unless otherwise stated. 'Former directorships (last 3 years)' quoted above are directorships held in the last 3 years for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.
Company Secretary Rebecca Dean (appointed on 4 March 2026) Ms Rebecca Dean was appointed to the role of Company Secretary and General Counsel on 4 March 2026. A trusted governance and legal leader, Rebecca brings extensive experience in ASX-listed, health, aged care and highly regulated environments. Prior to joining Monash IVF Group, Rebecca held senior leadership roles at Regis Healthcare Limited and SEEK Limited. Rebecca holds a Bachelor of Laws (Honours) from La Trobe University and a Bachelor of Commerce/Bachelor of Arts from Monash University. She is admitted as a barrister and solicitor of the Supreme Court of Victoria and is a graduate of the Australian Institute of Company Directors Company Directors Course. Malik Jainudeen (resigned on 2 April 2026) Mr Malik Jainudeen was appointed to the role of Monash IVF Company Secretary on 15 April 2019 and resigned on 2 April 2026. Meetings of Directors The number of meetings of the Company's Board of Directors ('the Board') and of each Board committee held during the year ended 30 June 2026, and the number of meetings attended by each Director were: Remuneration and Nomination Committee Attended Held
Full Board Attended Held Mr Richard Davis (Chair) Ms Catherine West Ms Zita Peach Ms Catherine Aston Mr Neil Broekhuizen Dr Richard Henshaw Dr Dwayne Crombie* Dr Victoria Atkinson**
20 20 18 20 14 19 14 11
20 20 20 20 20 20 14 11
3 3 3 3 2
Audit and Risk Committee Attended Held 3 3 3 3 3
4 4 4 2 2
4 4 4 2 2
Held: represents the number of meetings held during the time the Director held office or was a member of the relevant committee. * **
Attendance from the date of appointment, 24 November 2025. Attendance from the date of appointment, 5 January 2026.
Environmental regulation In relation to environmental regulation under Australian Commonwealth law, the following disclosure standard will soon become effective. AASB S2 ‘Climate-related Disclosures’ sets out specific climate related disclosures. It applies to entities required to prepare and lodge a financial report with ASIC under Chapter 2M of the Corporations Act 2001 and is effective for different entities based on certain criteria. This mandatory sustainability reporting will be applicable to the Company for the first time for the year ending 30 June 2027. Environmental, Social and Governance In developing our sustainability actions, Monash IVF Group has continued to prioritise the following UN Sustainable Development Goals. This will continue to be evaluated and refined as Monash IVF Group prepares to report against the AASB S2 Climate-related Disclosures Standards from 1 July 2026.
12
Monash IVF Group Limited Directors' Report 30 June 2026 Environmental, Social and Governance (continued) The below provides a summary on the Group’s Sustainability Strategy to highlight the key areas of focus where the Group can achieve the maximum impact in delivering safe, effective healthcare services, that give every person the best opportunity to create or grow their family.
13
Monash IVF Group Limited Directors' Report 30 June 2026 Letter from the Chair of Remuneration and Nomination Committee Dear Shareholders, On behalf of the Board, I am pleased to present Monash IVF Group’s 2026 Remuneration Report. FY26 was a year of significant transition for the Group, with changes to senior leadership, continued Board renewal and a challenging operating environment. The Committee’s focus throughout the year has been to ensure that remuneration outcomes are aligned with shareholder experience, business performance, executive contribution, patient and clinical outcomes, and the need to retain and motivate the leadership required to execute the Group’s new strategic priorities. As outlined in the overall commentary at the start of the Directors Report, FY26 performance was impacted by softer Australian market conditions, lower domestic market share and inflationary cost pressures, partly offset by growth in International and ancillary revenue streams. The Board has considered these factors carefully in determining FY26 remuneration outcomes. In assessing executive remuneration for FY26, the Committee has applied a disciplined approach. While management has continued to progress important operational and cost efficiency initiatives, strengthen the clinical network and prepare the business for improved performance in FY27, the Committee recognises that the Group’s financial performance was below original expectations and that shareholder returns remained under pressure. Remuneration outcomes have therefore been assessed having regard to the overall shareholder experience, the revised earnings outlook, progress against strategic and operational priorities, and the importance of maintaining leadership stability during a period of change. As the financial targets were not met, 70% of the STI opportunity was not payable to KMP. In addition, no LTI award vested because the applicable performance hurdles were not achieved. FY26 also involved a number of important leadership changes. Dr Victoria Atkinson commenced as Managing Director and Chief Executive Officer on 5 January 2026, bringing deep clinical, operational and governance experience to the Group. Since Dr Atkinson’s appointment a refreshed leadership team has been established. The Board renewal process progressed during the year, with the appointment of Dr Dwayne Crombie as an Independent NonExecutive Director on 24 November 2025. Richard Davis will step down as Chairman and retire from the Board in October 2026 after more than 12 years’ service as Chairman. Catherine West will be appointed Chairman upon Richard’s retirement. Neil Broekhuizen will retire following the announcement of the FY26 full year results and Dr Richard Henshaw will retire in October 2026. The Board thanks Richard and Neil for their significant contributions and leadership. The Board is also pleased to announce the appointment of Gerd Schenkel as a new Non-Executive Director, effective 1 September 2026, and will continue its recruitment for another Non-Executive Director. The Committee remains committed to a remuneration framework that is simple, transparent and aligned to long-term value creation. For 2026, this meant ensuring that fixed remuneration remains market appropriate, that variable reward outcomes are genuinely performance-based, and that any incentive outcomes appropriately reflect both financial results and nonfinancial priorities, including patient experience, clinical quality, doctor engagement, operational improvement, people engagement and governance. The Committee believes that a clear link between pay for performance reinforces shareholder alignment. Looking ahead, the Committee will continue to review the remuneration framework to ensure it supports the execution of the Group’s strategy, including the delivery of operational efficiencies, growth in international markets, strengthening of the clinical network, continued investment in technology and systems, and disciplined capital management. We will also continue to consider feedback from shareholders and other stakeholders as we refine our approach. On behalf of the Committee, I thank shareholders for their continued support and engagement. We remain focused on ensuring remuneration outcomes are fair, responsible and aligned with the interests of shareholders, patients, doctors and our people.
Ms Zita Peach Chair of Remuneration and Nomination Committee
14
Monash IVF Group Limited Directors' Report 30 June 2026 Remuneration report (audited) 1.0 Remuneration Governance 1.1 Remuneration Governance Framework Committee Structure and Membership The Monash IVF Group Board is responsible for the overall governance of remuneration matters. To support the Board in fulfilling this responsibility, the Remuneration and Nomination Committee (the Committee) operates under the authority of the Remuneration and Nomination Committee Charter. In accordance with the Charter, the Committee must comprise at least three members, the majority of whom (including the Chair) must be independent and all of whom must be Non-Executive Directors. As at 2026, the Committee consists of four independent Non-Executive Directors: ● Ms Zita Peach (Chair) ● Mr Richard Davis ● Ms Catherine West ● Ms Catherine Aston The Committee met 3 times during 2026, with full attendance by all members, in addition to out of cycle informal meetings to address leadership and board renewal matters. The CEO, CFO, Chief People and Culture Officer, and other Non-Executive Directors (who are not Committee members) may be invited to attend Committee meetings to provide input, except where matters relate to their own remuneration or performance. In 2026, the Committee did not seek any remuneration recommendations as defined under section 9B of the Corporations Act 2001. Key Responsibilities of the Committee The Committee is responsible for reviewing and making recommendations to the Board in the following areas: Remuneration Strategy and Executive Reward ● Group-wide remuneration principles, strategy and policy. ● Executive remuneration packages, including fixed and variable components. ● Design, operation and terms of short- and long-term incentive plans (STI and LTI), including:
- Eligibility, performance metrics and targets,
- Plan rules, disposal restrictions, escrow arrangements,
- Application of malus and clawback provisions. ● Terms and conditions of Executive and Doctor Service Agreements (e.g., notice periods, restraints). ● Termination payments and treatment of outstanding incentives upon cessation of employment. Non-Executive Director Remuneration ● Framework for Non-Executive Director fees, including allocation, aggregate fee pool, benchmarking, and consideration of workload and roles. Appointments and Succession ● Appointment and succession planning for the CEO and senior executives. ● Director succession planning and Board renewal. ● Appointment of new Directors, and regular review of Board and Committee composition. ● Board Skills Matrix. Governance, Culture and Diversity ● Monitoring of industry remuneration benchmarks to ensure competitiveness. ● Assessment of performance outcomes for the purposes of incentive plan payments. ● Monitoring of employee engagement and organisational culture. ● Oversight of diversity and inclusion initiatives, including gender pay equity reporting and associated action plans. ● Board effectiveness and performance. The Remuneration and Nomination Committee Charter is available on the Company’s website at www.monashivfgroup.com.au/investor-centre/corporate-governance. The Charter is reviewed annually. Further information on the Remuneration and Nomination Committee is provided in the Corporate Governance Statement in this Financial Report.
15
Monash IVF Group Limited Directors' Report 30 June 2026 1.0 Remuneration Governance (continued) 1.2 Principles of remuneration and framework Monash IVF Group’s approach to remuneration remains consistent and aligned with our overarching objectives and guiding principles. The following section outlines the key principles that underpin the structure of Executive Remuneration arrangements across the Group. Remuneration principles Principle
Design and Operational Implications of remuneration framework
Aligned to organisation's strategy ▪ The remuneration framework aligns with the Group’s overall business strategy and and business priorities supports the attraction and retention of key personnel who deliver shareholder value. ▪ Operates in support of Our Principles and reinforces the organisation’s desired culture. ▪ Incentives are designed to reward results and the behaviours demonstrated in achieving them. Market competitive
▪ Remuneration for all employees, including Executive Key Management Personnel (KMP), is fair and competitive, reflecting role accountability, market benchmarks, skills, experience, and performance. ▪ Remuneration decisions are informed by independent and relevant market benchmarking.
Performance based
▪ Incorporates both short-term and long-term incentive components, linked to performance outcomes. ▪ Incentive structures are designed for individuals who directly impact organisational performance. ▪ Performance targets are set with reference to past performance, forecasts, and approved budgets, with thresholds required for incentive payout.
Simple and transparent
▪ The remuneration framework is simple, scalable, and consistent across the organisation, supporting sustainable growth. ▪ The structure is clearly communicated and reinforces the Group’s mission, values, and culture.
Effective governance
▪ The Remuneration and Nomination Committee and Board ensure remuneration outcomes are aligned with both risk and performance. ▪ Remuneration arrangements are regularly reviewed and comply with all applicable legal and regulatory requirements. ▪ The framework promotes ethical and responsible behaviour. ▪ Variable remuneration is subject to malus and clawback to protect against unearned or inappropriate outcomes.
Alignment to Patient, People and ▪ Outcomes for Patients, People, and Doctors are integrated into variable Doctor outcomes remuneration metrics for Executive KMP and management, ensuring alignment with broader stakeholder expectations. 2.0 Remuneration Structure 2.1 Executive Remuneration structure The Group’s remuneration structure is designed to reflect the principles outlined above, balancing fixed and variable components to support performance, align with shareholder interests, and ensure market competitiveness. Remuneration arrangements for KMP and other Executives include a mix of fixed remuneration variable incentives that are aligned to both short- and long-term strategic objectives. The structure is intended to drive sustainable performance, retain and attract highcalibre talent, and reinforce accountability.
16
Monash IVF Group Limited Directors' Report 30 June 2026 2.0 Remuneration Structure (continued) Total Fixed Remuneration (TFR)
Purpose of each remuneration component Short-Term Incentive (At Risk)
To attract and retain, Rewards performance for achieving paying competitively, reflecting the stretch targets and further rewards the individual’s accountability, position achievement of both financial and nonrequirements and experience. TFR is financial goals. determined as base salary and inclusive of all standard leave provisions, salary Achievement is measured using an sacrifice items, any associated FBT and annual balanced scorecard of measures superannuation guaranteed aligned to the organisations strategic contributions. vision and objectives and includes a non-financial gateway of success rates.
Long-Term Incentive (At Risk)
Rewards and retains key contributors by creating alignment with long-term shareholder interests and rewards the creation of sustainable shareholder wealth.
Modifier applies from 2026 ensuring outcomes reflect the experience of stakeholders. Monash IVF Group has maintained a consistent remuneration framework in FY26 for the Chief Executive Officer (CEO), Chief Financial Officer (CFO) and Chief Operating Officer (COO). The framework retains the three elements of fixed remuneration and at-risk components being STI and LTI. The remuneration structure aligns the total remuneration opportunity with the size of role and position accountability, reinforcing pay for performance and shareholder alignment. 2.2 Executive Remuneration Structure for FY26 The diagram below summarises the framework for FY26. The framework continues to be reviewed each year. Performance Driven
Alignment with Shareholder Interests
Total Fixed Remuneration (TFR) TFR is determined based on market rates. Where applicable, individual role accountability and complexity alongside the individual’s experience relative to position requirements are considered. TFR Comprises of: • Cash salary • Salary sacrifice items and any associated Fringe Benefits Tax (FBT) • Employer superannuation contributions in line with statutory regulations
Market Competitive Remuneration
At Risk Remuneration Short-Term Incentive (STI) Long-Term Incentive Plan (LTI) Balanced Scorecard Model that includes Earnings per Share (EPS) growth a Non-financial Gateway (ANZARD(1)) hurdles based on predefined growth Success rate average. rates over a 3-year period (70%). 70% financial Measure based on Underlying NPAT(2).
Total Shareholder Return (TSR) hurdles based on Group’s relative TSR performance against ASX300 Healthcare Index (excluding CSL) over a 3-year period (30%)
TFR levels are reviewed annually by the Non-financial measures (30%) are linked Comprise performance rights which vest Committee through a process that to key strategic initiatives built around a in accordance with 3-year EPS growth considers the experience in the position balanced scorecard. These measures and relative TSR being above threshold and the relevant external market, are focused on long-term sustainable performance requirements. including industry benchmarks. growth including but not limited to: TFR is also reviewed on promotion.
- Engagement (Employee, Patient and There are no guaranteed increases in Doctor) executive remuneration.
- Market share growth
- Scientific Success Rates
- Strategic Project Milestones and Outcomes
17
Monash IVF Group Limited Directors' Report 30 June 2026 2.0 Remuneration Structure (continued) (1)
Australia and New Zealand Assisted Reproduction Database.
(2)
Underlying NPAT is a non-IFRS measure that adjusts profit after tax for certain non-regular items.
3.0 Executive and Non-Executive Remuneration 3.1 Executive Remuneration Key Management Personnel (% of Total Maximum Pay)
Fixed Pay
Dr Victoria Atkinson (from 5 January 2026) Mr. Malik Jainudeen (from 1 July 2025 to 5 March 2026)(1) Mr. Malik Jainudeen (from 6 March 2026 to 2 April 2026)(2) Dr. Richard Henshaw Rebecca Redden
50.0% 39.7% 47.6% 100.0% 58.8%
(1)
In his role as Acting CEO & Company Secretary.
(2)
In his role as CFO & Company Secretary.
STI 25.0% 19.8% 23.8% 23.5%
LTI 25.0% 23.8% 28.6% 17.6%
At Risk 50.0% 43.7% 52.4% 41.2%
KMP
Component
Commentary
Dr Victoria Atkinson – Chief Executive Officer & Managing Director For the period of 5 January 2026 – 30 June 2026
TFR
5 January to 30 June 2026 - $800,000 per annum (pro rata)
KMP
STI
The CEO had the opportunity to earn a maximum annual incentive of 50% of total fixed remuneration pro rata based on meeting certain defined criteria. The 2026 STI was subject to both financial (70%) and non-financial (30%) outcomes and meeting a gateway of the clinical pregnancy rate at or above the ANZARD mean. LTI (performance rights) The CEO had the opportunity to earn a maximum LTI of 50% of TFR calculated on a pro rata basis from commencement date of 5 January 2026, subject to shareholder approval at the 2026 Annual General Meeting. This is equivalent to 134,671 performance rights.
Notice period Term of Agreement
These rights vest in accordance with 3-year EPS growth and relative TSR being above threshold performance requirements. 6 months No Fixed Term
Component
Commentary
Mr. Malik Jainudeen - Acting CEO & TFR Company Secretary For the period of 1 July 2025 5 March 2026 STI and LTI (performance rights) Chief Financial Officer & Company Secretary For the period of 6 March 2026 – 2 April 2026
Effective from 1 July 2025 to 5 March 2026 a higher duties allowance of $228,000 pro rata per annum was payable for an aggregate of $629,007 pro rata per annum. No STI was payable and the FY26 LTI was forfeited due to the CFO’s resignation and departure from the business on 2 April 2026. TFR 6 March 2026 to 2 April 2026 - $460,000 per annum STI No STI was payable due to the CFO’s resignation and departure from the business on 2 April 2026. LTI (performance rights) The CFO had the opportunity to earn a maximum LTI of 60% of TFR. All on foot LTI (2024, 2025 and 2026) were forfeited due to his resignation and departure from the business on 2 April 2026. Notice period 3 months Term of Agreement No Fixed Term 18
Monash IVF Group Limited Directors' Report 30 June 2026 3.0 Executive and Non-Executive Remuneration (continued) KMP
Component
Dr. Richard Henshaw - Executive Director
TFR
KMP
Component
Commentary
Dr. Henshaw had the opportunity to earn a total TFR of $366,289. Dr. Henshaw was the only doctor during 2026 who served as a Director. He was paid a salary for his clinician duties and medical leadership and as a Director. STI Not eligible for a STI payment LTI (performance rights) Not eligible for a LTI offer Notice period 6 months Term of Agreement No Fixed Term Commentary
Rebecca Redden - Chief Operating TFR Officer (COO) For the period of 18 August 2025 – STI 30 June 2026
18 August 2025 to 30 June 2026 - $430,000 pro rata per annum. The COO had the opportunity to earn a maximum annual incentive of 40% of TFR based on meeting certain defined criteria. The 2026 STI was subject to both financial (70%) and non-financial (30%) outcomes and meeting a gateway of the clinical pregnancy rate is at or above the ANZARD mean. LTI (performance rights) The COO had the opportunity to earn a maximum LTI of 30% of TFR. These rights vest in accordance with 3-year EPS growth and relative TSR being above threshold performance requirements. Notice period 6 months Term of Agreement No Fixed Term
3.2 Non-Executive Director (NED) Remuneration policy Under the Constitution, the Directors decide the total amount paid to all Directors as remuneration for their services as Directors. However, under the ASX Listing Rules, the total amount paid to all Directors for their services must not exceed in aggregate in any financial year, the amount approved by shareholders in a general meeting. The maximum annual amount approved is $950,000. For the 2026 financial year, the fees payable to the current NEDs were $745,474, inclusive of superannuation, with no increase compared to FY25. Role Fees Chair(1) Other Non-Executive Directors Additional Fees Audit and Risk Committee – Chair Audit and Risk Committee – Member Remuneration and Nomination Committee – Chair Remuneration and Nomination Committee – Member (1)
2026 $
2025 $
200,000 102,000
200,000 102,000
20,000 10,000 20,000 10,000
20,000 10,000 20,000 10,000
Chair Fee is inclusive of committee fees.
At the 20 November 2025 AGM, 91.71% of the votes received supported the adoption of the remuneration report for the year ended 30 June 2025.
19
Monash IVF Group Limited Directors' Report 30 June 2026 4.0 At-Risk remuneration framework Each year, the Remuneration and Nomination Committee, in collaboration with the CEO, sets performance targets for the upcoming financial year. These targets are developed with reference to the Group’s strategic objectives and financial results from the prior year. The Committee may adjust performance targets where there are material changes to the operating environment. Such changes may include, but are not limited to, significant events, alterations to the capital structure, or material acquisitions or divestments. Any adjustments are made in accordance with applicable ASX Listing Rules. The Board retains discretion to adjust incentive outcomes where it considers this necessary to preserve the intent and purpose of the incentive plan and performance standards and to reflect the experience of stakeholders. This includes ensuring that participants are not materially advantaged or disadvantaged relative to the position reasonably anticipated at the time the performance measures were set. The following table outlines the short-term and long-term incentive components for Executive KMP, including the relevant performance measures and delivery mechanisms applicable to the performance period ended 30 June 2026.
Incentive Opportunity CEO CFO COO
Short-Term Incentive (At Risk)
Short-Term Incentive (At Risk)
Short-Term Incentive (At Risk)
Long-Term Incentive (At Risk)
Long-Term Incentive (At Risk)
At Threshold
At Target
At Stretch
At Threshold
At Target
30% 30% 30%
100% 100% 100%
N/A 150% N/A
20% 20% 30%
Performance Measures
100% 100% 100%
• STI scorecard KPIs include financial and non- • LTI KPIs are Earnings Per Share growth financial measures (EPS) (70%) and relative Total Shareholder Return (TSR) (30%). • A non-financial gateway is in-place whereby no • TSR measures returns relative to performance STI is payable if the Group’s clinical pregnancy against ASX300 Healthcare Index (excluding rates (success rates) is below the ANZARD CSL) of a comparator group with hurdles average based on predefined growth rates over a 3 year period. • 70% of STI is based on Underlying NPAT • EPS compound annual growth rate (CAGR) provides a tangible measure of shareholder value creation with hurdles based on predefined growth rates over a 3 year period. • 30% of STI is based on specific, measurable, qualitative non-financial measures which include delivery of key strategic priorities • Pro-rata payment of STI is made if achievement is between threshold and target. Stretch is available where financial achievement is above target up to 150% Delivery Mechanisms • STI awards for the CEO, CFO and COO are • LTI awards are granted as performance rights, paid as cash and subject to continued subject to testing against the above employment at the time of audited results performance measures and continued announced to market. employment. • The CEO, CFO and COO were not required to pay any money to be granted performance rights. STI and LTI opportunities are expressed as a percentage of total opportunity to earn - refer to section 3.1
20
Monash IVF Group Limited Directors' Report 30 June 2026 4.0 At-Risk remuneration framework (continued) 4.1 2026 Short-Term Incentive Both the CEO and COO commenced their roles part way through the year (the COO commenced in August 2025 with the CEO commencing in January 2026). Financial and non-financial STI measures were developed in line with the At Risk Remuneration Framework and for the CEO are payable on a pro rata basis. The CFO forfeited his 2026 STI on resignation prior to the end of the financial year. The STI is subject to a non-financial gateway of the Group’s clinical pregnancy rates (success rates). The assessment period for the ANZARD average was 1 July 2025 to 30 April 2026. This period was applicable due to the availability of pregnancy outcomes information at the time of reporting. The available ANZARD target average applicable was 41.6%. The Group’s clinical pregnancy rates for the period between July 2025 to April 2026 was 44.6% and accordingly, the non-financial gateway to STI was achieved. The quantitative financial measure defined for the CEO and COO in 2026 was as follows: Financial Objective
Weighting
Underlying Net Profit After Tax 70% (NPAT)(1) (1)
Measure
2026 Outcome
Underlying NPAT was set at 2026 Group Budget ($21m) and threshold set at 95% ($20m)
Not achieved
Underlying NPAT is a non-IFRS measure that adjusts profit after tax for certain non-regular items, including the Class Action.
The qualitative non-financial measures defined for KMP in 2026 included the following: Strategic Objective
Weighting
Measure
MVF 2030 Strategic plan
10% CEO, COO
Develop and deliver the new Board Achieved endorsed strategic plan by date agreed with the Board. Board endorsed plan with Achieved achievement of all agreed FY26 milestones completed by end of FY26. Medical leadership model plan and Achieved costings completed by end of FY26.
Deliver Project Blueprint (Victorian) 10% CEO, plan COO Deliver medical leadership model 10% CEO, plan and costings COO
FY25 Outcome
4.2 2024 Long-Term Incentive No executives were eligible for LTI vesting in 2026. The EPS component of the 2024 performance rights was not achieved as at 30 June 2026 based on performance targets during 2024 - 2026. The formal testing of the TSR component of the 2024 performance rights granted will occur in September 2026. Financial Objective
Weighting
Earnings per share (EPS)
70%
Relative TSR
30%
Measure
2026 Outcome
Threshold – 10% per annum Threshold – Equal to index return
Not achieved Subject to testing in September 2026
4.3 2026 Long-Term Incentive grant The LTI plan is a performance rights scheme where vesting depends on meeting pre-established performance hurdles and maintaining continuous employment. Grants under the LTI plan are awarded annually to ensure Executives remain focused on sustainable long-term growth and returns, balancing with short-term incentives that target annual performance. 21
Monash IVF Group Limited Directors' Report 30 June 2026 4.0 At-Risk remuneration framework (continued) The terms and overview of the 2026 LTI grant to KMP and other eligible employees, are summarised below. Performance Rights Granted EPS Compound Annual Growth Rate ("EPS Hurdle") Relative Total Shareholder Return ("TSR Hurdle") 70% of allocation subject to the hurdle 30% of allocation subject to the hurdle Vesting Framework
Vesting Framework
The EPS component of the allocation will be measured at the The TSR component of the allocation will be measured at the end of the 3-year performance period: end of the 3-year performance period relative to the • 30% will vest at threshold performance - EPS threshold ASX300 Healthcare Accumulation Index (Index) excluding performance is 10% growth per annum over the 3-year CSL performance: period • 30% will vest at threshold performance - TSR equals index • 100% will vest at maximum performance - EPS threshold returns performance is 12% growth per annum over the 3-year • 100% will vest at maximum performance - TSR equals period index returns +5 percentage points on an annualised • Pro rata vesting between threshold and maximum basis • Pro-rata vesting between threshold and maximum The LTI award opportunity is based on a percentage of the participant’s total fixed remuneration as at the grant date. The number of performance rights issued is determined by dividing the long-term incentive component of the participant’s fixed remuneration by the volume weighted average price of Monash IVF Group Limited shares traded on the Australian Stock Exchange over the 10 trading days immediately following the release of the 2026 full-year results announcement (VWAP). The VWAP applied to the 2026 performance rights issue was $0.694. Performance rights were granted in two tranches during FY26. Executives did not pay any money to be granted the performance rights and the expiry date of the rights will be on the fifth anniversary of their grant. Details of the FY26 LTI grant to KMP is set out below: KMP
% of TFR
Performance rights granted
Dr Victoria Atkinson(1)
50%
Mr Malik Jainudeen (CFO) - forfeited due to resignation on 2 April 2026 Rebecca Redden
60%
(1)
EPS TSR EPS TSR EPS TSR
30%
Allocation
of performance
rights 70% 30% 70% 30% 70% 30%
403,289 172,838 242,583 103,964 130,061 55,740
Subject to shareholder approval at the AGM.
The performance periods and vesting schedules for the 2026 performance rights are set out in the following table: Earnings per Share (70% weighting) Relative TSR (30% weighting) Portion of performance 1 July 2025 to 30 June 2028 11 days after 2026 results announcement to 11 rights that will vest days after 2028 results announcement against the relevant target Less than 10% per annum Less than Index return 0% 10% per annum Equal to Index return 30% Between 10% to 12% per annum Between Index return and Index return +5% 30% - 100% pro rata At or above 12% per annum Equal to or less than Index return +5% 100% The graduated vesting scale in the LTI plan was designed to minimise the likelihood of excessive risk taking as a performance threshold is approached. The Board believes this vesting framework strengthens the performance link over the long-term and accordingly encourages Executives to focus on long term performance. The Board also acknowledges that the value of certain strategic initiatives may take several years to deliver.
22
Monash IVF Group Limited Directors' Report 30 June 2026 4.0 At-Risk remuneration framework (continued) Further terms and conditions of the LTI plan are as follows: Invitation The invitations issued to eligible persons will include information such as award conditions and, upon acceptance of an invitation, the Board will grant awards in the name of the eligible person. Awards may not be transferred, assigned or otherwise dealt with except with the approval of the Board. Lapse of award Awards will only vest where the conditions advised to the participant by the Board have been satisfied. An unvested award will lapse in a number of circumstances, including where conditions are not satisfied within the relevant time period, or in the opinion of the Board, a participant has committed an act of fraud or misconduct or gross dereliction of duty. If a participant’s engagement with the Company (or one of its subsidiaries) terminates before an award has vested, the Board may determine the extent to which the unvested awards that have not lapsed will become vested awards or, if the award offer does not so provide and the Board does not decide otherwise, the unvested awards will automatically lapse. Malus and clawback Awards are subject to malus and clawback conditions whereby the Board may, in its discretion, and subject to applicable laws, determine the performance rights or shares already allocated following the vesting or exercise of a performance right are forfeited, recovered or the conditions modified. The Board’s decision in regard to unfair benefits obtained by the participant is final and binding. Change of control Where there is a takeover bid or a scheme of arrangement proposed in relation to the Company, the Board may determine that the participant’s unvested awards will become vested awards. In such circumstances, the Board shall promptly notify each participant in writing that the awards have become vested awards, or that he or she may, within the time period specified in the notice and where applicable in accordance with the class or category of award, exercise such vested awards. A participant is not entitled to participate, in their capacity as holder of awards, in any new issue of shares in the Company, nor in any return of capital, buyback or other distribution or payment to shareholders, unless the Board determines otherwise. In the event of a bonus issue or rights issue, the rights of the award will be altered in a manner (if any) determined by the Board, consistent with the ASX Listing Rules. Capital reorganisation In the event of any reorganisation of the issued ordinary capital of the Company before the exercise of an award, the number of shares attached to each award will be reorganised in the manner specified in the LTI plan and in accordance with the ASX Listing Rules or, if the manner is not specified, the Board will determine the reorganisation. In any event, the reorganisation will not result in any additional benefits being conferred on participants which are not conferred on shareholders of the Company. Voting rights Participants who hold an award issued pursuant to the LTI plan have no rights to vote under the LTI award at meetings of the Company until that award has vested (and is exercised, if applicable) and the participant is the holder of a valid share in the Company. Shares acquired upon vesting of the award will, upon issue, rank equally in all respects with other shares. Regulatory requirements No award or share may be offered under the LTI plan if to do so would contravene the Corporations Act, the ASX Listing Rules or instruments of relief issued by ASIC from time to time. 5.0 Details of remuneration for Key Management Personnel 5.1 Key Management Personnel (KMP) KMP have authority and responsibility for planning, directing, and controlling the activities of the Group, directly or indirectly, including directors of the Company and other Executives. KMP comprise the directors of the Company and the senior Executives for the Group named in this report.
23
Monash IVF Group Limited Directors' Report 30 June 2026 5.0 Details of remuneration for Key Management Personnel (continued) Name Non-Executive Directors Mr Richard Davis Ms Catherine West Ms Zita Peach Ms Catherine Aston Mr Neil Broekhuizen Dr Dwayne Crombie Executive Directors Dr Richard Henshaw Dr Victoria Atkinson Other KMP Mr Malik Jainudeen
Ms Rebecca Redden
Position
Period covered under this Report
Non-Executive Chair Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director
Full Financial Year Full Financial Year Full Financial Year Full Financial Year Full Financial Year 24 November 2025 - 30 June 2026
Executive Director Managing Director and Chief Executive Officer
Full Financial Year 5 January 2026 - 30 June 2026
Chief Executive Officer and Company Secretary Chief Financial Officer and Company Secretary Chief Operating Officer
1 July 2025 - 5 January 2026 5 January 2026 - 2 April 2026 18 August 2025 - 30 June 2026
Details of the remuneration of key management personnel of the Group are set out in the following tables. Short-term employee benefits
Share-based payments
Post-employment benefits
Salary and fees
STI Cash incentive
Other benefit
Superannuation
2026
$
$
$
$
Non-Executive Directors: Mr Richard Davis Ms Catherine West Ms Zita Peach Ms Catherine Aston Mr Neil Broekhuizen Dr Dwayne Crombie
178,571 100,000 108,896 117,857 100,000 60,278
21,429 12,000 13,068 14,143 12,000 7,233
200,000 112,000 121,964 132,000 112,000 67,511
Executive Directors: Dr Richard Henshaw Dr Victoria Atkinson
291,961 352,248
58,191
21,769 27,336
30,000 15,000
(50,429) 6,196
293,301 458,971
462,478 324,235 2,096,524
61,130 119,321
49,105
24,231 30,000 179,104
4,640 (39,593)
215,072 215,072
(107,951) 12,371 (95,580)
593,830 432,376 2,523,953
Other KMP: Mr Malik Jainudeen Ms Rebecca Redden
24
Other long- Termination term benefits benefits $
$
Rights
Total
$
$
Monash IVF Group Limited Directors' Report 30 June 2026 5.0 Details of remuneration for Key Management Personnel (continued) Short-term employee benefits
Share-based payments
Post-employment benefits
Salary and fees
STI Cash incentive
Other benefit
Superannuation
2025
$
$
$
$
Non-Executive Directors: Mr Richard Davis Ms Catherine West Ms Zita Peach Mr Neil Broekhuizen Ms Catherine Aston Mr Josef Czyzewski
179,372 100,448 109,417 100,448 112,407 39,462
20,628 11,552 12,583 11,552 12,927 4,538
200,000 112,000 122,000 112,000 125,334 44,000
Executive Directors: Dr Richard Henshaw Mr Michael Knaap
336,357 623,842
34,465 2,764
29,932 30,000
(15,241) 16,093
334,173
(333,562)
385,513 673,310
383,217 344,972 2,329,942
9,917 7,990 55,136
30,000 30,000 193,712
9,852 41,798 52,502
334,173
62,355 (102,454) (373,661)
495,341 322,306 2,591,804
Other KMP: Mr Malik Jainudeen Mr Hamish Hamilton
Other long- Termination term benefits benefits* $
Rights
Total
$
$
$
Details of unvested performance rights and the movement during the financial year is detailed below: 2026 Hurdles
Name
Mr Malik Jainudeen TSR EPS TSR EPS TSR EPS TSR EPS
Ms Rebecca Redden
EPS TSR
Testing Grant date date
Expired/ lapsed / forfeited
Vested and unexerClosing cised unvested
Exercisable at 30 June 2026
FV per security
$
Opening*
Granted
Vested and exercised
Number
Number
Number
Number
Number
Number
Number
23/11/2022 11/09/2025 23/11/2022 11/09/2025 28/11/2023 11/09/2026 28/11/2023 30/06/2026 27/11/2024 11/09/2027 27/11/2024 30/06/2027 07/11/2025 11/09/2028 07/11/2025 30/06/2028
47,934 111,846 51,226 119,527 59,701 139,301 529,535
103,964 242,583 346,547
(47,934) (111,846) (51,226) (119,527) (59,701) (139,301) (103,964) (242,583) (876,082)
$0.60 $1.02 $0.79 $1.28 $0.65 $1.21 $0.61 $0.31
22/09/2025 30/06/2028 22/09/2025 11/09/2028
130,061 55,740 185,801
130,061 55,740 185,801
$0.61 $0.31
529,535
532,348
(876,082)
185,801
Opening balances include rights that are vested and unexercised, as well as unvested rights. During the year, 346,547 unvested performance rights lapsed as the service period conditions were not met.
25
Monash IVF Group Limited Directors' Report 30 June 2026 5.0 Details of remuneration for Key Management Personnel (continued) 5.2 Analysis of incentives included in remuneration Details of the vesting profile of the STI cash incentives awarded as remuneration to each director of the Company and other KMP are detailed below: 2026
2026
2026
2025
2025
2025
Payable and Payable and Payable and Payable and paid paid Not Payable paid paid Not Payable Executive Directors: Dr Victoria Atkinson Other KMP: Mr. Malik Jainudeen Ms Rebecca Redden
58,191 58,191
100%
61,130 61,130
100%
100%
100%
119,321
5.3 Loans to Key Management Personnel No loans were issued to Key Management Personnel during 2026. 5.4 Key Management Personnel Shareholdings The following details the direct and indirect holdings of Monash IVF Group ordinary shares held by Directors and KMP as of 30 June 2026:
Name Non-Executive Directors: Mr Richard Davis Ms Catherine West Ms Zita Peach Ms Catherine Aston Mr Neil Broekhuizen Dr Dwayne Crombie Executive Directors: Dr Richard Henshaw Dr Victoria Atkinson Other KMP: Mr Malik Jainudeen(1) Ms Rebecca Redden
(1)
Balance at 1 July 2025 Number
Granted during 2026 Number
Net change Number
Balance at 30 June 2026 Number
182,067 37,100 92,803 77,000 350,000 738,970
(75,000) (75,000)
182,067 37,100 92,803 2,000 350,000 663,970
1,358,842 1,358,842
1,358,842 1,358,842
203,884 203,884
203,884 203,884
2,301,696
(75,000)
2,226,696
Malik Jainudeen resigned as a KMP effective 2 April 2026. Closing balance reflects their holding as at that date.
26
Monash IVF Group Limited Directors' Report 30 June 2026 6.0 Link to Group Performance The revenue and earnings of the Group for the five years to 30 June 2026 are summarised below: Measure
2026 $'000
2025 $'000
2024 $'000
2023 $'000
2022 $'000
Revenue Underlying EBITDA(1) Reported EBITDA Underlying NPAT(1) Reported NPAT
269,459 53,419 43,510 16,111 8,326
271,917 66,335 65,431 27,419 25,676
254,960 62,806 13,234 29,851 (5,949)
213,590 53,431 48,461 25,429 21,966
192,294 48,145 43,157 22,232 18,502
30.0% 6.6%
42.9%
84.0% 15.2%
49.1% 27.0%
16.7% 21.0%
STI payable(2) Total Shareholder Return(3) (1)
Underlying EBITDA and NPAT are non-IFRS measures that are utilised for internal reporting purposes.
(2)
For period of service as a KMP on a pro-rate basis.
(3)
The Net Profit after Tax, total shareholder return and earnings per share are not comparable for certain years due to the capital structure and discontinued operations.
The factors that are considered to affect total shareholders return ('TSR') are summarised below: 2026 Share price at financial year end ($) Total dividends declared (cents per share) Basic earnings per share (cents per share) Diluted earnings per share (cents per share)
2025
0.73 2.50 1.91 1.90
0.71 2.60 6.40 6.40
2024 1.29 5.00 (1.70) (1.70)
2023 1.15 4.40 5.60 5.60
2022 0.94 4.40 4.70 4.70
During the period, Revenue, Underlying EBITDA, Underlying NPAT, TSR and EPS were key performance measures. Underlying NPAT is a major component of the STI plans for KMP including the CEO, CFO and COO. TSR and EPS growth are long term metrics used to measure the CEO, CFO and COO’s remuneration via the Executive Long Term Incentive Plan. CEO, CFO and COO remuneration varies with the outcomes of these measures above a required threshold performance level. This concludes the remuneration report, which has been audited. Shares under option There were no unissued ordinary shares of Monash IVF Group Limited under option outstanding at the date of this report. Shares issued on the exercise of options There were no ordinary shares of Monash IVF Group Limited issued on the exercise of options during the year ended 30 June 2026 and up to the date of this report. Shares under performance rights Unissued ordinary shares of Monash IVF Group Limited under performance rights at the date of this report are as follows: Exercise price
Grant date 28/11/2023 27/11/2024 14/11/2025 10/07/2026
$0.00 $0.00 $0.00 $0.00
Number under rights 152,572 204,825 346,761 453,989 1,158,147
No person entitled to exercise the performance rights had or has any right by virtue of the performance right to participate in any share issue of the Company or of any other body corporate.
27
Monash IVF Group Limited Directors' Report 30 June 2026 Shares issued on the exercise of performance rights There were no ordinary shares of Monash IVF Group Limited issued on the exercise of performance rights during the year ended 30 June 2026 and up to the date of this report. Indemnity and insurance of officers and auditor The Company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor, the Directors and executives of the Company or any related entity against a liability incurred by the auditor. During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the Company or any related entity. Proceedings on behalf of the Company No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings. Non-audit services Details of the amounts paid or payable to the auditor for non-audit services provided during the financial year by the auditor are outlined in note 30 to the financial statements. The Directors are satisfied that the provision of non-audit services during the financial year, by the auditor (or by another person or firm on the auditor's behalf), is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001. The Directors are of the opinion that the services as disclosed in note 30 to the financial statements do not compromise the external auditor's independence requirements of the Corporations Act 2001 for the following reasons: ● all non-audit services have been reviewed and approved to ensure that they do not impact the integrity and objectivity of the auditor; and ● none of the services undermine the general principles relating to auditor independence as set out in APES 110 Code of Ethics for Professional Accountants (including Independence Standards) issued by the Accounting Professional and Ethical Standards Board, including reviewing or auditing the auditor's own work, acting in a management or decisionmaking capacity for the Company, acting as advocate for the Company or jointly sharing economic risks and rewards. Officers of the Company who are former partners of KPMG There are no officers of the Company who are former partners of KPMG. Rounding of amounts The Company is of a kind referred to in Corporations Instrument 2026/183, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest thousand dollars, or in certain cases, the nearest dollar. Auditor's independence declaration A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this Directors' report and forms part of this report. This report is made in accordance with a resolution of Directors, pursuant to section 298(2)(a) of the Corporations Act 2001. On behalf of the Directors
Mr Richard Davis Chair
Dr Victoria Atkinson Chief Executive Officer & Managing Director
31 August 2026 Melbourne
28
Lead Auditor’s Independence Declaration under Section 307C of the Corporations Act 2001 To the Directors of Monash IVF Group Limited I declare that, to the best of my knowledge and belief, in relation to the audit of the financial report of Monash IVF Group Limited for the financial year ended 30 June 2026 there have been: i.
no contraventions of the auditor independence requirements as set out in the Corporations Act 2001 in relation to the audit; and
ii.
no contraventions of any applicable code of professional conduct in relation to the audit.
KPM_INI_01
KPMG
Andrew Hounsell Partner Melbourne 31 August 2026
29 KPMG, an Australian partnership and a member firm of the KPMG global organisation of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organisation. Liability limited by a scheme approved under Professional Standards Legislation.
Monash IVF Group Limited Corporate Governance Statement 30 June 2026 This statement reports on the key governance framework, principles and practices of Monash IVF Group Limited (the Group). This statement has been approved by the Group Board of Directors and is current as at 30 June 2026. The principles and practices referred to in this statement are subject to regular review and are revised when necessary to reflect legislative changes or corporate governance best practice. The Board is committed to maintaining the Group’s pre-eminent status as a leader in the fields of Assisted Reproductive Services (ARS) and specialist women’s imaging. This commitment is intended to lead to sustainable growth and shareholder returns. The Board is a strong advocate of good corporate governance and its fulfilment of these practices and obligations will enhance the ability for shareholders to be appropriately rewarded. The Group complies in all material respects with the fourth edition of the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations. The details of this compliance and reasons for any non-compliance are set out in this statement. A separate Appendix 4G has been lodged with the Australian Securities Exchange Limited (ASX). Principle 1 Lay solid foundations for management and oversight 1.1 Roles and responsibilities of the Board and Management and delegation The role of the Board is to oversee good governance practice in all aspects of the Group’s undertakings. This includes setting and approving the strategic direction of the Group, as well as guiding and monitoring Group management and its businesses in achieving their strategic objectives. The Board is committed to maximising performance through continued investment in all aspects of the business including research, education and innovation in clinical services to improve patient outcomes. The Board is committed to a high standard of corporate governance practice and fosters a culture of compliance which values ethical behaviour, integrity, teamwork and respect for others. The Group Board Charter outlines the role and responsibilities of the Board along with direction on Board composition, structure and membership requirements. The Charter clearly outlines matters expressly reserved for the Board’s determination and those matters delegated to Management. The Monash IVF Group Limited Board Charter is available on the Monash IVF Group Limited website: Corporate Governance | Monash IVF Group. 1.2 and 1.3 Board and Senior Executive appointments In the event of a new appointment to a director or senior executive role, appropriate probity and integrity checks, including verification of experience, education, criminal record and bankruptcy history, are undertaken to ensure the individual has an appropriate background to hold the role within the Group. Where a person is standing for election of a director for the first time, a comprehensive check of the candidates’ personal and professional history is undertaken including details of any other material directorships or non-executive roles. With the exception of the Chief Executive Officer, one third of all eligible Directors, and any other Director who has held office for over three years since their last election, must retire in rotation at the Annual General Meeting (AGM). This is in accordance with the Group’s Constitution. A retiring Director holds office until the conclusion of the meeting at which he or she retires. They may stand for re-election by security holders at that meeting. The Board may appoint a new Director to fill a casual vacancy and that Director will hold office until the close of the next AGM, unless elected at that meeting. The Board makes recommendations in respect of the election or re-election of each Director based on the tenure, skills and experience of the Director in relation to Board composition. The Remuneration and Nomination Committee ensures that appropriate background checks take place for the appointment of a new Director. The details of those Directors who stand for re-election will be provided in the Notice of Meeting which is sent to security holders prior to the AGM. The Board provides security holders with all material information in its possession relevant to a decision on whether or not to elect or re-elect a Director in the Notice of Meeting, together with a statement by the Board as to whether it supports the election or re-election of the candidate and a summary of the reasons as to why the Board has taken this view. Additionally, each Director standing for re-election makes a short presentation to security holders at the meeting itself. All Board members have a written agreement outlining the terms of their appointment clearly articulating the expectations, roles and responsibilities and remuneration of their role. All employment agreements for senior executives clearly set out their terms of appointment, remuneration and requirements to adhere to Company policies and procedures. Industry regulation and Group policy require police checks for employees prior to commencement of employment. Employment contracts require employees to disclose any offences that would result in an adverse police check. 1.4 Company Secretary Ms Rebecca Dean was appointed Company Secretary and General Counsel of Monash IVF Group Limited, effective 4 March 2026. The Company Secretary is responsible for all matters relating to the proper functioning of the Board and is accountable to the Board, through the Chair of the Board. 30
Monash IVF Group Limited Corporate Governance Statement 30 June 2026 Mr. Malik Jainudeen ceased as Company Secretary following the appointment of Ms. Rebecca Dean. Malik had served as Company Secretary since April 2019 and subsequently acted as Chief Executive Officer before Dr Victoria Atkinson commenced as Chief Executive Officer and Managing Director. 1.5 Diversity and Inclusion Policy The Group recognises that its business success reflects the quality of its people and is proud of its diverse and inclusive workforce. The Group’s workforce is made up of individuals with a diverse set of skills, values, experiences, backgrounds and attributes including those gained on account of their gender, age, disability, ethnicity, marital or family status, religious or cultural background and sexual orientation. Monash IVF Group is committed to supporting and further developing this through attracting, engaging and retaining diverse talent as supported by a Diversity and Inclusion Policy. Monash IVF Group is a relevant employer under the Workplace Gender Equity Act 2012 and is compliant with the requirements of the Australian Government Workplace Gender Equity Agency. The breakdown of gender diversity at Monash IVF Group is listed below: Organisational Level
Number of Women
% of Women
Target
Non-Executive Directors
3
50%
No less than 40% male / 40% female / 20% any gender
Senior Management
14
61%
No less than 40% male / 40% female / 20% any gender
Team leader
127
91%
50%
Total staff (including above)
892
93%
The Board recognises the high proportion of women in the workplace and acknowledges that this gender diversity is reflective of the nature of the organisation. The Remuneration and Nomination Committee sets measurable objectives to support gender diversity, including a 40:40:20 objective for Non-Executive Directors and Senior Management. As shown in the table above, the Group met this objective for Non-Executive Directors, with women representing 50% of Non-Executive Directors. Women represented 61% of Senior Management during FY2026, reflecting continued strong female representation at senior leadership level. Senior Management is defined as Executive Directors and Management personnel in operational leadership positions generally specific to state leadership teams. Monash IVF Group has a Flexible Work Arrangements Policy in place to promote work/life balance and accommodate family care in line with the operational requirements of the business. Flexible working arrangements are widely used and supported across Monash IVF Group, both formally and informally. During FY2026, employees also accessed the Group’s Parental Leave Policy, including primary and secondary carer leave arrangements. The Diversity and Inclusion Policy is overseen by the Remuneration and Nomination Committee. The Board approved an updated Diversity and Inclusion Policy on 17 February 2026. The Board is ultimately accountable for the Policy, while the Managing Director/CEO and members of the Executive Team are responsible for its implementation and monitoring compliance. The Chief People & Culture Officer and Company Secretary are responsible for administration of the Policy, including reporting to the Board or its relevant Committee as appropriate. The Diversity and Inclusion Policy is available on the Group website. The Group is committed to providing a diverse and culturally inclusive work environment to ensure that all employees are valued and feel able to bring their whole selves to work in a safe workplace environment. The Group provides an Equal Employment Opportunity Policy framework in relation to harassment, bullying, discrimination and grievance procedures. The policies are available to all employees via the Company intranet. The Group also offers an employee assistance program that provides a confidential counselling service to support employee wellbeing in the workplace. To ensure a full understanding of respectful workplace obligations, the organisation uses a Learning Management System, an online learning portal, to manage and track compliance with respectful workplace training. The Group continued its partnership with Pride in Diversity, a national not-for-profit employer support program for LGBTI workplaces, which is designed to assist employers and employees with all aspects of inclusion, including awareness and education. 1.6 Director Performance Evaluation The Remuneration and Nomination Committee Chair undertakes the process of performance reviews of the Board, its Committees and the Chair. The objectives of the review are to ensure the Board adheres to ASX governance principles and to identify opportunities to improve the functioning of the Board as a whole. The focus is on the performance of the Board as a whole and, to a lesser extent, the Board committees. The Chair undertakes individual appraisals of each Director.
31
Monash IVF Group Limited Corporate Governance Statement 30 June 2026 The Group Board undertook its annual review in FY2026. It involved Directors completing a confidential questionnaire covering aspects outlined in the Board Charter. The aggregated results were considered by the Board and used to identify opportunities to improve Board effectiveness. 1.7 Senior Executive Evaluations The Group has an annual Performance Review and Development Plan Policy for all senior executives and managers as stated in the Board Charter. Senior executive and manager performance is reviewed by the CEO against Key Performance Indicators (KPIs) which are both financial and non-financial in nature. The performance evaluation process has been undertaken in accordance with this policy for the current financial year. The Remuneration and Nomination Committee has oversight of this process. The Chair of the Board performs the CEO performance review against annual KPIs. During FY2026, the Board oversaw executive performance and succession matters in the context of the appointment of Dr Victoria Atkinson as Chief Executive Officer and Managing Director and other executive leadership changes. The Board also monitors the KPIs and strategic plan for the Group, which enables the Board to monitor the performance of senior executives outside the annual review process. Principle 2 Structure of the Board to be effective and add value The Group’s Constitution provides that the number of Directors must at any time be no more than ten and no less than three members. The Group Board currently consists of eight Directors, six independent and two non-independent members. The Board Charter prescribes that the Chair of the Board must be independent and the Board should consist of individuals who contribute a mix of skills and diverse professional backgrounds. Further information on the Board members is available in the Directors’ Report. The Board believes the current Board of eight members allows its members to carry out their responsibilities effectively, without an excessive number of Directors hindering individual engagement or involvement. To support the efficient operation of the Board, two committees are in place: the Remuneration and Nomination Committee and the Audit and Risk Management Committee. The Board Charter prescribes that all committee members be independent Directors. 2.1 Remuneration and Nomination Committee The Remuneration and Nomination Committee is governed by the Remuneration and Nomination Committee Charter as found on the Monash IVF Group Limited website at Corporate Governance | Monash IVF Group. The Remuneration and Nomination Committee consists of four independent Directors of the Board: •
Ms Zita Peach (Chair)
•
Mr Richard Davis
•
Ms Catherine Aston
• Ms Catherine West The Committee met three times with all Committee members in attendance, in addition to numerous informal out-of-cycle meetings in relation to leadership transition and Board renewal activities. The Committee assists the Board by reviewing and making recommendations to the Board in relation to: •
the Company's Remuneration Policy;
•
Board succession issues and planning;
•
Board member appointments and the re-election of Directors to the Board and its committees;
•
Director induction and continuing professional development programs for Directors;
•
remuneration packages of senior executives;
•
non-executive Directors and executive Directors, equity-based incentive plans and other employee benefit programs;
•
Company superannuation arrangements;
•
the Company's recruitment, retention and termination policies;
•
succession plans of the CEO, senior executives and executive Directors;
•
the process for the evaluation of the performance of the Board, its Board Committees and individual Directors;
•
the review of the performance of senior executives;
•
review of the Company's remuneration policies and packages; and
•
the size and composition of the Board and strategies to address Board diversity and the Company's performance in respect of the Company's Diversity and Inclusion Policy, including whether there is any gender or other inappropriate bias in remuneration for Directors, senior executives or other employees. 32
Monash IVF Group Limited Corporate Governance Statement 30 June 2026 2.2 Board Skill Matrix The skills and experience of the Group’s Board of Directors reflect the Group’s strategy, principal activities and operating environment. The Board uses a skills matrix to assess its collective capability and identify areas for ongoing focus. The Board has identified the skills and experience required to support effective oversight and the long-term success of the Group. The FY26 skills matrix comprises leadership and strategy, healthcare and clinical expertise, finance and risk management, governance and regulation, technology and cyber security, people and culture, growth and M&A, international markets and ESG. The Board reviews the skills matrix annually to assess whether its collective skills, experience and diversity remain aligned with the Group’s strategic objectives, regulatory environment and evolving business needs. During FY26, the Board consolidated existing skill categories to create a clearer and more contemporary matrix, while retaining the key capabilities required to support the Group’s strategy and operations. The Board considers that the current Directors provide an appropriate and diverse mix of backgrounds, expertise, experience and qualifications to support the Board’s oversight of the Group’s strategy and growth. The skills matrix below outlines the Board’s collective skill set during FY2026: Skill and experience Leadership and Strategy Executive leadership in a publicly listed or large private multinational organisation, with strong commercial acumen and experience in strategic planning, organisational transformation, stakeholder management and delivery of sustainable outcomes. Growth, Commercial & M&A Business development, growth strategy, mergers and acquisitions, partnerships, customer/patient experience and marketing. International Business Development International markets, including regulated overseas markets and relevant markets. Healthcare & Clinical/Medical Experience Healthcare sector knowledge, fertility industry experience and clinical/medical expertise. Finance, Audit & Risk Financial accounting and reporting, audit, capital allocation, and enterprise risk management and internal controls. Governance, Legal & Regulatory Corporate governance, legal, compliance and regulatory engagement. Technology, Digital & Cyber Technology, digital and cyber security, artificial intelligence (AI), digital transformation and governance. People, Culture & Remuneration Workforce strategy, talent, remuneration, succession planning and culture. ESG & Sustainability Sustainability, WHS, community, environmental and social responsibilities.
0
0
0
1
7
0
0
0
3
5
0
1
1
2
4
0
1
2
1
4
0
0
1
5
2
0
0
1
4
3
0
2
2
4
0
0
0
4
1
3
0
3
3
0
2
33
Monash IVF Group Limited Corporate Governance Statement 30 June 2026 2.3, 2.4 and 2.5 Board Members, Roles and Independence A summary of the Board members, their roles, independence and appointment dates are as follows: Director
Position
Independent
Mr Richard Davis
Independent Chairman
Yes
4 June 2014
Ms Catherine Aston
Independent non-executive Director
Yes
26 February 2024
Ms Catherine West
Independent non-executive Director
Yes
8 September 2020
Ms Zita Peach
Independent non-executive Director
Yes
12 October 2016
Mr Neil Broekhuizen
Independent non-executive Director
Yes
4 June 2014
Dr Dwayne Crombie
Independent non-executive Director
Yes
24 November 2025
Dr Victoria Atkinson
Executive Director
No
5 January 2026
Dr Richard Henshaw
Executive Director (Fertility Specialist with Monash IVF Group Limited)
No
Appointment Date
30 April 2014
The Board Charter outlines that at least half of the Board should be independent Directors, one of whom is the Chairman. A Director is deemed to be “independent” if free of any business or other relationship with the Company that could materially interfere with, or could reasonably be perceived to interfere with, the exercise of unfettered and independent judgement. The Board has assessed, using the criteria set out in the ASX Corporate Governance Principles and Recommendations, the independence of non-executive Directors in light of their interests and relationships, and considers at least half to be independent. The independence status and length of service of each Director is outlined in the table above. The percentage of Board members considered independent was 75%. Of the independent Directors, Mr Richard Davis and Mr Neil Broekhuizen have been Directors of the Group for more than 10 years. Notwithstanding this, the Board is of the opinion that their tenure does not compromise the independence of any of these Directors because, in the exercise of their duties, they demonstrate independent judgement and objective assessment of matters before the Board and their tenure has not resulted in any change in behaviour which would bring their independence into question. During FY2026, Dr Dwayne Crombie joined the Board as an independent non-executive Director and Dr Victoria Atkinson joined the Board as Chief Executive Officer and Managing Director. These appointments added further healthcare, clinical governance, operational, and executive leadership experience to the Board. Mr Richard Davis was appointed Monash IVF Group Limited Chair in June 2014. He is a non-executive Independent Director. Mr Davis, in his role as Chair, provides leadership to the Board and advice and support to the CEO. The Chair of the Board is responsible for overseeing Board dynamics and ensuring all Directors contribute effectively and constructively to Group meetings and strategic agendas. Mr Davis will step down from the Board on 28 October 2026. Following a comprehensive succession process, Ms Catherine West has been appointed to succeed Mr Davis as Chair upon his retirement. Mr Broekhuizen will step down on 31 August 2026 and Dr Henshaw will step down on 28 October 2026. As part of the Board’s renewal process, Mr Gerd Schenkel has been appointed as an independent non-executive Director, effective 1 September 2026. 2.6 Director Induction and Professional Development The Group has a comprehensive induction process for Directors and senior executives. This induction includes meetings with senior management and staff to gain an understanding of the core business, strategy, financial, operational and risk management matters and factors relevant to the sectors and environments in which the Company operates as well as visits to laboratories and clinics to gain a more in depth understanding of the business. The Chair periodically reviews whether there is a need for Directors to undertake professional development to maintain the skills and knowledge needed to perform their role as Directors effectively. Directors are active in undertaking professional development opportunities for the purpose of development and maintenance of their skills. The Board and its Committees are provided with updates and information from both management and external experts on various topics relevant to the Company’s circumstances, including emerging business and governance issues relevant to the Company and material developments in laws and regulations. The Board and individual Directors attend at operational sites, meet staff in operations, and receive presentations from management across the Group’s operations. Board members have been continuously informed via research papers and presentations, financial and business results and discussion involving market strategic initiatives contributing to the continued professional development of the Board. 34
Monash IVF Group Limited Corporate Governance Statement 30 June 2026 Principle 3 Instil a culture of acting lawfully, ethically, and responsibly 3.1 Organisational Values The Board and senior executives are firmly committed to ensuring that all employees observe high standards of lawful, ethical behaviour and conduct. Setting the cultural tone for the organisation, the Group's core values are as follows:
35
Monash IVF Group Limited Corporate Governance Statement 30 June 2026 The Group’s performance review process requires assessment of the extent to which personnel have demonstrated behaviour consistent with these values. The values also form the foundation for the monthly and annual employee CUDOS Awards, recognising and celebrating outstanding employee behaviour in line with these values. The principles are provided with sufficient guidance to enable personnel to make decisions consistent with the Board’s risk appetite and core values. 3.2 Code of Conduct The Group recognises the need to observe the highest standards of corporate practice, business conduct and responsible decision making. Accordingly, the Board adheres to a formal Code of Conduct which outlines the Group’s policies on various matters including ethical conduct, business and personal conduct, compliance, privacy, security of information, financial integrity, and conflicts of interest. This Code of Conduct clearly states the standard of responsibility and ethical conduct expected of staff, Directors or doctors engaged by the Company. The Code recognises the numerous legislative and compliance matters that affect the business. The Code promotes ethical and responsible decision making by Directors, contractors, and employees. The Code also gives direction in the avoidance of conflicts of interest and mandates high standards of personal integrity, objectivity and honesty in the dealings of all Group Board members and staff, detailing guidelines to ensure the highest standards are maintained. The Group expects all staff to act according to this Code to maintain standards in confidentiality and general behaviour. The Code is provided to all staff as part of the Group induction process and compliance is reviewed regularly. The Board or Audit and Risk Management Committee are informed of any material breaches of the entity’s Code. 3.3 Whistleblower Policy The Company has a Whistleblower Policy which has been communicated to all Company personnel and published on the Company’s website. The Whistleblower Policy was reviewed during FY2026. The Whistleblower Policy promotes and supports the reporting of matters of concern and suspected wrongdoing, such as dishonest or fraudulent conduct, breaches of legislation and other conduct that may cause financial loss or be otherwise detrimental to its reputation or interests. The Policy sets out the approach to disclosure, investigation and reporting and outlines the protection to be afforded to those who report such conduct against reprisals, discrimination, harassment, or other disadvantage resulting from their reports. All material disclosures received under the Whistleblower Policy are reported to the Audit and Risk Management Committee with details of investigations completed. The Group's Code of Conduct and Whistleblower Policy can be found in full on the Company’s website under Corporate Governance | Monash IVF Group. 3.4 Anti-Bribery and Corruption Policy The Company has an Anti-Bribery and Corruption Policy which has been communicated to all Company personnel and published on the Company’s website. The Anti-Bribery and Corruption Policy describes the standards of ethical conduct and behaviour required of all individuals within the Group, noting that all representatives must act within the law and not engage in corrupt practices or acts of bribery that expose the Group, its employees and clinical partners to the risks of prosecution, fines and imprisonment, as well as endangering the Group’s reputation. Where these standards are not met, appropriate disciplinary action may be taken. The Group applies a zero-tolerance approach to acts of bribery or corruption by any individual or third-party representative. The Board is informed of any material breaches of the entity’s Anti-Bribery and Corruption Policy. The Group's Anti-Bribery and Corruption Policy can be found in full on our website under Corporate Governance | Monash IVF Group. Principle 4 Safeguard integrity in corporate reporting 4.1 Audit and Risk Management Committee The Audit and Risk Management Committee for the Group is responsible for supervising the process of corporate governance, financial reporting and risk management, internal control, continuous disclosure, non-financial risk monitoring, and external audit. The Committee’s role, as outlined in the Audit and Risk Management Committee Charter, is to monitor the Group’s compliance with laws and regulations and adherence to the Group Code of Conduct and to promote discussion with regard to risk between Board, management and the external auditor. The Group engages in the services of an external auditor, whose independence and performance is monitored and reviewed by the Audit and Risk Management Committee. The external auditor, the Audit and Risk Management Committee and the Audit Chair met on a number of occasions independently of Management.
36
Monash IVF Group Limited Corporate Governance Statement 30 June 2026 The Audit and Risk Management Committee consists of four non-executive independent Directors with experience and qualifications in financial management, healthcare, governance and risk, as outlined in the Audit and Risk Management Committee Charter. Current members of the Committee are:
• • • •
Ms Catherine Aston (Chair) Mr Richard Davis Mr Neil Broekhuizen
Dr Dwayne Crombie The Committee met four times during the year. Details of the Committee members’ experience and technical expertise are set out in the Directors’ biographies which can be viewed on the Board of Directors pages in the latest Annual Report. The Audit and Risk Management Committee Charter is available on the Monash IVF Group Limited website at Corporate Governance | Monash IVF Group. 4.2 Financial Statement Approval For the half-year reporting period ended 31 December 2025, Dr Victoria Atkinson, Chief Executive Officer and Managing Director, and the Chief Financial Officer reviewed and verified that the half-year reporting statements provided to the ASX and shareholders were true and accurate. For the full-year reporting period ended 30 June 2026, the Chief Executive Officer and Managing Director and Chief Financial Officer provided the relevant declarations in accordance with the Corporations Act 2001, Australian accounting standards and the Company’s financial reporting governance processes. A detailed questionnaire is completed by senior operational, administrative and financial management attesting to the validity and integrity of the processes that they control prior to the approval of the financial statements. These questionnaires are reviewed by the Audit and Risk Management Committee. 4.3 Process for verifying Periodic Corporate Reports The Group is committed to providing security holders and other external stakeholders with timely, consistent and transparent corporate reporting. The process which is followed to verify the integrity of periodic corporate reports is tailored based on the nature of the relevant report, its subject matter and where it will be published. The Group seeks to adhere to the following general principles with respect to the preparation and verification of its corporate reporting:
•
periodic corporate reports prepared by, or under the oversight of, the relevant subject matter expert for the area being reported on;
• •
the relevant report is in compliance with any applicable legislation or regulations; the relevant report is reviewed, including any underlying data, to ensure it is not inaccurate, false, misleading or deceptive; and
•
where required by law or by Group policy, relevant reports are authorised for release by the appropriate approver required under that law or policy. Consistent with these principles, the non-audited sections of the Financial Report and Corporate Governance Statement for the reporting period were prepared by the relevant subject matter experts and reviewed and verified by relevant senior executives and senior managers prior to Board approval. ASX announcements (other than administrative announcements) during the reporting period were also reviewed and approved in accordance with the Continuous Disclosure Policy, which includes review by the Board, Chief Executive Officer and Managing Director, Chief Financial Officer and Company Secretary prior to publication, as appropriate. Principle 5 Make timely and balanced disclosure 5.1 Continuous Disclosure The Group is committed to effective communication with its investors and the wider community. The Company strives to ensure that all stakeholders, market participants, patients and the wider community are informed in a timely manner of its activities and performance in line with its Continuous Disclosure Policy. This Policy complies with the continuous disclosure obligations under the Corporations Act 2001 and the ASX Listing Rules and, as far as possible, seeks to achieve and exceed best practice to promote investor confidence in Monash IVF Group Limited. Continuous disclosure principles and requirements are well understood by the Group Company Secretary and the Board of Directors and are in place to ensure all relevant information, especially of a sensitive nature, is made available in a timely manner. Any matters requiring disclosure are raised for consideration whenever necessary. The Group website is structured to provide shareholders and the community with easy access to information.
37
Monash IVF Group Limited Corporate Governance Statement 30 June 2026 5.2 and 5.3 Material Market Announcements and Presentations The Company Secretary ensures that the Board receives copies of all material market announcements promptly after they have been made and ensures that any new investor or analyst presentation is released on the ASX before the presentation is given. The Continuous Disclosure Policy can be found on the Group website at Corporate Governance | Monash IVF Group. Principle 6 Respect the rights of security holders 6.1 Communication with Shareholders The Group ensures shareholders are fully informed of its governance processes and are notified of any major developments affecting the Group. In line with the Group’s Communication Policy, the Company's website is considered to be the primary means to provide information to all stakeholders. It has been designed to enable information to be accessed in a clear and readily accessible manner including:
• • • • • • • •
Company information including Board members; a ‘Corporate Governance’ landing page with documents including the Company's Codes, Policies and Charters; all announcements and releases to the ASX; copies of presentations to shareholders, institutional investors, brokers and analysts; any media or other releases; all notices of meetings and explanatory material; annual and half yearly reports;
any other relevant information concerning non-confidential activities of the Company including business developments. The Group website can be found at www.monashivfgroup.com.au where information can be clearly located under heading:
• • • • •
Home – homepage with Company history and overview About – information on Our People, Collaborations and Career Opportunities Our Business – information on brands and operating locations Innovations in Research – lists current and published research and our scientific firsts Investor Centre 6.2 Investor Relations In addition to the Group website, there is a dedicated Investor Relations page found at Corporate Governance | Monash IVF Group which provides investors and shareholders with information on the Group Board members, Announcements, Corporate Governance documents, results presentations and webcasts. The Investor Centre also acts as a portal for two-way communication between the Company and investors with links to a ‘Contact Us’ page which allows individuals to email enquiries and also provides a postal address and contact number to allow access to the Company. The Communication Policy can be located at Corporate Governance | Monash IVF Group. 6.3 and 6.4 Attendance at Company meetings As cited in the Group Communications Policy, the Company encourages full participation of shareholders at the Annual General Meeting which provides an excellent opportunity for the Company to provide information to its shareholders and to receive Shareholder feedback. The next Annual General Meeting is planned to be held on 26 November 2026. In the event shareholders are not able to attend the meetings, questions can be directed to the Group for addressing at the Annual General Meeting and the presentations and webcasts are promptly added to the website. These can be found at Presentations and Webcasts | Monash IVF Group. All substantive resolutions put to the Annual General Meeting were decided by way of a poll. Shareholders are also able to direct any questions via the Group’s share registry provider, MUFG Corporate Markets. 6.5 Electronic Communication The Company recognises that electronic communication is often a more efficient and more desired form of communication. The Group Communications Policy addresses this and accordingly shareholders are given the option to communicate with the Company share registry electronically. The Company's email system allows staff and stakeholders to communicate with ease with management and staff of the Company. Doctors, employees and other stakeholders have access to this system and are encouraged to use it to improve the flow of information and communication generally. The Group Communications Policy can be located at Corporate Governance | Monash IVF Group. 38
Monash IVF Group Limited Corporate Governance Statement 30 June 2026 Principle 7 Recognise and Manage Risk The Group Board, primarily through the Audit and Risk Management Committee, reviews and manages risk areas for the Group. Refer to section 4.1 for further information. 7.1 Audit and Risk Management Committee The identification and appropriate management of risks is an important priority for the Group Board. ‘Risks’ are identified as any possible outcomes that could materially impact the Company's financial performance, assets, reputation, people or the environment. Risk recognition and management are viewed by the Company as integral to its objectives of creating and maintaining shareholder value, and to the successful execution of the Company's strategies. The Audit and Risk Management Committee assist the Board in overseeing and governing risk management strategy and policy, to monitor risk management and to review procedures which seek to provide assurance that major business risks are identified, consistently assessed and appropriately addressed. The Committee abides by the Audit and Risk Management Committee Charter to assist the Board in fulfilling its corporate governance and oversight responsibilities in actively identifying risks and developing appropriate mitigating actions. The Committee adheres to the Risk Management Policy for the business which highlights the risks relevant to Company operations and oversees that the entity is operating with due regard to the risk appetite set by the Board. The Group’s Audit and Risk Management Committee Charter can be found on the website at Corporate Governance | Monash IVF Group. This Charter prescribes that the Audit and Risk Management Committee consist of at least three Board Directors that are nonexecutive independent Directors. 7.2 Risk Management The Group provides a framework for risk management which supports the achievement of our strategic and operational objectives. We are committed to maintaining an organisational philosophy and culture which ensures that effective risk management is integrated into day-to-day activities. The Group maintains a Risk Register that documents all identified material risks, lists appropriate preventative actions to mitigate risks, reviews the process of risk reduction and nominates responsible persons who take ownership of the risk strategy process. The Risk Register is reviewed by Risk Owners, Leadership Teams and the Executive Team to help determine whether risks remain current, controls are effective and any emerging risks should be flagged to the Audit and Risk Management Committee. The Board is responsible for determining the Group’s risk appetite. The Audit and Risk Management Committee reviewed the risk management framework and risk appetite during FY2026. Specialist software used to record clinical adverse events and feedback ensures that exposures to risk are continually monitored to ensure they are adequately understood and managed. This system of reporting also allows for formal monitoring of patient safety, identification of training needs and informs policy decision making. 7.3 Internal Audit The Group does not maintain a designated Internal Audit Function at present; however, it undertakes a range of internal audit and assurance activities from a clinical and operational perspective to ensure compliance with various external accreditation requirements and company policy. The Chief Executive Officer and Managing Director and Chief Financial Officer have key responsibility for ensuring that internal controls are in place, operating effectively and reviewed for continual improvement. As part of the various accreditation and licensing processes undertaken by the business, key internal audit activities are undertaken. These audits are then made available to accreditation and licensing bodies. Certain financial internal controls are tested by KPMG as part of their financial statement audit procedures. The Group believes internal controls implemented such as segregation of duties, delegation processes, treasury controls and structured approval processes counter many risks. The Group will continue to assess whether an independent third-party internal audit function or designated in-house internal audit function is required. 7.4 Risk Exposure The Group provides ARS in Australia and South East Asia and specialist women’s imaging services in Australia. The Group is committed to performing services in an open and transparent environment and in a manner that is honest and ethical. The Group embraces responsibility for corporate actions and encourages a positive impact on the environment and stakeholders including patients, employees, investors and the community. Since its early pioneering days in assisted reproductive treatment, resulting in the first IVF pregnancy in 1973, Monash IVF has played an important role in the local communities it serves and society at large. Its focus on evidence-based fertility care provides the opportunity to commit resources to scientific research, clinical teaching and training. The Group’s services are offered to all and do not discriminate, including in relation to the nature and complexities of infertility. 39
Monash IVF Group Limited Corporate Governance Statement 30 June 2026 From an ethical and social perspective, the Group and its subsidiary companies ensure national regulation and state legislation drives the standards of care to ensure it protects its patients, donors and any children born as a result of treatment provided by the Group. All Monash IVF Group facilities meet the appropriate standards for accreditation including:
•
Assisted reproductive treatment sites in Australia are accredited with the Reproductive Technology Accreditation Committee (RTAC) and the Group ensures appropriate documentation is held by sites, doctors, nurses and scientists. This accreditation incorporates components covering ethics and safety in practice and management of adverse events.
•
Day surgeries are accredited with National Safety and Quality Health Service (NSQHS) standards which ensure quality standards are consistent with an exceptional standard of care expected by consumers in health facilities.
•
Diagnostic laboratories are accredited to ISO 15189 and relevant National Pathology Accreditation Advisory Council (NPAAC) Guidelines.
•
Diagnostic imaging (ultrasound) facilities are accredited with the Department of Health Diagnostic Imaging Accreditation Scheme (DIAS).
•
The Group’s Southeast Asian clinics, while not legally requiring the same level of regulation, operate to the same standards and have been externally accredited to the International Reproductive Technology Accreditation Committee (RTAC) standards. The Group recognises that its staff and doctors are instrumental to the success of the Group. Comprehensive recruitment, credentialing, induction, training and development programs are designed to attract and retain staff equipped to deliver outstanding customer care. Staff actively participate in the continual improvement of the Group’s internal policies and processes and are encouraged to participate in innovation and research. The Group Workplace Health and Safety Policy framework covers policies on general safety in the workplace. The Group adopts a philosophy of clinical excellence in an environment of safe and supportive service provision. No material environmental or social sustainability risks have been identified. The Group adopts the approach of a responsible corporate citizen with regard to the management of waste and hazardous materials. The Group is not a significant consumer of electricity, water or gas and accordingly, the opportunities for material reductions in utility consumption are limited. The Quality Management System in place in each laboratory supports the review and monitoring of quality of product from suppliers. New consumables undergo a full quality screening process and products are thoroughly evaluated to review where and how products are manufactured before being used in the laboratories. All suppliers are reviewed formally on an annual basis to ensure they maintain quality standards and informally on a day-to-day basis. Currently all Group clinics use predominantly products from the top two suppliers of laboratory products in Australia in order to maintain consistency in quality. The Group recognises cybersecurity as a key business risk. The Group has security platforms, processes and skilled personnel to detect, contain and respond to cyber threats. The Group’s threat detection, redundancy and backup arrangement support system availability and data protection. To maintain and enhance its cybersecurity posture, the Group regularly engages independent, qualified vendors to review cybersecurity maturity and assess risk exposure, including benchmarking against the ACSC Essential Eight guidelines. The Group’s commitment to cybersecurity is further reflected in the cybersecurity awareness it supports through internal training and its continued focus on protecting employee and patient data against evolving threats. Regulatory and funding risk remains potentially material to the Group. In Australia, the Group’s services are indirectly funded to a significant extent by the Australian Federal Government through the Medicare Benefit Schedule and Extended Medicare Safety Net. Any change to the funding arrangements, or to the regulatory settings applying to ARS, could affect patient affordability, demand for services and the Group’s revenue and financial performance. The Group also operates in an environment of increasing expectations regarding data quality, outcome reporting and transparency. The Group has continued to advocate for transparent reporting of treatment outcomes to support informed patient decision-making and improve outcomes for patients and the industry more broadly. Economic and market risk also remain relevant to the Group. Market contraction, changes in patient demand and shifts in competitive dynamics may affect business outcomes. Market competitiveness has heightened in recent years, including through the introduction of low-cost providers and greater competition across the fertility services sector. Principle 8 Remunerate fairly and responsibly 8.1 Remuneration and Nomination Committee As outlined above under ‘Structure the Board to be effective and to add value’ the Group has a combined Remuneration and Nomination Committee which assists the Board with discharging its responsibilities to shareholders with regard to developing and monitoring remuneration policies and practices for Directors, Senior Executives and employees. 40
Monash IVF Group Limited Corporate Governance Statement 30 June 2026 The Committee works under the guidance of the Remuneration and Nomination Committee Charter and Remuneration Policy. All members of the Committee are non-executive independent Directors. Details of the Committee members’ experience and technical expertise are set out in the Directors’ biographies which can be viewed on the Board of Directors pages in the latest Appendix 4E and/or Annual Report. Details of the number of times the Committee met throughout the period and individual attendances of the members can be viewed in the Directors Report in the latest Appendix 4E and/or Annual Report. 8.2 Remuneration of Executive and Non-Executive Directors Under the guidance of the Remuneration and Nomination Committee and the Remuneration Policy the Group Board has established a framework for remuneration that is designed to ensure consistent and reasonable remuneration policies and practices are observed which optimise the attraction and retention of Directors and management and fairly rewards Directors and senior management for positive performance. Monash IVF Group Limited remuneration practices for Executive appointments are expanded on in the Remuneration Report. The Monash IVF Group Limited Remuneration Policy can be found on the Group website at Corporate Governance | Monash IVF Group. 8.3 Equity Based Remuneration The Board may award incentive payments to the CEO, CFO and Senior Executives in the form of equity. The Corporations Act 2001 prohibits key management personnel (or closely-related parties) of an ASX-listed Australian company from entering into an arrangement that would limit their exposure to an element of their remuneration subject to a holding lock. Equity-based awards are made on the condition that Corporations Act 2001 requirements are complied with. Directors and officers cannot buy and sell securities when in possession of price sensitive information or during designated prohibited periods, including the period from the end of the Company’s financial year (30 June) until the announcement of the Company’s full year results to the ASX and the period from the end of the Company’s half year (31 December) until the announcement of the Company’s half year results to the ASX. Approval from the Chair is required prior to any transacting in shares contemplated by Directors and the Chief Executive Officer and Managing Director, and approval from the Chief Executive Officer and Managing Director is required prior to any transacting contemplated by members of the Executive Team. A copy of the Securities Trading Policy is available on the Company’s website. Directors and senior executives are not permitted to hedge their exposure to Company securities. Employees, Directors and senior executives are not permitted to use Company securities as collateral in any financial transaction, including margin loan arrangements.
41
Monash IVF Group Limited Consolidated statement of profit or loss and other comprehensive income For the year ended 30 June 2026 Note Revenue from contracts with customers
4
Expenses Materials and consumables used Clinician fees Employee benefits expense Depreciation and amortisation expense Impairment of investment Marketing and advertising expense IT and communication expense Property expense Professional and other fees Other expenses Operating profit Net finance costs
6
Profit before income tax expense Income tax expense
7
Profit after income tax expense for the year
Consolidated 2026 2025 $'000 $'000 269,459
271,917
(30,736) (50,122) (103,320) (23,348) (6,969) (6,731) (8,515) (11,593) (7,963)
(29,465) (47,163) (97,789) (22,019) (761) (8,058) (6,239) (7,187) (9,518) (306)
20,162
43,412
(8,777)
(7,289)
11,385
36,123
(3,059)
(10,447)
8,326
25,676
Other comprehensive income Items that will not be reclassified subsequently to profit or loss Remeasurement of put option reserve Items that may be reclassified subsequently to profit or loss Cash flow hedges, net of tax Translation of foreign operations
43
212 (141)
(345) 425
Other comprehensive income for the year, net of tax
114
80
Total comprehensive income for the year
8,440
25,756
Profit for the year is attributable to: Non-controlling interest Owners of Monash IVF Group Limited
901 7,425
668 25,008
8,326
25,676
901 7,539
668 25,088
8,440
25,756
Total comprehensive income for the year is attributable to: Non-controlling interest Owners of Monash IVF Group Limited
Cents Basic earnings per share Diluted earnings per share
8 8
Cents 1.9 1.9
6.4 6.4
The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes 42
Monash IVF Group Limited Consolidated statement of financial position As at 30 June 2026 Note
Consolidated 2026 2025 $'000 $'000
Assets Current assets Cash and cash equivalents Trade and other receivables Inventories Current tax asset Total current assets
9 10 11
8,842 24,789 10,372 122 44,125
9,427 23,149 9,003 104 41,683
10 12 13 14 15 16 7
510 1,337 27 84,245 81,508 295,551 5,050 468,228
182 1,337 69,614 76,423 297,235 6,133 450,924
512,353
492,607
18,358 11,860 11,166 4,512 15,052 4,791 65,739
20,527 12,182 9,722 27 14,591 4,365 61,414
109,400 79,052 1,416 3,277 193,145
98,529 71,780 4,803 1,168 4,495 180,775
Total liabilities
258,884
242,189
Net assets
253,469
250,418
506,786 (143,237) (162,735) 48,343 249,157 4,312
506,786 (143,370) (162,735) 45,594 246,275 4,143
253,469
250,418
Non-current assets Trade and other receivables Investment accounted for using the equity method Derivative financial instruments Plant and equipment Right-of-use assets Intangible assets Deferred tax asset Total non-current assets Total assets Liabilities Current liabilities Trade and other payables Contract liabilities Lease liabilities Derivative financial instruments Employee benefits Contingent consideration Total current liabilities
17 18 13 20 26
Non-current liabilities Borrowings Lease liabilities Derivative financial instruments Employee benefits Contingent consideration Total non-current liabilities
21 13 20 26
Equity Issued capital Reserves Accumulated losses Profits reserve Equity attributable to the owners of Monash IVF Group Limited Non-controlling interest Total equity
22 23
The above consolidated statement of financial position should be read in conjunction with the accompanying notes 43
Monash IVF Group Limited Consolidated statement of changes in equity For the year ended 30 June 2026
Consolidated Balance at 1 July 2024
Issued capital $'000
Profit after income tax expense for the year Other comprehensive income for the year, net of tax Total comprehensive income for the year Transactions with owners in their capacity as owners: Share-based payments (note 36) Dividends paid to non-controlling interests Dividends paid (note 24) Balance at 30 June 2026
Total equity $'000
(162,735)
40,507
4,754
246,659
25,008
668
25,676
80
80
80
25,008
668
25,756
(797)
(50)
(600)
(797) (650)
(19,871)
(679)
(679) (19,871)
506,786
(143,370)
(162,735)
45,594
4,143
250,418
Noncontrolling interest $'000
Total equity $'000
Transactions with owners in their capacity as owners: Share-based payments (note 36) Share buy-back Dividends paid to non-controlling interests Dividends paid (note 24)
Balance at 1 July 2025
Noncontrolling interest $'000
(142,653)
Total comprehensive income for the year
Consolidated
Reserves $'000
Profits reserve $'000
506,786
Profit after income tax expense for the year Other comprehensive income for the year, net of tax
Balance at 30 June 2025
Accumulated losses $'000
Issued capital $'000
Accumulated losses $'000
Reserves $'000
Profits reserve $'000
506,786
(143,370)
(162,735)
45,594
4,143
250,418
7,425
901
8,326
114
114
114
7,425
901
8,440
19
19
(4,676)
(732)
(732) (4,676)
506,786
(143,237)
(162,735)
48,343
4,312
253,469
The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes 44
Monash IVF Group Limited Consolidated statement of cash flows For the year ended 30 June 2026 Note Cash flows from operating activities Receipts from customers (inclusive of GST) Payments to suppliers and employees (inclusive of GST)(1) Cash generated from operations Income taxes paid
Consolidated 2026 2025 $'000 $'000 267,523 (228,829)
270,378 (254,592)
38,694 (1,994)
15,786 (2,884)
Net cash flows generated from operating activities
37
36,700
12,902
Cash flows from investing activities Payment for purchase of business, net of cash acquired Payments for plant and equipment Payments for intangibles Proceeds from sale of business
14 16 12
(22,935) (834)
(3,039) (12,434) (1,993) 35
Net cash used in investing activities
(23,769)
(17,431)
Cash flows from financing activities Proceeds from borrowings Repayment of borrowings Repayment of lease liabilities Interest paid on borrowings Lease incentives received Dividends paid to shareholders Dividends paid to non-controlling interest
18,000 (7,000) (14,234) (6,495) 1,789 (4,676) (732)
65,000 (26,000) (12,446) (4,017) (19,871)
(13,348)
2,666
(417) 9,427 (168)
(1,863) 11,333 (43)
8,842
9,427
24
Net cash (used in)/from financing activities Net decrease in cash and cash equivalents Cash and cash equivalents at the beginning of the financial year Effects of exchange rate changes on cash and cash equivalents Cash and cash equivalents at the end of the financial year (1)
9
Payment to suppliers and employees in the prior comparison period includes $39,000,000 NiPGT class action payments net of insurance recoveries made.
The above consolidated statement of cash flows should be read in conjunction with the accompanying notes 45
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 1. Material accounting policy information The accounting policies that are material to the Group are set out either in the respective notes or below. The accounting policies adopted are consistent with those of the previous financial year, unless otherwise stated. New or amended Accounting Standards and Interpretations adopted The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. The adoption of these Accounting Standards does not have any significant impact for the full financial year ending 30 June 2026. Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. New Accounting Standards and Interpretations not yet mandatory or early adopted Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the Group for the annual reporting period ended 30 June 2026. The Group's assessment of the impact of these new or amended Accounting Standards and Interpretations, most relevant to the Group, are set out below. AASB 18 Presentation and Disclosure in Financial Statements This standard is applicable to annual reporting periods beginning on or after 1 January 2027 and early adoption is permitted. The standard replaces AASB 101 'Presentation of Financial Statements', with many of the original disclosure requirements retained and there will be no impact on the recognition and measurement of items in the financial statements. However the standard will affect presentation and disclosure in the financial statements, including introducing five categories in the statement of profit or loss and other comprehensive income: operating, investing, financing, income taxes and discontinued operations. The standard introduces two mandatory sub-totals in the statement: 'Operating profit' and 'Profit before financing and income taxes'. There are also new disclosure requirements for 'management-defined performance measures', such as earnings before interest, taxes, depreciation and amortisation ('EBITDA') or 'adjusted profit'. The standard provides enhanced guidance on grouping of information (aggregation and disaggregation), including whether to present this information in the primary financial statements or in the notes. The Group will adopt this standard from 1 July 2027 and it is expected that there will be a significant change to the layout of the statement of profit or loss and other comprehensive income. AASB 2024-2 Amendments to Australian Accounting Standards – Classification and Measurement of Financial Instruments The AASB has issued AASB 2024-2 to amend AASB 7 Financial Instruments: Disclosures and AASB 9 Financial Instruments. This Standard amends requirements related to: ● settling financial liabilities using an electronic payment system; and ● assessing contractual cash flow characteristics of financial assets with environmental, social and corporate governance (ESG) and similar features. This Standard also amends disclosure requirements relating to investments in equity instruments designated at fair value through other comprehensive income and adds disclosure requirements for financial instruments with contingent features that do not relate directly to basic lending risks and costs. AASB 2024-2 applies to annual periods beginning on or after 1 January 2026. Earlier application is permitted. The Group does not expect these amendments to have a material impact. Basis of preparation These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the Corporations Act 2001, as appropriate for for-profit oriented entities. These financial statements also comply with IFRS Accounting Standards as issued by the International Accounting Standards Board ('IASB'). Historical cost convention The financial statements have been prepared under the historical cost convention, except for derivative financial instruments and contingent consideration assumed in a business combination, which have been measured at fair value. Non-IFRS information The notes to the financial statements include certain financial measures which are not prescribed by the AASBs, namely the reference to EBITDA in note 3. Earnings Before Interest, Tax, Depreciation and Amortisation (‘EBITDA') is used to report the operating segments given the Directors assess this to be one of the core earnings measures for the Group.
46
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 1. Material accounting policy information (continued) Going concern As at 30 June 2026, the Group has net current liabilities of $21,614,000 (30 June 2025: $19,731,000). The Directors consider that there are reasonable grounds to believe the Group will be able to pay its debts as and when they are due. Consistent with prior years, the Group's approach to invoicing for certain procedures in advance also contributes to the net current asset deficiency with deferred revenue amounting to $11,860,000 recognised at reporting date (2025: $12,182,000). Forecast operating cash flows and scenarios indicate that cash generation continues to be sufficient to fund operations. In forming this view, the Directors have considered the nature of certain current liabilities, including employee entitlements and contract liabilities are unlikely to be fully settled in the short-term and therefore do not cause a liquidity shortfall. Current forecasts indicate that the Group will generate positive free cashflows for at least 12 months from the date of authorisation of these financial statements. The Group also remains comfortably within its covenant ratios and has the ongoing support of its banking partner. As a result, the Directors have adopted the going concern basis of accounting to prepare these financial statements. Parent entity information In accordance with the Corporations Act 2001, these financial statements present the results of the Group only. Supplementary information about the parent entity is disclosed in note 32. Principles of consolidation The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Monash IVF Group Limited ('Company' or 'parent entity') as at 30 June 2026 and the results of all subsidiaries for the year then ended. Monash IVF Group Limited and its subsidiaries together are referred to in these financial statements as the 'Group'. Subsidiaries are all those entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date that control ceases. Intercompany transactions, balances and unrealised gains on transactions between entities in the Group are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognised directly in equity attributable to the parent. Non-controlling interest in the results and equity of subsidiaries are shown separately in the statement of profit or loss and other comprehensive income, statement of financial position and statement of changes in equity of the Group. Losses incurred by the Group are attributed to the non-controlling interest in full, even if that results in a deficit balance. Where the Group loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and non-controlling interest in the subsidiary together with any cumulative translation differences recognised in equity. The Group recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss. Rounding of amounts The Company is of a kind referred to in Corporations Instrument 2026/183, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest thousand dollars, or in certain cases, the nearest dollar.
47
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 2. Critical accounting judgements, estimates and assumptions The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed in the respective notes. Note 3. Operating segments The Group determines and presents operating segments based on information that internally is provided to and used by the Chief Executive Officer (CEO), who is the Group’s Chief Operating Decision Maker (CODM). An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Group’s other components. The financial results of each operating segment are regularly reviewed by the Group’s CEO in order to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available. Segment results that are reported to the CEO include items directly attributable to a segment, as well as those that can be allocated on a reasonable basis. Unallocated items comprise mainly corporate assets, head office expenses and income tax assets and liabilities. Segment capital expenditure is the total cost incurred during the period to acquire property, plant and equipment and intangible assets other than goodwill. The basis of inter-segmental transfers is market pricing. Results are calculated before consideration of net borrowing costs and tax expense. Identification of reportable operating segments The two geographic segments being Australia and International reflect Monash IVF Group’s reporting structure to the CODM. Monash IVF Group considers that the two geographic segments are appropriate for segment reporting purposes under AASB 8 Operating Segments. These segments comprise the following operations: ● ●
Australia IVF and Ultrasound: provider of Assisted Reproductive Services, Ultrasound and other related services. International IVF: provider of Assisted Reproductive Services in South East Asia.
48
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 3. Operating segments (continued) Operating segment information Australia IVF International and IVF Ultrasound $'000 $'000
Consolidated - 2026 Revenue Revenue to external customers Total revenue EBITDA (before non-regular items)(1) Depreciation and amortisation expense Net finance costs Commissioning costs Class action and acquisition costs SaaS expenses and other costs Professional service costs and additional measures in response to incidents Business restructuring Profit before income tax expense Income tax expense Profit after income tax expense Assets Segment assets Total assets Total assets includes: Acquisition of non-current assets Liabilities Segment liabilities Total liabilities (1)
Non-IFRS measure.
49
Total $'000
248,237 248,237
21,222 21,222
269,459 269,459
48,069 (21,690) (8,951) (1,623) (191) (2,414) (4,485) (986) 7,729
5,350 (1,658) 174 (210) 3,656
53,419 (23,348) (8,777) (1,623) (191) (2,414) (4,485) (1,196) 11,385 (3,059) 8,326
497,104
15,249
512,353 512,353
12,575
12,575
243,260
15,624
258,884 258,884
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 3. Operating segments (continued) Australia IVF and International Ultrasound IVF $'000 $'000
Consolidated - 2025 Revenue Revenue to external customers Total revenue EBITDA (before non-regular items)(1) Depreciation and amortisation expense Net finance costs Commissioning costs Class action and acquisition costs SaaS expenses and other costs Professional service costs and additional measures in response to incidents Business restructuring Impairment of investment Profit before income tax expense Income tax expense Profit after income tax expense Assets Segment assets Total assets Total assets includes: Acquisition of non-current assets Liabilities Segment liabilities Total liabilities (1)
Total $'000
253,434 253,434
18,483 18,483
271,917 271,917
61,454 (20,344) (7,083) (503) 3,752 (1,562) (1,314) (516) 33,884
4,881 (1,675) (206) (761) 2,239
66,335 (22,019) (7,289) (503) 3,752 (1,562) (1,314) (516) (761) 36,123 (10,447) 25,676
476,628
15,979
492,607 492,607
5,775
3,060
8,835
226,999
15,190
242,189 242,189
Non-IFRS measure.
Note 4. Revenue from contract with customers Disaggregation of revenue is provided in note 3. Accounting policies: Revenue recognition Revenue is recognised when performance obligations have been satisfied, recovery of the consideration is probable and the amount of revenue can be measured reliably. Revenue is measured at the fair value of the consideration received or receivable. Rendering of services Revenue from rendering of services is recognised on completion of services provided. Revenue is recognised when the customer has consumed the benefits of the service, whether on completion of a medical procedure, on supply of drugs, or on completion of analytical tests.
50
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 5. Expenses Consolidated 2026 2025 $'000 $'000 Profit before income tax includes the following specific expenses: Superannuation expense (included as part of employee benefits expense) Defined contribution superannuation expense Share-based payments expense (included as part of employee benefits expense) Share-based payments expense
9,293
8,491
27
767
Accounting policies: Defined contribution superannuation expense Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred. Note 6. Net finance costs Consolidated 2026 2025 $'000 $'000 Finance income Interest revenue calculated using the effective interest method
(425)
(101)
Finance costs Interest and finance charges paid/payable on borrowings Amortisation of borrowing costs(1) Interest and finance charges paid/payable on lease liabilities Total finance costs
5,780 502 2,920 9,202
4,459 321 2,610 7,390
Net finance costs
8,777
7,289
(1)
Includes interest and amortisation of ancillary costs incurred in connection with the arrangement of borrowings.
Accounting policies: Finance costs Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred.
51
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 7. Income tax Consolidated 2026 2025 $'000 $'000 Income tax expense Current tax Deferred tax - origination and reversal of temporary differences Adjustment recognised for prior periods
3,099 992 (1,032)
1,275 9,089 83
Aggregate income tax expense
3,059
10,447
Deferred tax included in income tax expense comprises: Decrease in deferred tax assets Decrease in deferred tax liabilities
1,094 (102)
14,841 (5,752)
992
9,089
Numerical reconciliation of income tax expense and tax at the statutory rate Profit before income tax expense
11,385
36,123
Tax at the statutory tax rate of 30%
3,416
10,837
Tax effect amounts which are deductible in calculating taxable income: Research and development Sundry items
(250) 757
(250) (120)
Adjustment recognised for prior periods Difference in overseas tax rates
3,923 (1,032) 168
10,467 83 (103)
Income tax expense
3,059
10,447
Deferred tax - origination and reversal of temporary differences
Consolidated 2026 2025 $'000 $'000 Amounts recognised directly to equity Deferred tax assets Deferred tax liabilities
52
91
169 (113)
91
56
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 7. Income tax (continued) Consolidated 2026 2025 $'000 $'000 Deferred tax asset Deferred tax asset comprises temporary differences attributable to: Amounts recognised in profit or loss: Employee benefits Lease liabilities Trade and other payables Other Set-off from deferred tax liabilities as per set-off provisions
4,989 27,065 513 3,651 (31,160)
4,743 24,414 435 5,991 (29,533)
5,058
6,050
(8)
83
Deferred tax asset
5,050
6,133
Movements: Opening balance Charged to profit or loss Charged to equity Set-off from deferred tax liabilities as per set-off provisions
6,133 (1,094) 11
15,278 (14,841) (169) 5,865
Closing balance
5,050
6,133
Amounts recognised in equity: Set-off from deferred tax liabilities as per set-off provisions
53
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 7. Income tax (continued) Consolidated 2026 2025 $'000 $'000 Deferred tax liability Deferred tax liability comprises temporary differences attributable to: Amounts recognised in profit or loss: Property, plant and equipment Intangible assets Right-of-use assets Set-off against deferred tax assets as per set-off provisions
Amounts recognised in equity: Derivative financial instruments Set-off against deferred tax assets as per set-off provisions
Deferred tax liability Movements: Opening balance Credited to profit or loss Charged/(credited) to equity Set-off against deferred tax assets as per set-off provisions Closing balance
203 6,505 24,452 (31,160)
661 5,945 22,927 (29,533)
8 (8)
(83) 83
(102) 91 11
(5,752) (113) 5,865
Accounting policies: Tax consolidation Monash IVF Group Limited (the 'head entity') and its wholly-owned Australian subsidiaries have formed an income tax consolidated group under the tax consolidation regime. The head entity and each subsidiary in the tax consolidated group continue to account for their own current and deferred tax amounts. The tax consolidated group has applied the 'separate taxpayer within group' approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated group. In addition to its own current and deferred tax amounts, the head entity also recognises the current tax liabilities (or assets) and the deferred tax assets arising from unused tax losses and unused tax credits assumed from each subsidiary in the tax consolidated group. Assets or liabilities arising under tax funding agreements with the tax consolidated entities are recognised as amounts receivable from or payable to other entities in the tax consolidated group. The tax funding arrangement ensures that the intercompany charge equals the current tax liability or benefit of each tax consolidated group member, resulting in neither a contribution by the head entity to the subsidiaries nor a distribution by the subsidiaries to the head entity. Key estimate and judgement: Recovery of deferred tax assets Deferred tax assets are recognised for deductible temporary differences only if the Group considers it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realised.
54
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 7. Income tax (continued) Income taxes The Group is subject to income taxes in Australia and jurisdictions where it has foreign operations. Significant judgement is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The Group recognises liabilities for uncertain tax positions based on the Group's current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made. Note 8. Earnings per share Consolidated 2026 2025 $'000 $'000 Profit after income tax Non-controlling interest
8,326 (901)
25,676 (668)
Profit after income tax attributable to the owners of Monash IVF Group Limited
7,425
25,008
Number
Number
Weighted average number of ordinary shares used in calculating basic earnings per share Adjustments for calculation of diluted earnings per share:(1) Performance rights outstanding
389,634,840
389,634,840
1,271,067
1,325,255
Weighted average number of ordinary shares used in calculating diluted earnings per share
390,905,907
390,960,095
(1)
The calculation of the weighted average number of shares has been adjusted for the effect of share-based rights granted from the date of issue. Refer to note 36 for further details.
Cents Basic earnings per share Diluted earnings per share
Cents 1.9 1.9
6.4 6.4
Note 9. Cash and cash equivalents Consolidated 2026 2025 $'000 $'000 Current assets Cash at bank Cash on deposit
8,842
8,884 543
8,842
9,427
Accounting policies: Cash and cash equivalents Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. For the statement of cash flows presentation purposes, cash and cash equivalents also includes bank overdrafts, which are shown within borrowings in current liabilities on the statement of financial position.
55
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 10. Trade and other receivables Consolidated 2026 2025 $'000 $'000 Current assets Trade receivables Less: Allowance for expected credit losses Other receivables Accrued revenue Prepayments GST receivable
Non-current assets Other receivables Prepayments
7,659 (825) 6,834
7,644 (725) 6,919
5,250 862 7,291 4,552
3,768 993 9,295 2,174
24,789
23,149
178 332
182
510
182
25,299
23,331
Allowance for expected credit losses The Group recognised a loss allowance of $100,000 (2025: $100,000) in profit or loss in respect of the expected credit losses for the year ended 30 June 2026. Accounting policies: Trade and other receivables Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Other receivables are recognised at amortised cost, less any allowance for expected credit losses. Expected credit losses The Group recognises a loss allowance for expected credit losses on financial assets (including trade receivables) which are measured at amortised cost. The measurement of the loss allowance depends upon the Group's assessment at the end of each reporting period as to whether the financial instrument's credit risk has increased significantly since initial recognition, based on reasonable and supportable information that is available, without undue cost or effort to obtain. Where there has not been a significant increase in exposure to credit risk since initial recognition, a 12-month expected credit loss allowance is estimated. This represents a portion of the asset's lifetime expected credit losses that is attributable to a default event that is possible within the next 12 months. Where a financial asset has become credit impaired or where it is determined that credit risk has increased significantly, the loss allowance is based on the asset's lifetime expected credit losses. The amount of expected credit loss recognised is measured on the basis of the probability weighted present value of anticipated cash shortfalls over the life of the instrument discounted at the original effective interest rate. The Group has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue. Prepayments Payments made for the receiving of goods or services rendered in future years are recognised as a prepayment.
56
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 10. Trade and other receivables (continued) Key estimate and judgement: Allowance for expected credit losses The Group calculates the doubtful debts provision under the expected credit loss (ECL) model. The Group assesses credit losses based on the Group’s historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment. Note 11. Inventories Consolidated 2026 2025 $'000 $'000 Current assets Consumables - at cost
10,372
9,003
Inventories include medical supplies to be consumed in providing future patient services. Accounting policies: Inventories Consumables are stated at the lower of cost and net realisable value on a 'first in first out' basis. Cost comprises of direct materials and delivery costs, direct labour, import duties and other taxes, an appropriate proportion of variable and fixed overhead expenditure based on normal operating capacity. Costs of purchased inventory are determined after deducting rebates and discounts received or receivable. Note 12. Investment accounted for using the equity method Interests in associates are accounted for using the equity method of accounting. Information relating to associates that are material to the Group are set out below:
Name
Principal place of business and principal activity
Compass Fertility Trust (trading as 'Compass Fertility')
Australia - fertility services
Ownership interest 2026 2025 % % 30%
30%
Accounting policies: Investment accounted for using the equity method (associate) Associates are entities over which the Group has significant influence but not control or joint control. Investments in associates are accounted for using the equity method. Under the equity method, the share of the profits or losses of the associate is recognised in profit or loss and the share of the movements in equity is recognised in other comprehensive income. Investments in associates are carried in the statement of financial position at cost plus post-acquisition changes in the Group's share of net assets of the associate. Goodwill relating to the associate is included in the carrying amount of the investment and is neither amortised nor individually tested for impairment. Dividends received or receivable from associates reduce the carrying amount of the investment. When the Group's share of losses in an associate equals or exceeds its interest in the associate, including any unsecured long-term receivables, the Group does not recognise further losses, unless it has incurred obligations or made payments on behalf of the associate. The Group discontinues the use of the equity method upon the loss of significant influence over the associate and recognises any retained investment at its fair value. Any difference between the associate's carrying amount, fair value of the retained investment and proceeds from disposal is recognised in profit or loss.
57
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 13. Derivative financial instruments Consolidated 2026 2025 $'000 $'000 Non-current assets Interest rate swap contracts - cash flow hedges Current liabilities Interest rate swap contracts - cash flow hedges Put option liability over non-controlling interest Non-current liabilities Interest rate swap contracts - cash flow hedges Put option liability over non-controlling interest
27
(4,512) (4,512)
(27) (27)
(248) (4,555) (4,803)
(4,485)
(4,830)
Refer to note 25 for further information on financial risk management and note 26 for further information on fair value measurement. In April 2023, the Group entered into an interest rate swap of $15 million which is in a hedging relationship with existing debt. The swap matured on 14 April 2026. As a result, in June 2025, the Group entered into an interest rate swap of $25 million which is in a hedging relationship with existing debt. The swap will mature on 30 June 2028. In June 2026, the Group entered into an interest rate swap of $30 million which is in a hedging relationship with existing debt. The swap will mature on 29 June 2029. The put option liability is over the ordinary shares of the non-controlling interest in Fertility North Holdings Pty Ltd, based on the present value of the amounts expected to be paid at the time of exercise. Accounting policies: Derivative financial instruments Derivatives are initially recognised at fair value on the date the derivative contract is entered into and are subsequently remeasured to their fair value at each reporting date. The accounting for subsequent changes in fair value depends on whether the derivative is designated as a hedging instrument, and if so, the nature of the item being hedged. Derivatives are classified as current or non-current depending on the expected period of realisation. Cash flow hedges Cash flow hedges are used to cover the Group's exposure to variability in cash flows that is attributable to particular risks associated with a recognised asset or liability or a firm commitment which could affect profit or loss. The effective portion of changes in the fair value of derivatives and other qualifying hedging instruments that are designated and qualify as cash flow hedges is recognised in other comprehensive income and accumulated in the cash flow hedging reserve, limited to the cumulative change in fair value of the hedged item from inception of the hedge. The gain or loss relating to the ineffective portion is recognised immediately in profit or loss, and is included in the ‘other gains and losses’ line item. Amounts previously recognised in other comprehensive income and accumulated in equity are reclassified to profit or loss in the periods when the hedged item affects profit or loss, in the same line as the recognised hedged item. However, when the hedged forecast transaction results in the recognition of a non-financial asset or a non-financial liability, the gains and losses previously recognised in other comprehensive income and accumulated in equity are removed from equity and included in the initial measurement of the cost of the non-financial asset or non-financial liability. This transfer does not affect other comprehensive income. Furthermore, if the Group expects that some or all of the loss accumulated in the cash flow hedging reserve will not be recovered in the future, that amount is immediately reclassified to profit or loss.
58
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 13. Derivative financial instruments (continued) The Group discontinues hedge accounting only when the hedging relationship (or a part thereof) ceases to meet the qualifying criteria (after rebalancing, if applicable). This includes instances when the hedging instrument expires or is sold, terminated or exercised. The discontinuation is accounted for prospectively with any gain or loss accumulated in the cash flow hedge reserve reclassified to profit or loss when the forecast transaction occurs. When a forecast transaction is no longer expected to occur, the gain or loss accumulated in the cash flow hedge reserve is reclassified immediately to profit or loss. Put option liability The put option liability over non‑controlling interest is initially recognised at the present value of the amounts expected to be paid at the time of exercise with a corresponding entry to other reserves. At each reporting period, the put option liability over non‑controlling interests is reassessed and any changes in the estimates of the amounts expected to be paid at the time of exercise are recognised in the consolidated statement of profit or loss and the interest discount is unwound in finance costs. Key estimate and judgement: Put option liability The estimates and judgements applied in determining the Group’s put option liability over non‑controlling interest involves a high degree of complexity, as the amounts expected to be paid may differ from the actual amounts paid at the time that the option is exercised. The value of the put option liability over non‑controlling interest has been determined as the present value of management’s best estimate of the amounts expected to be paid at the time of exercise. In the determination of the amount expected to be paid at the time of exercise, the Group considers the key terms of the shareholders agreement and the business outlook. The valuations used to determine the carrying amounts of put option liability is based on forward‑looking key assumptions that are, by nature, uncertain, and include estimations of future performance, such as EBITDA. Note 14. Plant and equipment Consolidated 2026 2025 $'000 $'000 Non-current assets Leasehold improvements - at cost Less: Accumulated depreciation
11,659 (4,250) 7,409
11,166 (3,722) 7,444
Plant and equipment - at cost Less: Accumulated depreciation
124,412 (73,428) 50,984
117,962 (65,652) 52,310
Construction in progress - at cost
25,852
9,860
84,245
69,614
59
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 14. Plant and equipment (continued) Reconciliations Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:
Consolidated
Leasehold improvements
Plant and equipment
Construction in progress
Total
$'000
$'000
$'000
$'000
Balance at 1 July 2024 Additions Transfers in/(out) Depreciation expense
3,171 3,167 1,866 (760)
51,762 7,067 1,561 (8,080)
11,087 2,200 (3,427)
66,020 12,434 (8,840)
Balance at 30 June 2025 Additions Transfers in/(out) Depreciation expense
7,444 493 (528)
52,310 5,619 831 (7,776)
9,860 16,823 (831)
69,614 22,935 (8,304)
Balance at 30 June 2026
7,409
50,984
25,852
84,245
Capital commitments Expenditure contracted for but not recognised as liabilities: 2026 $'000 Capital plant and equipment
2025 $'000 667
8,897
Accounting policies: Plant and equipment Items of plant and equipment are measured at cost less accumulated depreciation and any accumulated impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and direct labour, any other costs directly attributable to bringing the assets to a working condition for their intended use, the costs of dismantling and removing the items and restoring the site on which they are located and capitalised borrowing costs. When parts of an item of plant and equipment have different useful lives, they are accounted for as separate items (major components) of plant and equipment. Depreciation is calculated on a straight-line basis to write off the net cost of each item of plant and equipment over their expected useful lives as follows: Leasehold improvements Plant and equipment Construction in progress
over the unexpired period of the lease or the estimated useful life of the assets, whichever is shorter 2-10 years not depreciated until ready for use
The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date. An item of property, plant and equipment is derecognised upon disposal or when there is no future economic benefit to the Group. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss. Gains and losses on disposal of an item of plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of plant and equipment and are recognised on a net basis within “other income” in profit or loss. The cost of replacing part of an item of plant and equipment is recognised in the carrying amount of the item if it is probable that the future economic benefits embodied with the part will flow to the Group and its cost can be measured reliably. The carrying amount of the replaced part is derecognised. The costs of the day-to-day servicing of the plant and equipment are recognised in profit or loss as incurred.
60
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 14. Plant and equipment (continued) Key estimate and judgement: Depreciation Depreciation methods, useful lives and residual values are reviewed at each reporting date. Depreciation is recognised in profit or loss on a straight line basis over the estimated useful lives of each part of an item of plant and equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Estimation of useful lives of assets The Group determines the estimated useful lives and related depreciation charges for its plant and equipment. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down. Note 15. Right-of-use assets Consolidated 2026 2025 $'000 $'000 Non-current assets Buildings Less: Accumulated depreciation Equipment Less: Accumulated depreciation
135,478 (54,119) 81,359
118,450 (42,352) 76,098
1,770 (1,621) 149
1,770 (1,445) 325
81,508
76,423
The Group leases buildings and equipment. The leases typically run for a period of between one to ten years, with an option to renew the lease after this date. Lease payments are renegotiated at periods to reflect market rentals. The Group has elected not to recognise right-of-use assets and lease liabilities for short-term and/or low-value assets such as IT and office equipment. Some leases contain extension options exercisable by the Group up to one year before the end of the non-cancellable contract period. Where practicable, the Group seeks to include extension options in new leases to provide operational flexibility. The extension options held are exercisable by the Group and not by the lessors. The Group assesses at lease commencement date whether it is reasonably certain to exercise the extension options. The Group reassesses whether it is reasonably certain to exercise the options if there is a significant event or significant changes in circumstances within its control. For AASB 16 Lease disclosures refer to: ● note 6 for interest on lease liabilities; ● note 37 for lease liabilities and total cash outflow for leases; and ● consolidated statement of cash flows for repayment of lease liabilities.
61
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 15. Right-of-use assets (continued) Reconciliations Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below: Buildings $'000
Consolidated
Equipment $'000
Total $'000
Balance at 1 July 2024 Additions Depreciation expense
71,587 15,431 (10,920)
501 (176)
72,088 15,431 (11,096)
Balance at 30 June 2025 Additions Lease incentives Lease modifications Depreciation expense
76,098 14,960 (2,385) 5,036 (12,350)
325 (176)
76,423 14,960 (2,385) 5,036 (12,526)
Balance at 30 June 2026
81,359
149
81,508
Accounting policies: Right-of-use assets A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset. Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the Group expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of use assets are subject to impairment or adjusted for any remeasurement of lease liabilities. The Group has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred. Key estimate and judgement: Lease term The lease term is a significant component in the measurement of both the right-of-use asset and lease liability. Judgement is exercised in determining whether there is reasonable certainty that an option to extend the lease or purchase the underlying asset will be exercised, or an option to terminate the lease will not be exercised, when ascertaining the periods to be included in the lease term. In determining the lease term, all facts and circumstances that create an economical incentive to exercise an extension option, or not to exercise a termination option, are considered at the lease commencement date. Factors considered may include the importance of the asset to the Group's operations; comparison of terms and conditions to prevailing market rates; incurrence of significant penalties; existence of significant leasehold improvements; and the costs and disruption to replace the asset. The Group reassesses whether it is reasonably certain to exercise an extension option, or not exercise a termination option, if there is a significant event or significant change in circumstances.
62
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 16. Intangible assets Consolidated 2026 2025 $'000 $'000 Non-current assets Goodwill - at cost
273,351
273,351
Trademarks - at cost
19,850
19,850
Software - at cost Less: Accumulated amortisation
19,824 (17,474) 2,350
18,990 (14,956) 4,034
295,551
297,235
Reconciliations Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below: Goodwill $'000
Consolidated
Trademarks $'000
Software $'000
Total $'000
Balance at 1 July 2024 Additions Amortisation expense
273,351
19,850
4,124 1,993 (2,083)
297,325 1,993 (2,083)
Balance at 30 June 2025 Additions Amortisation expense
273,351
19,850
4,034 834 (2,518)
297,235 834 (2,518)
Balance at 30 June 2026
273,351
19,850
2,350
295,551
Impairment testing Goodwill and other indefinite life intangible assets become impaired when their carrying value exceeds their recoverable amount. Recoverable amount is the greater of fair value less costs to sell or value in use. In determining the recoverable amount, judgments and assumptions are made in the determination of likely net sale proceeds or in the determination of future cash flows which support a value in use. Specifically, with respect to future cash flows, judgments are made in respect to the quantum of those future cash flows and the discount rates (cost of capital and debt) applied to determining the net present value of these future cash flows. The carrying amounts of the Group’s non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists then the asset’s recoverable amount is estimated. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows of other assets or groups of assets (the ‘cash-generating’ units). The recoverable amount of an asset or cash-generating unit (CGU) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU. An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its recoverable amount. Impairment losses are recognised in profit or loss. Impairment losses recognised in respect of CGUs are allocated first to reduce the carrying amount of any goodwill allocated to the CGU and then to reduce the carrying amount of the other assets in the CGU (group of CGUs) on a pro rata basis. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation and amortisation, if no impairment loss had been recognised.
63
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 16. Intangible assets (continued)
Goodwill allocated to:
Consolidated 2026 2025 $'000 $'000
Australia Ultrasound International
239,367 28,232 5,752
239,367 28,232 5,752
273,351
273,351
Consolidated 2026 2025 $'000 $'000
Trademark allocated to: Australia
19,850
19,850
Impairment testing assumptions The recoverable amount of a CGU is based on value-in-use calculations. The following key assumptions were utilised for the impairment testing: ● The respective discount rate was a pre-tax measure based on the rate of 10 year Government bonds issued by the Australian and Malaysian Government respectively in the relevant market, adjusted for a risk premium to reflect the increased risk of investing in equities generally and the systemic risk of the specific CGU. A pretax discount rate of 12.0% (2025: 11.6%) for the Australian CGU, 12.0% (2025: 11.7%) for the Ultrasound CGU and 11.6% (2025: 12.6%) for the International CGU was applied in determining the recoverable amount. ● Cash flow forecasts are based on the Board-approved FY27 budget, projected for four years plus a terminal value. The FY27 budget reflects management’s best estimate of forecast operating performance having regard to the IVF markets in Australia and Malaysia and anticipated ultrasound activity. ● A 3% growth rate has been applied across all cash-generating units for the purpose of extrapolating future cash flows. ● A long-term growth rate into perpetuity of 3% (2025: 3%) has been determined based on an assessment of historical growth rates, expectations of future growth rates and market specific dynamics. Impact of possible changes in key assumptions All CGU’s in the Group have been tested for impairment and have met their required hurdle rates to support the current carrying values. Any reasonable possible change to relevant assumptions and inputs would not result in the recoverable amount being lower than the carrying amount. Result of impairment testing The recoverable amount of all CGU’s exceed their carrying amounts. Accounting policies: Intangible assets Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising from the derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period. Goodwill Goodwill arises on the acquisition of a business. Goodwill is not amortised. Instead, goodwill is tested annually for impairment, or more frequently if events or changes in circumstances indicate that it might be impaired, and is carried at cost less accumulated impairment losses. Impairment losses on goodwill are taken to profit or loss and are not subsequently reversed.
64
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 16. Intangible assets (continued) Trademarks Trademarks are reported at historical cost less impairment. Trademarks have an indefinite useful life where there is no expiry and no foreseeable limit on the period of time over which these assets are expected to contribute to the cash flows of the Group. Similar to goodwill, these are tested for impairment annually. Software Software has a finite useful life and is carried at cost less accumulated amortisation and impairment losses. The cost of system development, including purchased software, is capitalised and amortised over the estimated useful life, being three to ten years. Amortisation methods, useful lives and residual values are reviewed at each financial year end and adjusted if appropriate. Software-as-a-Service (SaaS) arrangements SaaS arrangements are service contracts providing the Group with the right to access the cloud provider’s application software over the contract period. As such, the Group does not receive a software intangible asset at the contract commencement date. The following outlines the accounting treatment of costs incurred in relation to SaaS arrangements: ● costs recognised as an operating expense over the term of the service contract include fees for use of application software and customisation costs; ● costs recognised as an operating expense as the service is received include configuration costs, data conversion and migration costs, testing costs and training costs; ● costs incurred for the development of software code that enhance, modify or create additional capability to an existing premise system, and meets the definition of and recognition criteria for an intangible asset are recognised as intangible software assets. Key estimate and judgement: Impairment of non-financial assets other than goodwill and other indefinite life intangible assets The Group assesses impairment of non-financial assets other than goodwill and other indefinite life intangible assets at each reporting date by evaluating conditions specific to the Group and to the particular asset that may lead to impairment. If an impairment trigger exists, the recoverable amount of the asset is determined. This involves fair value less costs of disposal or value-in-use calculations, which incorporate a number of key estimates and assumptions. Goodwill and other indefinite life intangible assets The Group tests annually, or more frequently if events or changes in circumstances indicate impairment, whether goodwill and other indefinite life intangible assets have suffered any impairment, in accordance with the above accounting policy for intangible assets. The recoverable amounts of cash-generating units have been determined based on value-in-use calculations. These calculations require the use of assumptions, including estimated discount rates based on the current cost of capital and growth rates of the estimated future cash flows. Estimation of useful lives of assets The Group determines the estimated useful lives and related amortisation charges for its finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other event. The amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.
65
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 17. Trade and other payables Consolidated 2026 2025 $'000 $'000 Current liabilities Trade payables Accrued expenses
5,046 13,312
5,775 14,752
18,358
20,527
Accounting policies: Trade and other payables Trade and other payables represent liabilities for goods and services provided to the Group prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are paid in accordance with vendor terms. Note 18. Contract liabilities Consolidated 2026 2025 $'000 $'000 Current liabilities Deferred revenue
11,860
12,182
Accounting policies: Contract liabilities Contract liabilities represent the Group's obligation to perform fertility treatments and are recognised when a customer pays consideration, or when the Group recognises a receivable to reflect its unconditional right to consideration (whichever is earlier) before the Group has transferred the goods or services to the customer. Note 19. Lease liabilities Refer to note 25 for further information on financial risk management. Accounting policies: Lease liabilities A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Group's incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred. Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.
66
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 20. Employee benefits Consolidated 2026 2025 $'000 $'000 Current liabilities Annual leave Long service leave
Non-current liabilities Long service leave
7,776 7,276
7,258 7,333
15,052
14,591
1,416
1,168
16,468
15,759
Accounting policies: Short-term employee benefits Liabilities for wages and salaries, including non-monetary benefits, annual leave, long service leave and any other employee benefits expected to be settled wholly within twelve months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled. Long-term employee benefits The liability for annual leave and long service leave not expected to be settled within twelve months of the reporting date are measured at the present value of expected future payments to be made in respect of services provided by employees up to the reporting date. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows. Note 21. Borrowings Consolidated 2026 2025 $'000 $'000 Non-current liabilities Bank loans Capitalised finance facility fees
110,000 (600)
99,000 (471)
109,400
98,529
Assets pledged as security The banking facilities are secured via a first ranking security over substantially all of the Group’s entities assets. The Group is subject to certain financial undertakings under the banking facilities. As at 30 June 2026, the Group is compliant with its financial undertakings. The bank loans are subject to certain financial covenants and these are assessed at the end of each quarter. The loans will be repayable immediately if the covenants are breached. The Group is not aware of any facts or circumstances that indicate that it may have difficulty complying with the covenants within 12 months after the reporting period.
67
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 21. Borrowings (continued) Financing arrangements Unrestricted access was available at the reporting date to the following lines of credit: Consolidated 2026 2025 $'000 $'000 Total facilities Bank loans - Syndicated debt facility A NAB - Working capital facility (bank guarantees)* Used at the reporting date Bank loans - Syndicated debt facility A NAB - Working capital facility (bank guarantees)* Unused at the reporting date Bank loans - Syndicated debt facility A NAB - Working capital facility (bank guarantees)* *
130,000 10,000 140,000
100,000 9,329 109,329
110,000 5,473 115,473
99,000 3,896 102,896
20,000 4,527 24,527
1,000 5,433 6,433
The NAB working capital facility is used for lease bank guarantees which is off-balance sheet.
Accounting policies: Borrowings Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They are subsequently measured at amortised cost using the effective interest method. Note 22. Issued capital 2026 Shares Ordinary shares - fully paid
389,634,840
Consolidated 2025 2026 Shares $'000 389,634,840
506,786
2025 $'000 506,786
Accounting policies: Ordinary shares Ordinary shares entitle the holder to participate in any dividends declared and any proceeds attributable to shareholders should the Company be wound up, in proportions that consider both the number of shares held and the extent to which those shares are paid up. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital. On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.
68
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 22. Issued capital (continued) Capital management The Group’s policy is to maintain a strong capital base so as to maintain investor and market confidence and to sustain future growth of the business. Management monitors the return on capital as well as the level of dividends to ordinary shareholders. The Board of Directors seeks to maintain a balance between the higher returns that might be possible with higher levels of borrowings and the advantages and security afforded by a sound capital structure. In order to maintain an optimal capital structure, the Group may amend the amount of dividends declared and paid, return capital to shareholders or increase borrowings or equity to fund growth and future acquisitions. Escrow arrangements The following ordinary shareholders have entered into voluntary escrow arrangements in relation to certain ordinary shares they hold in Monash IVF Group Ltd. An ‘escrow’ is a restriction on sale, disposal, or encumbering of, or certain other dealings in respect of, the shares concerned for the period of the escrow, subject to exceptions set out in the escrow arrangement. 30 June 2026 30 June 2025 Escrowed Escrowed Number of shares (as a % Number of shares (as a % shares subject of shares on shares subject of shares on to escrow (m) issue to escrow (m) issue
Doctors(1) Sydney Ultrasound for Women Total (1)
8.83 0.57 9.40
2.3% 0.1%
10.44 0.57 11.01
2.7% 0.1%
2026 includes 0.5 million shares subject to escrow held by Richard Henshaw (Executive Director) (2025: 0.5 million shares)
The escrow applied to a pre-IPO Doctor was calculated by reference to the aggregate value of that person’s pre-reorganisation equity interests in Healthbridge Enterprises Pty Ltd as follows: ● Shares equivalent to 10% of a Doctor’s interest prior to the reorganisation were held in short-term escrow, with 3.33% released each year from escrow on the first trading day in Shares following the Company’s FY15, FY16 and FY17 financial results announcements to the ASX. This concluded the release of the pre-IPO doctor short-term escrow. Shares held in long-term doctors escrow are subject to the following conditions:
- Shares equivalent to 20% of a Doctor’s interest prior to the reorganisation will be released when the Doctor reaches the age of 63. These shares may be otherwise released from escrow in the following circumstances: ● for Doctors who were aged 63 or older at the time of reorganisation or who turned 63 within two years of Completion, these shares can be released from escrow from June 2016; or ● where a Doctor becomes a ‘relocated leaver’ (as described below), these Shares can be released from escrow five years after the date that they become a ‘relocated leaver’; or ● where a Doctor dies or leaves the Group as a result of becoming permanently disabled or seriously disabled, these shares can be released from escrow on the date of the relevant occurrence (as resolved by the Board acting reasonably); or ● if the Board determines to release the shares from escrow earlier.
- Shares equivalent to 20% of a Doctor’s interest prior to reorganisation can be released from escrow: ● on retirement by the Doctor from the Assisted Reproductive Services (ARS) industry (provided a Doctor must have used their best endeavours to transition their practice to another Doctor to the satisfaction of the Board); or ● if the Doctor becomes a ‘good leaver’ or a ‘relocated leaver’ (as described below); or ● five years after the Doctor leaves Monash IVF Group in other circumstances. Doctors will be able to sell any non-escrowed Shares at any time, subject to complying with insider trading restrictions and the Group’s Securities Trading Policy. The escrow arrangements describe the circumstances in which a Doctor is a ‘good leaver’ or a ‘relocated leaver’ in the following manner:
69
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 22. Issued capital (continued) (a) A Doctor is a ‘good leaver’ where: ● they leave the Group as a result of death, serious disability or permanent incapacity through ill health (as determined by the Group’s Board, acting reasonably); or ● they or the Group terminates the Doctor’s contract in specific circumstances; or ● the Board determines, in its discretion, that the Doctor is a ‘good leaver’. (b) A Doctor is a ‘relocated leaver’ if they terminate their contract and the Board is satisfied that: ● the Doctor genuinely intends to relocate permanently to a place which is more than 100 km from any clinic operated by the Group or any of its subsidiaries; and ● the Doctor also intends to provide ARS in the place the Doctor is relocating to; and ● the Doctor has used their best endeavours to transition their practice to another Doctor at the Group. Shares held in long-term escrow of SUFW doctors are subject to the following conditions: All shares issued to the vendors of SUFW are escrowed such that 53.3% of the shares issued were escrowed until the first trading day after the release of the FY16 results. 3.3% were escrowed until the first trading day after the release of the FY17 results and 3.3% are escrowed until the first trading day after the release of the FY18 results. The remaining 40.1% is subject to escrow and is consistent with the Doctors above in points 1 and 2. Doctors will be able to sell any non-escrowed Shares at any time, subject to complying with insider trading restrictions and the Group’s Securities Trading Policy. The escrow arrangements describing the circumstances in which a SUFW Doctor is a ‘good leaver’ or a ‘relocated leaver’ is the same as described above. Note 23. Reserves Included as part of the Reserves balance are the following: Foreign currency translation reserve The foreign currency translation reserve, with a debit balance of $168,000 as at 30 June 2026, is used to recognise exchange differences arising from the translation of the financial statements of foreign operations to Australian dollars (30 June 2025: $27,000). Hedging reserve - cash flow hedges The hedge reserve, with a credit balance of $19,000 as at 30 June 2026, is used to recognise the effective portion of the gain or loss of cash flow hedge instruments that is determined to be an effective hedge (30 June 2025: $193,000 debit balance). Share-based payments reserve The share-based payments reserve is used to recognise the value of equity benefits provided to employees and Directors as part of their remuneration, and other parties as part of their compensation for services. Other equity reserve The other equity reserve, with a debit balance of $136,811,000 as at 30 June 2026, represents the difference between the issued capital in Healthbridge Enterprises Pty Ltd and Monash IVF Group Ltd on 26 June 2014, being the date Monash IVF Group Ltd acquired Healthbridge Enterprises Pty Ltd (30 June 2025: $136,811,000 debit balance). Put option liability reserve The put option liability reserve, with a debit balance of $4,512,000 as at 30 June 2026 arises on recognition of put option liabilities over non‑controlling interests (30 June 2025: $4,555,000). Subsequent to initial recognition, the put option liabilities are measured at the present value of the amounts expected to be paid at the time of exercise, with any changes recognised in profit or loss.
70
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 23. Reserves (continued) Movements in reserves Movements in each class of reserve during the current and previous financial year are set out below:
Consolidated
Foreign currency translation reserve $'000
Hedging reserve cash flow hedges $'000
Share-based payments Other equity reserve reserve $'000 $'000
Put option liability reserve $'000
Total $'000
Balance at 1 July 2024 Revaluation Foreign currency translation Equity-settled share-based payments Treasury shares acquired
(452) 425
152 (345)
(987)
(136,811)
(4,555)
(142,653) (345) 425
(423) (374)
(423) (374)
Balance at 30 June 2025 Revaluation Foreign currency translation Equity-settled share-based payments
(27) (141)
(193) 212
(1,784)
(136,811)
(4,555) 43
(143,370) 255 (141)
19
19
Balance at 30 June 2026
(168)
19
(1,765)
(136,811)
(4,512)
(143,237)
Note 24. Dividends Dividends Dividends paid during the financial year were as follows: Consolidated 2026 2025 $'000 $'000 Fully franked final dividend for the year ended 30 June 2026 of 1.3 cents (2025: 2.5 cents) per ordinary share Fully franked interim dividend for the year ended 30 June 2026 of 1.2 cents (2025: 2.6 cents) per ordinary share
5,065
9,742
4,676
10,129
9,741
19,871
Monash IVF Group’s dividend policy is to target a payout ratio of between 60% and 70% of Underlying NPAT(1). The level of payout ratio is expected to vary between periods depending on general operating conditions, operating cashflow and profit, funding, strategic growth opportunities and availability of franking credits. Subsequent to 30 June 2026, the Board elected to declare a final fully franked dividend for the year of 1.3 cents per share, reflecting the improved outlook and stabilised FY2026 earnings. The record date for the final dividend is 4 September 2026 and the expected dividend payment date is 15 October 2026. (1)
Underlying NPAT is a non-IFRS measure that adjusts profit after tax for certain non-regular items.
Franking credits Consolidated 2026 2025 $'000 $'000 Franking credits available for subsequent financial years based on a tax rate of 30%
71
5,349
8,223
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 24. Dividends (continued) The above amounts represent the balance of the franking account as at the end of the financial year, adjusted for: ● franking credits that will arise from the payment of the amount of the provision for income tax at the reporting date ● franking debits that will arise from the payment of dividends recognised as a liability at the reporting date ● franking credits that will arise from the receipt of dividends recognised as receivables at the reporting date Note 25. Financial risk management Financial risk management objectives The Group's activities expose it to a variety of financial risks: ● market risk (including foreign currency risk, interest rate risk, and operational risk), ● credit risk; and ● liquidity risk. The Group's overall risk management program focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the financial performance of the Group. The Group uses derivative financial instruments such as interest rate swaps to hedge certain risk exposures. Derivatives are exclusively used for hedging purposes, i.e. not as trading or other speculative instruments. The Group uses different methods to measure different types of risk to which it is exposed. These methods include sensitivity analysis in the case of interest rate, foreign exchange and other price risks and ageing analysis for credit risk. Risk management is carried out by senior finance executives ('finance') under policies approved by the Board of Directors ('the Board'). These policies include identification and analysis of the risk exposure of the Group and appropriate procedures, controls and risk limits. Finance identifies, evaluates and hedges financial risks within the Group's operating units. Finance reports to the Board on a monthly basis. Market risk Foreign currency risk The Group is not exposed to material levels of foreign currency risk at the reporting date or during the financial year. Interest rate risk The Group's main interest rate risk arises from long-term borrowings. Borrowings obtained at variable rates expose the Group to cashflow interest risk. Borrowings obtained at fixed rates expose the Group to fair value interest rate risk. Interest rate risk may be managed using a mix of floating rate debt and fixed rate instruments. Interest rate swaps are not entered into for trading purposes and are not classified as held for trading. The policy is to maintain at least 50% of current borrowings at fixed rates using interest rate swaps to achieve this when necessary. Current interest rate hedges in place as at 30 June 2026 operate to fix approximately 40% of variable rate debt. The Group is working towards fixing at least 50% of its variable debt. The interest rate profile of the Group’s interest-bearing financial instruments, including the impact of hedging instruments: 2026 $'000 Fixed rate instruments Financial assets Financial liabilities Variable rate instruments Financial assets Financial liabilities
2025 $'000
(90,218) (90,218)
543 (81,502) (80,959)
8,842 (109,400) (100,558)
8,884 (98,529) (89,645)
Cash flow sensitivity analysis for variable rate instruments A reasonable possible change of a 100 basis points in interest rates at the reporting date would have increased /(decreased) equity and profit or loss by $1,005,580 (2025: $896,450). This assumes that all other variables remain constant.
72
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 25. Financial risk management (continued) Credit risk Credit risk is the risk of financial loss to the Group if a patient or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Group’s trade receivables, being patients. Patient fees for most treatments are received in advance and recognised as deferred revenue if the procedure is yet to be performed. This reduces the risk of non-collectability. Outstanding receivables predominantly relate to amounts owing from Medicare and storage fee patient accounts. Payment reminder notices are issued to patients with outstanding balances at 30, 60 and 90 days. After which, collection of this debt may be handled by a collection agency. The Group does not have any material credit risk exposure to any single receivable or group of receivables under financial instruments entered into by the Group. Liquidity risk Vigilant liquidity risk management requires the Group to maintain sufficient liquid assets (mainly cash and cash equivalents) and available borrowing facilities to be able to pay debts as and when they become due and payable. The Group manages this risk through the following mechanisms: ● preparing forward-looking financial analysis in relation to its operational, investing and financing activities; ● maintaining and monitoring undrawn credit facilities; ● obtaining funding from a variety of sources; ● maintaining a reputable credit profile; ● managing credit risk related to financial assets; ● only investing surplus cash with major financial institutions; and ● comparing the maturity profile of financial liabilities with the realisation profile of financial assets. Financing arrangements Refer to note 21 for details on financing arrangements. Remaining contractual maturities The following tables detail the Group's remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position.
Consolidated - 2026
Weighted average Between 1 interest rate 1 year or less and 5 years Over 5 years % $'000 $'000 $'000
Non-derivatives Non-interest bearing Trade and other payables Interest-bearing Bank loans Lease liabilities Total non-derivatives
6.26% 3.00%
73
Remaining contractual maturities $'000
18,358
18,358
7,990 13,757 40,105
125,979 54,839 180,818
36,210 36,210
133,969 104,806 257,133
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 25. Financial risk management (continued)
Consolidated - 2025
Weighted average Between 1 interest rate 1 year or less and 5 years Over 5 years % $'000 $'000 $'000
Non-derivatives Non-interest bearing Trade and other payables Interest-bearing Bank loans Lease liabilities Total non-derivatives
6.16% 3.00%
Remaining contractual maturities $'000
20,527
20,527
11,366 31,893
109,161 36,921 146,082
36,825 36,825
109,161 85,112 214,800
The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above. Note 26. Fair value measurement Fair value hierarchy The following tables detail the Group's assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date, such as payables (including variable rate secured bank loans); Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); Level 3: Unobservable inputs for the asset or liability Level 1 $'000
Consolidated - 2026
Level 2 $'000
Level 3 $'000
Total $'000
Assets Derivative financial instruments - interest rate swap contracts Total assets
27 27
27 27
Liabilities Put option liability Contingent consideration Total liabilities
4,512 8,068 12,580
4,512 8,068 12,580
Level 1 $'000
Consolidated - 2025 Liabilities Put option liability Contingent consideration Derivative financial instruments - interest rate swap contracts Total liabilities
Level 2 $'000
275 275
Level 3 $'000 4,555 8,860 13,415
Total $'000 4,555 8,860 275 13,690
There were no transfers between levels during the financial year. The carrying amounts of trade and other receivables, trade and other payables and variable rate bank loans are assumed to approximate their fair values due to their short-term nature. Valuation techniques for fair value measurements categorised within level 2 and level 3 Interest rate swaps have been valued using quoted market rates from broker quotes. This valuation technique maximises the use of observable market data where it is available and relies as little as possible on entity specific estimates. No significant unobservable inputs apply.
74
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 26. Fair value measurement (continued) The put option liability is based on the present value of the amounts expected to be paid at the time of exercise. The fair value is determined considering EBITDA for the most recent financial year and forecast EBITDA for the following twelve months. Contingent consideration measurement is based on the achievement of future earnings performance and is assessed for the likelihood of achievement. Note 27. Contingent asset - insurance recoverable The Board has considered the recoverability of professional and ancillary costs incurred in relation to claims that have been lodged and settled by the Group. The Board considers that these items are recoverable against our policy on a more likely than not that basis. The Group currently estimates that the potential insurance recoverable is up to $2.8 million. Pursuant to AASB 137 Provisions, Contingent Liabilities and Contingent Assets, the potential insurance recoveries have not been recognised as an asset as receipt of the recoveries is not considered virtually certain at the reporting date. The recoveries will be recognised when receipt becomes virtually certain. Note 28. Contingent liabilities The Group may be involved in legal claims, administrative actions, and proceedings related to the normal conduct of its business including, among other things, medical malpractice, general liability, commercial, employment, and intellectual property matters such as the significant proceeding listed below. Based upon existing information, it is not always possible to predict with certainty the outcome or cost of current legal claims, actions, and proceedings. The Group establishes accruals for estimated costs associated with such matters in a manner that complies with applicable accounting standards. The Directors believe that current matters of which they are aware, should not significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in subsequent financial periods. The Group has previously disclosed settlement of claims arising from the Brisbane and Clayton incidents. The Group’s insurers have confirmed indemnity for claims arising these incidents under the terms and conditions of the relevant policies. Based on information available at the reporting date, and having regard to insurance coverage in place, the Directors do not expect any material exposures to arise in connection with these matters. Notwithstanding the above, as at the date of these financial statements, the Group is not aware of any matter which should be disclosed as a contingent liability in these financial statements. Note 29. Key management personnel disclosures Compensation The aggregate compensation made to Directors and other members of key management personnel of the Group is set out below: Consolidated 2026 2025 $ $ Short-term employee benefits Post-employment benefits Termination benefits Share-based payments(1)
2,264,950 139,511 215,072 (95,580)
2,385,078 246,214 334,173 (373,661)
Total key management personnel compensation
2,523,953
2,591,804
(1)
This includes an adjustment for 346,547 (30 June 2025: 2,190,259) unvested performance rights that lapsed as the service period condition was not met.
Transactions with key management personnel Transactions between key management personnel are on normal commercial terms and conditions no more favourable than those available to other parties unless otherwise stated.
75
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 30. Remuneration of auditors During the financial year the following fees were paid or payable for services provided by KPMG, the auditor of the Company, and other unrelated audit firms: Consolidated 2026 2025 $ $ Audit services - KPMG Audit and review of the financial statements
367,216
356,520
Other services - KPMG Taxation services
53,469
168,569
420,685
525,089
39,628
41,951
Audit services - unrelated firms Audit and review of the financial statements Note 31. Related party transactions Parent entity Monash IVF Group Limited is the parent entity. Subsidiaries Interests in subsidiaries are set out in note 34. Associates Interests in associates are set out in note 12. Key management personnel Disclosures relating to key management personnel are set out in note 29. Transactions with related parties There were no transactions with related parties during the current and previous financial year.
Receivable from and payable to related parties There were no trade receivables from or trade payables to related parties at the current and previous reporting date. Loans to/from related parties There were no loans to or from related parties at the current and previous reporting date. Terms and conditions All transactions were made on normal commercial terms and conditions and at market rates.
76
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 32. Parent entity information Set out below is the supplementary information about the parent entity, Monash IVF Group Limited. Statement of profit or loss and other comprehensive income Parent 2026 $'000
2025 $'000
(Loss)/profit after income tax
(8,345)
16,039
Total comprehensive (loss)/income
(8,345)
16,039
Statement of financial position Parent 2026 $'000 Total current assets
2025 $'000
4,337
616,545
598,161
8,543
4,365
Total liabilities
118,058
91,391
Equity Issued capital Other reserve Other equity reserve Retained profits/(accumulated losses)
506,786 (78) (4,512) (3,709)
506,786 (97) (4,555) 4,636
Total equity
498,487
506,770
Total assets Total current liabilities
Guarantees entered into by the parent entity in relation to the debts of its subsidiaries The parent entity and some of its subsidiaries are party to a deed of cross guarantee under which Monash IVF Group Limited guarantees the debts of those subsidiaries. Refer to note 35. Contingent liabilities The parent entity had no contingent liabilities as at 30 June 2026 and 30 June 2025. Capital commitments - Property, plant and equipment Parent 2026 $'000 Committed at the reporting date but not recognised as liabilities, payable: Property, plant and equipment
2025 $'000 667
8,897
Material accounting policy information: The accounting policies of the parent entity are consistent with those of the Group, as disclosed in note 1, except for the following: ● Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity. ● Dividends received from subsidiaries are recognised as other income by the parent entity and its receipt may be an indicator of an impairment of the investment.
77
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 33. Asset acquisition There were no material acquisitions during 2025 and 2026. Accounting policies: Business combinations The acquisition method of accounting is used to account for business combinations regardless of whether equity instruments or other assets are acquired. This method is also used to account for business combinations when the acquired set of activities and assets meets the definition of a business and control is transferred to the Group. To determine whether a set of activities and assets constitutes a business, the Group has the choice to apply a `concentration test', which is met if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. Alternatively, to determine if a business has been acquired, the Group assesses whether (as a minimum) an input and substantive process has been acquired and whether there is an ability to produce outputs from these. The consideration transferred is the sum of the acquisition-date fair values of the assets transferred, equity instruments issued or liabilities incurred by the acquirer to former owners of the acquiree and the amount of any non-controlling interest in the acquiree. For each business combination, the non-controlling interest in the acquiree is measured at either fair value or at the proportionate share of the acquiree's identifiable net assets. All acquisition costs are expensed as incurred to profit or loss. On the acquisition of a business, the Group assesses the financial assets acquired and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic conditions, the Group's operating or accounting policies and other pertinent conditions in existence at the acquisition-date. Where the business combination is achieved in stages, the Group remeasures its previously held equity interest in the acquiree at the acquisition-date fair value and the difference between the fair value and the previous carrying amount is recognised in profit or loss. Contingent consideration to be transferred by the acquirer is recognised at the acquisition-date fair value. Subsequent changes in the fair value of the contingent consideration classified as an asset or liability is recognised in profit or loss. Contingent consideration classified as equity is not remeasured and its subsequent settlement is accounted for within equity. The difference between the acquisition-date fair value of assets acquired, liabilities assumed and any non-controlling interest in the acquiree and the fair value of the consideration transferred and the fair value of any pre-existing investment in the acquiree is recognised as goodwill. If the consideration transferred and the pre-existing fair value is less than the fair value of the identifiable net assets acquired, being a bargain purchase to the acquirer, the difference is recognised as a gain directly in profit or loss by the acquirer on the acquisition-date, but only after a reassessment of the identification and measurement of the net assets acquired, the non-controlling interest in the acquiree, if any, the consideration transferred and the acquirer's previously held equity interest in the acquirer. Business combinations are initially accounted for on a provisional basis. The acquirer retrospectively adjusts the provisional amounts recognised and also recognises additional assets or liabilities during the measurement period, based on new information obtained about the facts and circumstances that existed at the acquisition-date. The measurement period ends on either the earlier of (i) 12 months from the date of the acquisition or (ii) when the acquirer receives all the information possible to determine fair value.
78
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 34. Interests in subsidiaries The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 1:
Name
Principal place of business / Country of incorporation
Healthbridge Enterprises Pty Ltd Monash IVF Group Acquisitions Pty Ltd Healthbridge IVF Holdings Pty Ltd Healthbridge Shared Services Pty Ltd Healthbridge Repromed Pty Ltd Repromed Finance Pty Ltd Repromed Holdings Pty Ltd Repromed NZ Holding Pty Ltd Repromed Australia Pty Ltd Repromed Employee Investment Pty Limited Monash Direct Investment Pty Limited Adelaide Fertility Centre Pty Ltd Monash IVF Holdings Pty Ltd Monash IVF Finance Pty Ltd Monash IVF Pty Ltd Monash Reproductive Pathology and Genetics Pty Ltd Monash Ultrasound Pty Ltd Monash IVF Auchenflower Pty Ltd Yoncat Pty Ltd Palantrou Pty Ltd KL Fertility & Gynaecology Centre Sdn. Bhd. KL Fertility Daycare Sdn. Bhd. Sydney Ultrasound for Women Partnership Ultrasonic Diagnostic Services Trust No.2 ACN 604 384 661 Pty Ltd Ultrasonic Diagnostic Services Pty Ltd Fertility Australia Pty Ltd Fertility Australia Trust MVF Sunshine Coast Pty Ltd Monash IVF West Pty Ltd ART Associates Queensland No.2 Pty Ltd ACN 646 484 906 Pty Ltd Fertility North Holdings Pty Ltd Fertility North Unit Trust WA Ultrasound Pty Ltd Monash Discretionary Investment Pty Limited Monash IVF Asia Pte Ltd Monash IVF Asia (Singapore) Pte Ltd Monash IVF South Malaysia Pte Ltd Pt Mitra Kasih Medikatama
Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Malaysia Malaysia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Singapore Singapore Malaysia Indonesia
79
Ownership interest 2026 2025 % % 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 90% 100% 100% 100% 100% 100% 100% 100% 100% 90% 100% 59% 80% 80% 100% 100% 90% 68% 56% 54%
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 90% 100% 100% 100% 100% 100% 100% 100% 100% 90% 100% 59% 80% 80% 100% 90% 68% 56% 54%
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 35. Deed of cross guarantee The following entities are party to a deed of cross guarantee under which each company guarantees the debts of the others: Monash IVF Group Ltd Monash IVF Group Acquisition Pty Ltd Healthbridge Enterprises Pty Ltd Healthbridge Shared Services Pty Ltd Healthbridge IVF Holdings Pty Ltd Healthbridge Repromed Pty Ltd ACN 169060495 Pty Ltd My IVF Pty Ltd Monash IVF Holdings Pty Ltd Palantrou Pty Ltd Repromed Finance Pty Ltd Monash IVF Finance Pty Ltd Repromed Holdings Pty Ltd Monash IVF Pty Ltd Repromed Australia Pty Ltd Repromed Employee Investment Pty Limited Monash Direct Investment Pty Limited Repromed NZ Holding Pty Ltd Monash Ultrasound Pty Ltd Monash Reproductive Pathology & Genetics Pty Ltd Monash IVF Auchenflower Pty Ltd Yoncat Pty Ltd Adelaide Fertility Centre Pty Ltd Sydney Ultrasound for Women Partnership Ultrasonic Diagnostic Services Trust No. 2 ACN 604384661 Pty Ltd Ultrasonic Diagnostic Services Pty Ltd Fertility Australia Pty Ltd Fertility Australia Trust MVF Sunshine Coast Pty Ltd WA Ultrasound Pty Ltd By entering into the deed, the wholly-owned entities have been relieved from the requirement to prepare financial statements and Directors' report under Corporations Instrument 2016/785 issued by the Australian Securities and Investments Commission. The above companies represent a 'Closed Group' for the purposes of the Corporations Instrument, and as there are no other parties to the deed of cross guarantee that are controlled by Monash IVF Group Limited, they also represent the 'Extended Closed Group'.
80
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 35. Deed of cross guarantee (continued) Set out below is a consolidated statement of profit or loss and other comprehensive income and statement of financial position of the entities included as part of the deed. Statement of profit or loss and other comprehensive income
2026 $'000
2025 $'000
Revenue Materials and consumables used Clinician fees Employee benefits expense Depreciation and amortisation expense Marketing and advertising expense IT and communication expense Property expense Professional and other fees Other expenses
215,609 (19,614) (43,339) (86,767) (20,590) (5,900) (6,160) (5,151) (10,911) (5,580)
225,385 (19,577) (42,459) (82,423) (19,915) (7,395) (5,827) (4,275) (8,684) 1,530
Operating profit
11,597
36,360
Net finance costs
(8,967)
(7,083)
Profit before income tax expense Income tax expense
2,630 (581)
29,277 (9,497)
Profit after income tax expense
2,049
19,780
2,049
19,780
Other comprehensive income for the year, net of tax Total comprehensive income for the year
Equity - accumulated losses
2026 $'000
2025 $'000
Accumulated losses at the beginning of the financial year Profit after income tax expense Dividends paid
(125,316) 2,049 (913)
(129,188) 19,780 (15,908)
Accumulated losses at the end of the financial year
(124,180)
(125,316)
81
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 35. Deed of cross guarantee (continued) 2026 $'000
Statement of financial position Current assets Cash and cash equivalents Trade and other receivables Inventories
2025 $'000
4,261 16,923 8,632 29,816
4,888 17,056 7,839 29,783
27,274 1,274 27 70,617 78,309 284,854 5,197 467,552
19,299 1,274 56,050 72,137 286,521 6,283 441,564
497,368
471,347
15,794 11,568 8,754 4,512 879 13,460 4,791 59,758
17,897 11,926 9,137 27 1,238 13,083 4,365 57,673
109,400 78,102 1,341 3,276 192,119
98,529 67,930 4,803 1,105 4,495 176,862
Total liabilities
251,877
234,535
Net assets
245,491
236,812
Equity Issued capital Reserves Accumulated losses
506,934 (137,263) (124,180)
506,934 (144,806) (125,316)
Total equity
245,491
236,812
Non-current assets Trade and other receivables Investments Derivative financial instruments Plant and equipment Right-of-use assets Intangible assets Deferred tax asset Total assets Current liabilities Trade and other payables Contract liabilities Lease liabilities Derivative financial instruments Current tax payable Employee benefits Contingent consideration Non-current liabilities Borrowings Lease liabilities Derivative financial instruments Employee benefits Contingent consideration
Note 36. Share-based payments Senior executives’ long-term incentive plan Under the Company’s Long Term Incentive (“LTI”) Plan, awards constituting share appreciation rights, performance rights or options, or any different class or category of award on such terms as the Board determines, may be offered to eligible persons selected by the Directors. Key management personnel and other senior management are eligible to participate under the LTI Program.
82
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 36. Share-based payments (continued) The senior executive LTI are performance rights plans with vesting rights dependent upon the satisfaction of predefined performance hurdles and continuous employment. Current performance hurdles are based on achievement of pre-defined Earning Per Share (“EPS”) Hurdle and a Total Shareholder Return (“TSR”) Hurdle over a three year performance period. The Board may amend the performance hurdles or specify a different performance hurdle(s) if it considers it necessary. Long term incentive program (equity settled) A description of the equity plans applicable during the year are described below: Grant date
Vesting conditions
(FY2026 Plan) 14 November 2025
EPS - Subject to meeting certain Underlying EPS(1) hurdles and 3 year service period to 30 June 2028
(FY2025 Plan) 27 November 2024
TSR - Subject to Total Shareholder Return hurdles and a 3 year service period to the 11th trading day after the FY28 results announcement EPS - Subject to meeting certain Underlying EPS(1) hurdles and 3 year service period to 30 June 2027
(FY2024 Plan) 28 November 2023
TSR - Subject to Total Shareholder Return hurdles and a 3 year service period to the 11th trading day after the FY27 results announcement EPS - Subject to meeting certain Underlying EPS(1) hurdles and 3 year service period to 30 June 2026
(FY2023 Plan) 23 November 2022
TSR - Subject to Total Shareholder Return hurdles and a 3 year service period to the 11th trading day after the 2026 results announcement EPS - Subject to meeting certain Underlying EPS(1) hurdles and 3 year service period to 30 June 2025
(FY2022 Plan) 19 November 2021
TSR - Subject to Total Shareholder Return hurdles and a 3 year service period to the 11th trading day after the 2025 results announcement EPS - Subject to meeting certain Underlying EPS(1) hurdles and 3 year service period to 30 June 2024 TSR - Subject to Total Shareholder Return hurdles and a 3 year service period to the 11th trading day after the 2024 results announcement
(1)
Underlying EPS represents the earnings per share of the Group after adjusting statutory net profit for certain non-regular items.
Expected volatility has been based on an evaluation of the historical volatility of the Company’s share price, particularly over the historical period commensurate with the expected term. The expected term of the instruments has been based on historical experience and general instrument holder behaviour.
Opening*
Vested and Granted** exercised
Expired/ lapsed / forfeited
Vested and unexercised
Number
Number
Number
Number
112,183 126,107 294,249 159,286 371,668
446,471 1,041,767
(112,183) (80,335) (187,447) (97,840) (228,289) (172,371) (402,199)
45,772 106,802 61,446 143,379 274,100 639,568
1,063,493
1,488,238
(1,280,664)
1,271,067
2026 Plan
FY2023 FY2024 FY2025 FY2026
Testing Hurdles date
TSR TSR EPS TSR EPS TSR EPS
30/09/2025 30/09/2026 30/06/2026 11/09/2027 30/06/2027 11/09/2028 30/06/2028
Number
83
Closing unvested
Exercisable at 30 June 2026
FV per security
Number
Number
$ $0.60 $0.79 $1.28 $0.65 $1.22 $0.31 $0.61
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 36. Share-based payments (continued)
Opening*
Vested and Granted** exercised
Expired/ lapsed / forfeited
Vested and unexercised
Closing unvested
Exercisable at 30 June 2025
Number
Number
Number
Number
Number
Number
Number
35,832 83,604 260,376 319,897 746,427 332,563 775,979
61,665 383,695 895,288 1,340,648
(35,832) (83,604) (260,376)
2025 Testing Hurdles date
Plan
FY2021 FY2022 FY2023 FY2024 FY2025
TSR EPS TSR EPS TSR EPS TSR EPS Service TSR EPS
30/09/2023 30/06/2023 30/09/2024 30/06/2024 30/09/2025 30/06/2025 30/09/2026 30/06/2026 29/09/2025 11/09/2027 30/06/2027
2,554,678
(207,714) (746,427) (206,456) (481,730) (61,665) (224,409) (523,620) (379,812) (2,452,021)
112,183 126,107 294,249 159,286 371,668 1,063,493
FV per security
$0.32 $0.61 $0.49 $0.00 $0.60 $1.02 $0.79 $1.28 $1.21 $0.65 $1.22
Opening balances include rights that are vested and unexercised, as well as unvested rights.
**
On vesting, each performance right entitles the participant to one ordinary share in the Company plus an additional number of shares calculated on the basis of the dividends which would have been paid on that one share had it been issued at the time of grant of the performance right and assuming that those dividends were reinvested at the closing price of shares on the distribution date of those dividends. Prior to vesting, performance rights do not entitle the participant to any dividends or voting rights.
Accounting policies: Share-based payments The Group provides benefits to certain employees in the form of share-based payment options and/or performance rights. The fair values of these instruments granted under the plans are recognised as an employee benefit expense with a corresponding increase in equity. The fair value is measured at grant date and recognised over the period during which the employee becomes unconditionally entitled to the instruments. Fair value is measured at grant date using a combination of Binomial tree and Monte-Carlo Simulation models, for the respective performance hurdles. The valuation was performed by an independent valuer which models the future security price. The fair value of the instruments granted excludes the impact of any non-market vesting conditions. Non-market vesting conditions are included in assumptions about the number of instruments that are expected to become exercisable. At each reporting date, the entity revises its estimate of the number of instruments that are expected to become exercisable. The employee benefit expense recognised each period takes into account the most recent estimate. The impact of the revision to original estimates, if any, is recognised in profit or loss with a corresponding adjustment to equity. Key estimate and judgement: Share-based payments The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The accounting estimates and assumptions relating to equity-settled sharebased payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity. As a result of the combination of non-market (EPS) and market (TSR) vesting conditions, the fair value of the share rights plan has been measured using Binomial Tree and Monte Carlo simulations respectively. The inputs used in the measurement of the fair values at grant date of the equity-settled share-based payment plans were as follows:
84
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 36. Share-based payments (continued) 2026 Share price at grant date Expected volatility – Monash IVF Expected volatility – ASX 300 Healthcare Index (excluding CSL) Expected life (years) Expected dividends Risk free interest rate (based on government bonds)
2025
2024
2023
$0.61 40%
$1.22 40%
$1.28 40%
$1.02 40%
19% 6 0.00% 3.76%
16% 6 0.00% 3.97%
18% 6 0.00% 4.16%
17% 6 0.00% 3.27%
Note 37. Cash flow information Reconciliation of profit after income tax to net cash from operating activities Consolidated 2026 2025 $'000 $'000 Profit after income tax expense for the year
8,326
25,676
Adjustments for: Depreciation and amortisation expense Net finance costs included in financing activities
23,348 6,495
22,019 4,017
Change in operating assets and liabilities: (Increase)/decrease in trade and other receivables Increase in inventories Decrease in deferred tax assets Decrease in trade and other payables Decrease in contract liabilities Increase in employee benefits
(584) (1,369) 1,083 (986) (322) 709
15,438 (825) 9,145 (62,821) (738) 991
Net cash flows generated from operating activities
36,700
12,902
Non-cash investing and financing activities Consolidated 2026 2025 $'000 $'000 Additions to the right-of-use assets
14,960
85
15,431
Monash IVF Group Limited Notes to the consolidated financial statements 30 June 2026 Note 37. Cash flow information (continued) Changes in liabilities arising from financing activities Bank loans $'000
Consolidated
Lease liabilities $'000
Total $'000
Balance at 1 July 2024 Net cash used in financing activities Loans received Acquisition of leases Other changes
59,565 (26,000) 65,000 (36)
75,805 (12,446) 15,431 2,712
135,370 (38,446) 65,000 15,431 2,676
Balance at 30 June 2025 Net cash used in financing activities Loans received Acquisition of leases Other changes
98,529 (7,000) 18,000 (129)
81,502 (14,234) 14,960 7,990
180,031 (21,234) 18,000 14,960 7,861
Balance at 30 June 2026
109,400
90,218
199,618
Note 38. Events after the reporting period No matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.
86
Monash IVF Group Limited Consolidated entity disclosure statement As at 30 June 2026 Basis of preparation This consolidated entity disclosure statement ('CEDS') has been prepared in accordance with the Corporations Act 2001 and includes required information for each entity that was part of the consolidated entity as at the end of the financial year. Consolidated entity This CEDS includes only those entities consolidated as at the end of the financial year in accordance with AASB 10 Consolidated Financial Statements (AASB 10). Determination of tax residency Section 295(3A) of the Corporations Act 2001 requires that the tax residency of each entity which is included in the Consolidated Entity Disclosure Statement (CEDS) be disclosed. For the purposes of this section, an entity is an Australian resident at the end of a financial year if the entity is: ● An Australian resident (within the meaning in the Income Tax Assessment Act 1997) at that time; or ● A partnership, with at least one partner being an Australian resident (within the meaning of the Income Tax Assessment Act 1997) at that time; or ● A resident trust estate (within the meaning of Division 6 of Part III of the Income Tax Assessment Act 1936) in relation to the year of income (with the meaning of that Act) that corresponds to the financial year. The determination of tax residency involves judgment as the determination of tax residency is highly fact dependent and there are currently several different interpretations that could be adopted, and which could give rise to a different conclusion on residency. In determining tax residency, the consolidated entity has applied the following interpretations: Australian tax residency The consolidated entity has applied current legislation and judicial precedent, including having regard to the Commissioner of Taxation’s public guidance in Tax Ruling TR 2018/5. Foreign tax residency The consolidated entity has applied current legislation and where available judicial precedent in the determination of foreign tax residency. Where necessary, the consolidated entity has used independent tax advisers in foreign jurisdictions to assist in its determination of tax residency to ensure applicable foreign tax legislation has been complied with.
87
Monash IVF Group Limited Consolidated entity disclosure statement As at 30 June 2026
Entity name
Entity type
Place formed Ownership / interest Country of incorporatio % Tax residency n
Monash IVF Group Limited *
Body Corporate
Australia
Australia
Healthbridge Enterprises Pty Ltd Monash IVF Group Acquisitions Pty Ltd Healthbridge IVF Holdings Pty Ltd Healthbridge Shared Services Pty Ltd Healthbridge Repromed Pty Ltd Repromed Finance Pty Ltd Repromed Holdings Pty Ltd Repromed NZ Holding Pty Ltd Repromed Australia Pty Ltd
Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate
Australia Australia Australia Australia Australia Australia Australia Australia Australia
100% Australia 100% Australia 100% Australia 100% Australia 100% Australia 100% Australia 100% Australia 100% Australia 100% Australia
Australia Australia
100% Australia 100% Australia
Australia Australia Australia Australia
100% Australia 100% Australia 100% Australia 100% Australia
Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate Trust Body Corporate Body Corporate – Trustee of Ultrasonic Diagnostic Services Trust No.2 Body Corporate – Trustee of Fertility Australia Trust Trust Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate – Trustee of Fertility North Unit Trust Trust Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate Body Corporate
Australia Australia Australia Australia Australia Malaysia Malaysia Australia Australia Australia
100% Australia 100% Australia 100% Australia 100% Australia 100% Australia 90% Malaysia 100% Malaysia 100% Australia 100% Australia 100% Australia
Australia
100% Australia
Australia Australia Australia Australia Australia Australia
100% Australia 100% Australia 100% Australia 90% Australia 100% Australia 59% Australia
Australia Australia Australia Australia Singapore Singapore Malaysia Indonesia
80% Australia 80% Australia 100% Australia 100% Australia 90% Singapore 68% Singapore 56% Malaysia 54% Indonesia
Repromed Employee Investment Pty Limited Monash Direct Investment Pty Limited Adelaide Fertility Centre Pty Ltd Monash IVF Holdings Pty Ltd Monash IVF Finance Pty Ltd Monash IVF Pty Ltd Monash Reproductive Pathology and Genetics Pty Ltd Monash Ultrasound Pty Ltd Monash IVF Auchenflower Pty Ltd Yoncat Pty Ltd Palantrou Pty Ltd KL Fertility & Gynaecology Centre Sdn. Bhd KL Fertility Daycare Sdn. Bhd. Sydney Ultrasound for Women Partnership Ultrasonic Diagnostic Services Trust No.2 ACN 604 384 661 Pty Ltd Ultrasonic Diagnostic Services Pty Ltd Fertility Australia Pty Ltd Fertility Australia Trust MVF Sunshine Coast Pty Ltd Monash IVF West Pty Ltd ART Associates Queensland No.2 Pty Ltd ACN 646 484 906 Pty Ltd Fertility North Holdings Pty Ltd Fertility North Unit Trust WA Ultrasound Pty Ltd Monash Discretionary Investment Pty Limited Monash IVF Asia Pte Ltd Monash IVF Asia (Singapore) Pte Ltd Monash IVF South Malaysia Pte Ltd Pt Mitra Kasih Medikatama *
Parent entity
88
Monash IVF Group Limited Directors' declaration 30 June 2026 In the Directors' opinion: ●
the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
●
the attached financial statements and notes comply with International Financial Reporting Standards Accounting Standards as issued by the International Accounting Standards Board as described in note 1 to the financial statements;
●
the attached financial statements and notes give a true and fair view of the Group's financial position as at 30 June 2026 and of its performance for the financial year ended on that date;
●
there are reasonable grounds to believe that the Company and group entities will be able to pay its debts as and when they become due and payable;
●
at the date of this declaration, there are reasonable grounds to believe that the members of the Extended Closed Group will be able to meet any obligations or liabilities to which they are, or may become, subject by virtue of the deed of cross guarantee described in note 35 to the financial statements; and
●
the information disclosed in the attached consolidated entity disclosure statement is true and correct.
The Directors have been given the declarations required by section 295A of the Corporations Act 2001 by the CEO and CFO for the year ended 30 June 2026. Signed in accordance with a resolution of Directors made pursuant to section 295(5)(a) of the Corporations Act 2001. On behalf of the Directors
Mr Richard Davis Chair
Dr Victoria Atkinson Chief Executive Officer & Managing Director
31 August 2026 Melbourne
89
Independent Auditor’s Report To the shareholders of Monash IVF Group Limited Report on the audit of the Financial Report
Opinion We have audited the Financial Report of Monash IVF Group Limited (the Company). In our opinion, the accompanying Financial Report of the Company gives a true and fair view, including of the Group’s financial position as at 30 June 2026 and of its financial performance for the year then ended, in accordance with the Corporations Act 2001, in compliance with Australian Accounting Standards and the Corporations Regulations 2001.
The Financial Report comprises: •
Consolidated statement of financial position as at 30 June 2026
•
Consolidated Statement of profit or loss and other comprehensive income, Consolidated Statement of changes in equity, and Consolidated Statement of cash flows for the year then ended
•
Consolidated entity disclosure statement and accompanying basis of preparation as at 30 June 2026
•
Notes, including material accounting policies
•
Directors’ Declaration.
The Group consists of the Company and the entities it controlled at the year end or from time to time during the financial year. Basis for opinion We conducted our audit in accordance with Australian Auditing Standards. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the Financial Report section of our report. We are independent of the Group in accordance with the auditor independence requirements of the Corporations Act 2001 and the ethical requirements of the APES 110 Code of Ethics for Professional Accountants (including Independence Standards) issued by the Accounting Professional & Ethical Standards Board Limited (the Code) that are relevant to audits of the financial report of public interest entities in Australia. We have fulfilled our other ethical responsibilities in accordance with these requirements. 90 KPMG, an Australian partnership and a member firm of the KPMG global organisation of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organisation. Liability limited by a scheme approved under Professional Standards Legislation.
Key Audit Matters Key Audit Matters are those matters that, in our professional judgement, were of most significance in our audit of the Financial Report of the current period. This matter was addressed in the context of our audit of the Financial Report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on this matter.
Recoverable value of goodwill ($273.4m) Refer to Note 16 to the Financial Report The key audit matter
How the matter was addressed in our audit
A key audit matter for us was the Group’s annual testing of goodwill for impairment, given the size of the balance (being 53% of total assets) and the extent of judgement involved. We focused on the significant forward-looking assumptions the Group applied in its value in use models, including:
Our procedures included:
•
We considered the appropriateness of the Group’s value in use methodology to perform the annual test of goodwill for impairment against the requirements of the accounting standards.
•
We assessed the integrity of the value in use models used, including the accuracy of the underlying calculation formulas.
•
We compared the forecast cash flows contained in the value in use models to Board approved forecasts.
Discount rates, which vary according to the conditions and environment the specific CGU is subject to.
•
We assessed the accuracy of previous Group forecasts to inform our evaluation of forecasts included in the models.
The models are largely manually developed, use adjusted historical performance and a range of internal and external sources as inputs to the assumptions. Modelling using forward-looking assumptions tends to be prone to greater risk for potential bias, error and inconsistent application.
•
We assessed the Group’s underlying methodology and documentation for the allocation of corporate costs and corporate assets to each CGU, for consistency with our understanding of the business and the criteria in the accounting standards.
•
We considered the sensitivity of the models by varying key assumptions, such as forecast cash flows, growth rates and discount rates, within a reasonably possible range. We did this to identify those assumptions at higher risk of bias or inconsistency in application and to identify those CGUs at higher risk of impairment and to focus our further procedures.
•
Working with our valuation specialists, we:
•
•
Forecast cash flows, growth rates and terminal growth rates in light of current market conditions impacting each CGU and the broader macro economic environment. These conditions impact our consideration of forecasting risk; and
Where the Group has not met prior year forecasts in relation to a specific CGU, we factor this into our assessment of forecast assumptions. These conditions necessitate additional scrutiny by us, in particular to address the objectivity of sources used for assumptions, and their consistent application. We involved valuation specialists to supplement our senior audit team members in assessing this key audit matter.
91
independently developed a comparable
discount rate range from publicly available market data for comparable entities and adjusted by specific risk factors to the Group and the industry it operates in;
•
assessed the terminal growth rates based on the industry in which the Group operates and current economic environment; and
compared the implied multiples for comparable entities to the implied multiples from the Group’s value in use models.
We assessed the disclosures in the financial report using our understanding obtained from our testing and against the requirements of the accounting standards.
Other Information Other Information is financial and non-financial information in Monash IVF Group Limited’s annual report which is provided in addition to the Financial Report and the Auditor's Report. The Directors are responsible for the Other Information. The Other Information we obtained prior to the date of this Auditor’s Report was the Director’s Report (including the Remuneration Report), Appendix 4E and Corporate Governance Statement. The Chairman’s Report, Chief Executive Officer’s Report, Financial Overview, Chief Financial Officer’s Report and Shareholder Information are expected to be made available to us after the date of the Auditor’s Report. Our opinion on the Financial Report does not cover the Other Information and, accordingly, we do not and will not express an audit opinion or any form of assurance conclusion thereon, with the exception of the Remuneration Report and our related assurance opinion. In connection with our audit of the Financial Report, our responsibility is to read the Other Information. In doing so, we consider whether the Other Information is materially inconsistent with the Financial Report or our knowledge obtained in the audit, or otherwise appears to be materially misstated. We are required to report if we conclude that there is a material misstatement of this Other Information, and based on the work we have performed on the Other Information that we obtained prior to the date of this Auditor’s Report we have nothing to report.
92
Responsibilities of the Directors for the Financial Report The Directors are responsible for: •
preparing the Financial Report in accordance with the Corporations Act 2001, including giving a true and fair view of the financial position and performance of the Group, and in compliance with Australian Accounting Standards and the Corporations Regulations 2001
•
implementing necessary internal control to enable the preparation of a Financial Report in accordance with the Corporations Act 2001, including giving a true and fair view of the financial position and performance of the Group, and that is free from material misstatement, whether due to fraud or error
•
assessing the Group and Company’s ability to continue as a going concern and whether the use of the going concern basis of accounting is appropriate. This includes disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless they either intend to liquidate the Group and Company or to cease operations, or have no realistic alternative but to do so.
Auditor’s responsibilities for the audit of the Financial Report Our objective is: •
to obtain reasonable assurance about whether the Financial Report as a whole is free from material misstatement, whether due to fraud or error; and
•
to issue an Auditor’s Report that includes our opinion.
Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error. They are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Financial Report. A further description of our responsibilities for the audit of the Financial Report is located at the Auditing and Assurance Standards Board website at: https://www.auasb.gov.au/media/bwvjcgre/ar1_2024.pdf. This description forms part of our Auditor’s Report.
93
Report on the Remuneration Report Opinion
Directors’ responsibilities
In our opinion, the Remuneration Report of Monash IVF Group Limited for the year ended 30 June 2026 complies with Section 300A of the Corporations Act 2001.
The Directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with Section 300A of the Corporations Act 2001. Our responsibilities We have audited the Remuneration Report included in pages 15 to 27 of the Directors’ report for the year ended 30 June 2026. Our responsibility is to express an opinion as to whether the Remuneration Report complies in all material respects with Section 300A of the Corporations Act 2001, based on our audit conducted in accordance with Australian Auditing Standards.
KPMG
Andrew Hounsell Partner Melbourne 31 August 2026
94
Appendix 3A.1 - Notification of dividend / distribution
Announcement Summary
Entity name MONASH IVF GROUP LIMITED Security on which the Distribution will be paid MVF - ORDINARY FULLY PAID Announcement Type New announcement Date of this announcement 31/8/2026 Distribution Amount AUD 0.01300000 Ex Date 3/9/2026 Record Date 4/9/2026 Payment Date 15/10/2026 Refer to below for full details of the announcement
Appendix 3A.1 - Notification of dividend / distribution
1/4
Appendix 3A.1 - Notification of dividend / distribution
Announcement Details
Part 1 - Entity and announcement details
1.1 Name of +Entity MONASH IVF GROUP LIMITED 1.2 Registered Number Type
Registration Number
ABN
90169302309
1.3 ASX issuer code MVF 1.4 The announcement is New announcement 1.5 Date of this announcement 31/8/2026 1.6 ASX +Security Code MVF ASX +Security Description ORDINARY FULLY PAID
Part 2A - All dividends/distributions basic details
2A.1 Type of dividend/distribution Ordinary 2A.2 The Dividend/distribution: relates to a period of six months 2A.3 The dividend/distribution relates to the financial reporting or payment period ending ended/ending (date) 30/6/2026 2A.4 +Record Date 4/9/2026 2A.5 Ex Date 3/9/2026 2A.6 Payment Date 15/10/2026 2A.7 Are any of the below approvals required for the dividend/distribution before business day 0 of the timetable? Security holder approval Court approval Lodgement of court order with +ASIC ACCC approval FIRB approval Appendix 3A.1 - Notification of dividend / distribution
2/4
Appendix 3A.1 - Notification of dividend / distribution FIRB approval Another approval/condition external to the entity required before business day 0 of the timetable for the dividend/distribution. No 2A.8 Currency in which the dividend/distribution is made ("primary currency") AUD - Australian Dollar 2A.9 Total dividend/distribution payment amount per +security (in primary currency) for all dividends/distributions notified in this form AUD 0.01300000
2A.10 Does the entity have arrangements relating to the currency in which the dividend/distribution is paid to securityholders that it wishes to disclose to the market? No 2A.11 Does the entity have a securities plan for dividends/distributions on this +security? We do not have a securities plan for dividends/distributions on this security
2A.12 Does the +entity have tax component information apart from franking? No
Part 3A - Ordinary dividend/distribution
3A.1 Is the ordinary dividend/distribution estimated at this time? No
3A.1a Ordinary dividend/distribution estimated amount per +security AUD
3A.1b Ordinary Dividend/distribution amount per security AUD 0.01300000 3A.2 Is the ordinary dividend/distribution franked? Yes
3A.2a Is the ordinary dividend/distribution fully franked? Yes
3A.3 Percentage of ordinary dividend/distribution that is 3A.3a Applicable corporate tax rate for franking credit franked (%) 100.0000 %
30.0000 %
3A.4 Ordinary dividend/distribution franked amount per +security
3A.5 Percentage amount of dividend which is unfranked 0.0000 %
AUD 0.01300000 3A.6 Ordinary dividend/distribution unfranked amount per +security excluding conduit foreign income amount AUD 0.00000000
3A.7 Ordinary dividend/distribution conduit foreign Appendix 3A.1 - Notification of dividend / distribution
3/4
Appendix 3A.1 - Notification of dividend / distribution 3A.7 Ordinary dividend/distribution conduit foreign income amount per security AUD 0.00000000
Part 5 - Further information
5.1 Please provide any further information applicable to this dividend/distribution
5.2 Additional information for inclusion in the Announcement Summary
Appendix 3A.1 - Notification of dividend / distribution
4/4
1
ASX Announcement 31 August 2026
Monash IVF Group Limited (ASX: MVF)
FY26 Results – Monash announces revenue of $269.5 million Monash IVF today announces its FY26 financial results, with revenue of $269.5 million, Underlying EBITDA of $53.4 million and Underlying NPAT of $16.1 million. The result was below the Company's June 2026 updated guidance range of $17 million to $18 million and includes the impact of the writeoff of $1.4 million (after tax) of prepaid assets. Following a challenging first half, momentum and market share improved through 2H26. Revenue remained resilient, with slightly softer domestic stimulated cycle volumes, partly offset by growth in International, Genetics and ancillary revenue streams. FY26 revenue was resilient, softening 0.9% compared with FY25, while Underlying EBITDA decreased by 19.5%, reflecting domestic stimulated cycle volume and market share pressures in 1H26, deferred pricing increases across key East Coast markets, wage and supplier cost inflation and the predominantly fixed nature of the clinical operating cost base. Domestic market share improved through the second half, with domestic stimulated cycle market share increasing to 20.2% in 2H26, up 1.2% on 1H26. Strategic and operational highlights • • •
•
•
•
Momentum regained in 2H26, with domestic stimulated cycle volume improving from -11.7% in 1H26 to -1.6% in 2H26, market share increasing to 20.2% and Group NPS of 72.7. Near-term medical capacity strengthened, with 13 fertility specialists joining, increasing cycle volume outlook in key markets. Strategic FY26 capital investment completed, including the Brisbane fertility clinic and day hospital, the consolidation of Victorian surgical volumes into Monash IVF’s Cremorne facility and increased in-house surgical capacity to support greater scalability and revenue capture. Clinical outcomes continued to strengthen, with clinical pregnancy rates of 42.1% in women under 43, up 1.8% on FY25, and 44.0% in women under 40, up 1.1% on FY25, both above the ANZARD benchmark. Structural productivity program underway, with initiatives across centralised procurement, workforce efficiency and asset utilisation expected to improve operating leverage and earnings quality. Genetics and ancillary services continued to grow, with Genetics volumes maintained and PGT-A, PGT-M and PGT-SR each increasing by more than 20%, supported by improved turnaround times and expanded clinical capability.
2
•
•
•
International delivered record performance, with stimulated cycles up 8.3%, revenue up 15% to $21.2 million and EBITDA up 10% to $4.2 million. Johor Bahru delivered particularly strong growth, with revenue up 73% and EBITDA up 245%, while Singapore EBITDA increased 82%. Leadership, governance and operating capability strengthened, with refreshed executive and senior leadership teams, real-time performance dashboards, a new medical leadership model and a unified Asian leadership model established. Nurture 2030, Monash IVF’s three-year strategic plan, was approved, establishing the Group's FY27–FY29 strategy to accelerate growth, productivity and stronger returns across the Connected Patient Ecosystem, Clinical Excellence and Safety, Industry-Leading Talent, Science, Research and Technology, and Sustainable Growth and Performance.
FY26 financial outcomes summary • • • • • • •
Revenue was $269.5 million, down 0.9% compared with FY25. Underlying EBITDA was $53.4 million, down 19.5%. Underlying EBITDA margin was 19.8%. Underlying EBIT was $28.4 million, down 34.0%. Underlying NPAT was $16.1 million, down 41.2%. Reported EBITDA was $43.5 million and reported NPAT was $8.3 million. A final fully franked FY26 dividend of 1.3 cents per share has been declared, bringing total FY26 dividends to 2.5 cents per share at a payout ratio of 60% (record date: 4 September 2026; expected payment date: 15 October 2026).
Balance sheet and cash flow • • • • •
Net operating cash flow increased to $36.7 million, compared with $12.9 million in FY25. Free cash flow improved to $12.9 million, compared with negative $4.5 million in FY25. Capital expenditure was $23.8 million, reflecting the completion of major infrastructure investments. Net debt was $101.2 million at 30 June 2026, with leverage of 1.9x. The Group's debt facility was increased to $130 million and extended for three years.
FY27 outlook and priorities The Company enters FY27 with improving momentum, strengthened growth platforms and a clear strategy focused on sustainable growth, productivity and stronger returns. The Company expects financial performance to strengthen through the year, supported by improving market conditions, continued market share growth, increased medical capacity, reduced capital expenditure, pricing initiatives, continued momentum in Monash IVF’s International, Genetics and Diagnostics businesses, and embedded productivity and efficiency measures. FY27 priorities are: • • • • •
Connect the patient journey through data, digital and real-time insights. Grow the reproductive journey through an expanded clinical specialty matrix and deeper patient pathways. Amplify the medical workforce through doctor attraction, practice development and strengthened medical leadership. Lead the future of reproductive care through regulatory readiness, precision pathways, research, science and innovation. Reduce capital expenditure by approximately 50%.
3
• •
Reignite organic growth through market share gains, patient demand and conversion, with a focus on Victoria and NSW. Unlock the network by leveraging completed capital investments and embedding productivity and cost efficiency.
Monash IVF's established governance, quality and reporting capability positions the Group to efficiently implement the evolving national ARS regulatory framework, with the new standards expected to place greater value on established clinical governance, quality systems and demonstrated patient outcomes. A further update will be provided at the Annual General Meeting. CEO and Managing Director comment Monash IVF Group Chief Executive Officer and Managing Director, Dr Victoria Atkinson, said: "FY26 was a year of two halves for Monash IVF. While the first half was challenging, we exited the year with improving momentum, with domestic stimulated cycle volume trends strengthening, market share increasing through the second half and our international businesses delivering record performance. We have used FY26 to strengthen the foundations of the business—building our medical workforce, strengthening leadership and governance, completing significant infrastructure investment and commencing a structural productivity program. We have also launched Nurture 2030, our three-year strategy to accelerate sustainable growth and create stronger returns. We enter FY27 with multiple growth engines strengthened and a clear focus on execution: growing domestic stimulated cycle volumes, expanding market share, unlocking our completed capital investments, improving productivity and continuing to scale International, Genetics and Diagnostics. With the foundations now in place, Monash IVF is positioned to convert volume growth into stronger earnings through operating leverage and strategic execution." Authorised by the Board of Directors.
2026 Results Briefing Investor Presentation August 2026
Monash IVF Group | FY26 Results Presentation
Disclaimer The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) (“MVF”) (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF’s activities as at the date of this presentation. The information does not purport to be complete, is given in summary and may change without notice. This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. These should be considered, with or without professional advice, when deciding if an investment is appropriate. The presentation does not constitute or form part of an offer to buy or sell MVF securities. This presentation contains forward looking statements, including statements of current intention, statements of opinion and predictions as to possible future events. Such statements are not statements of fact and there can be no certainty of outcome in relation to the matters to which the statements relate. These forward-looking statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause the actual outcomes to be materially different from the events or results expressed or implied by such statements. Those risks, uncertainties, assumptions and other important factors are not all within the control of MVF and cannot be predicted by MVF and include changes in circumstances or events that may cause objectives to change as well as risks, circumstances and events specific to the industry, countries and markets in which MVF operate. They also include general economic conditions, exchange rates, interest rates, the regulatory environment, competitive pressures, selling price, market demand and conditions in the financial markets which may cause objectives to change or may cause outcomes not to be realised. None of MVF (and their respective officers, employees or agents) (the Relevant Persons) makes any representation, assurance or guarantee as to the accuracy or likelihood of fulfilment of any forward-looking statement or any outcomes expressed or implied in any forward-looking statements. The forward-looking statements in this presentation reflect views held only at the date of this presentation. Except as required by applicable law or the ASX Listing Rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any forwardlooking statements, whether as a result of new information or future events. Statements about past performance are not necessarily indicative of future performance. Certain jurisdictions may restrict the release, publication or distribution of this presentation. Persons in such jurisdictions should observe such restrictions. To the extent permitted by law the Relevant Persons do not accept liability for any use of this presentation, its contents or anything arising in connection thereto including any liability arising from the fault or negligence none of the Relevant Persons. This presentation includes a number of non-IFRS measures which include EBITDA, Underlying EBITDA, Underlying EBIT and Underlying NPAT. These non-IFRS measures are used by management to measure the performance of the business. These measures have not been subject to audit review.
Page 2
Monash IVF Group | FY26 Results Presentation
Page 3
Dr Victoria Atkinson Chief Executive Officer & Managing Director
Monash IVF Group | FY26 Results Presentation
Page 4
FY26: A Year of Two Halves 1
FY26 exits with momentum after challenging first half
• • • •
Resilient revenue $269.5m (-0.9%) Underlying EBITDA (1)(2) of $53.4m (-19.5%) Underlying NPAT (3) of $16.1m (41.2%) Final dividend declared of 1.3cps (full year 2.5cps) payout ratio of 60%
2
A stabilising Australian market with an attractive growth outlook
• • • •
Australian Assisted Reproduction Services (ARS) market broadly flat in FY26 13 new specialists & 3 trainees welcomed to the group Attractive short-to-medium-term domestic growth outlook Strong Asian market growth with accelerating outlook
3
Productivity and operational reset underway
• •
Structural cost and productivity initiatives to improve margins and earnings quality Growth engines strengthened through expanded medical capacity, with International, Diagnostics and Day Surgery investment achieving growth into FY27 and beyond
4
Nurture 2030: A clear three-year strategy driving growth, value and returns approved 2HFY
• • •
Nurture our patients — connected, personalised care Nurture clinical excellence — through talent, science and leadership Nurture sustainable shareholder value — growth, productivity and stronger returns
(1) Underlying EBITDA, EBIT and NPAT are non-IFRS measures (2) Refer to page 34 for reconciliation of Reported EBITDA, EBIT and NPAT to Underlying EBITDA, EBIT and NPAT
(3) NPAT including minority interest
Monash IVF Group | FY26 Results Presentation
Agenda
- FY26 Highlights and CEO Priorities Update
- FY26 Results
- Market Update & Outlook
- Nurture 2030: A New 3Y Strategy
- FY27 Priorities & Trading Outlook
- Q&A
Page 5
Monash IVF Group | FY26 Results Presentation
Page 6
1.FY26 Highlights and CEO Priorities Update
Monash IVF Group | FY26 Results Presentation
Page 7
5,753 Clinical Pregnancies
42.1% YTD Clinical Pregnancy Rates For women under 43 years. (+1.8%) vs FY25. Women under 40 years 44.0% (+ 1.1%) vs FY25. Outperforming ANZARD benchmark
#2 in Market Share Across the Australian stimulated cycle market in FY26.
3,000 episodes of patient care per month
Group NPS 72.7
7,980 Day Surgery procedures
Representing the individualised care we strive to deliver to every patient, every day.
Majority surgical volumes to be performed in house FY27 with completion of infrastructure program.
1,700 IVF patients, 660 DSU and 600 scans per month.
FY26
Monash IVF Group | FY26 Results Presentation
Page 88 Page
Execution against 2HFY CEO priorities 01
02
Deliver Sustainable Organic Growth
Align Medical and Executive Leadership for Performance
• Victorian Strategy Blueprint launched Foundational and transformational initiatives underway • Real-time performance dashboards deployed enterprise-wide Data now driving accountability across operations, finance, quality, people and marketing • Unified Asian leadership model established Integrating the region to unlock scale and growth
03
Revisit and Renew Strategic Priorities
• Executive leadership refreshed New Executive Leadership Team and Senior Leadership Team established, with CFO and CIO recruitment progressing • New medical leadership model established Industry-leading structure strengthening clinical governance and accountability • Nurture 2030 strategic plan launched FY27–29 strategy now providing the roadmap for sustainable growth
Monash IVF Group | FY26 Results Presentation
Page 9
- FY26 Results
Monash IVF Group | FY26 Results Presentation
Page10 10 Page
FY26 Overview FY26 Revenue
FY26 Underlying EBITDA(2)
FY26 Underlying EBITDA(2) Margin %
$269.5m
$53.4m
19.8%
Down 0.9% vs FY25
Down 19.5% vs FY25
Down 460 bps vs FY25
FY26 Underlying NPAT(2)
FY26 Fully Franked Dividend
FY26 Stimulated cycles(1)
1H26 Domestic Stimulated Cycles
2H26 Domestic Stimulated Cycles
11,423
-11.7%
-1.6%
Down 2.9% vs FY25
vs pcp
vs pcp
$16.1m Down 41.2% vs FY25
Egg collections in Australia and International Non-IFRS measures MBS items 13200/1
2.5 cps 60% payout ratio as per policy
1H26 Domestic Stimulated Cycle Market Share(3)
19%
2H26 Domestic Stimulated Cycle Market Share(3)
20.2% up 120bps vs 1H26
Monash IVF Group | FY26 Results Presentation
Page11 11 Page
FY26 Operational Highlights • • • •
Stimulated cycle volumes grew with strong FETs DSU strengthened labour management, productivity and procurement Strong NIPT in H2, indicator of future pipeline Strong market share growth
Productivity program underway
• •
Structural efficiency initiatives focusing on procurement, workforce efficiency and asset utilisation Supported by digital enablement, including progressing patient management system
Capital investment unlocks growth capacity
• •
Brisbane clinic completed, Victorian volumes consolidated to Cremorne Increased in-house surgical capacity improving scalability and revenue capture, and aligned with better patient outcomes
Growth platform strengthened for FY27
•
Initiatives across medical workforce, pricing, market share and patient pathways to accelerate domestic growth Strong doctor recruitment, particularly in VIC and NSW International and diagnostics primed as diversified growth avenues
Business repositioned
•
Momentum regained in 2H26
• •
Leadership, governance and strategy realigned to accelerate business priorities and sustainable growth
Monash IVF Group | FY26 Results Presentation
Page12 12 Page
Domestic IVF Overview Positioned to accelerate
•
20,010 IVF patient treatments in FY26, with domestic IVF cycles easing 5% to 19,181—predominantly concentrated in 1H26
•
Stimulated cycles were 7% softer at 10,057, while Frozen Embryo Transfers (FETS) remained resilient at 9,124 or -2.6%
•
19% fewer cancelled cycles vs FY25
•
2H26 cost initiatives and slightly lower treatment volumes resulted in a modest reduction of 1.7% in direct variable IVF costs, while fixed clinical costs constrained further margin protection
•
Net increase of 10 fertility specialists & 3 trainees delivering a significant net increase in practice capacity, cycles and pipeline
•
Clayton IVF surgery volume transferred to Cremorne significantly uplifting patient experience and revenue capture
•
New Clayton clinic site secured with fit out commenced ensuring premium patient offering
Australian market share 19.5%1 1.
Rolling 12-month average
FET market share 20.4%1
Monash IVF Group | FY26 Results Presentation
Page 13
FY26 Domestic Operational Overview Business Units
Ultrasound Scans
Genetics Volume Embryos Screened
Day Surgery Cases
82,905
21,079
7,980
Down 0.94% vs FY25
Consistent with FY25
Up 1% vs FY25
WA Ultrasound acquisition ramping in-line with expectations
PGT-A, PGT-M and PGT-SR all increased >20%
In-house training model now yielding new sonographer pipeline to address market shortages
Clinical geneticist addition in Victoria grew volumes PGT-M
DSU cases rose 1%; case mix, consumable and utilisation optimisation underway
Strong growth in referral network is increasing volumes NIPT above PCP in H2
Improved turnaround times enhanced service delivery for both clinicians and patients
Clayton volumes transferred to Cremorne June 26 doubling utilisation FY27 majority surgical volume & revenue will be retained in-house Brisbane DSU opened July 26
Monash IVF Group | FY26 Results Presentation
Page14 14 Page
FY26 International Overview
Strategic business model reset delivers record performance across Asia FY26 International Stimulated Cycles
FY26 Patient Treatments
FY26 International Revenue
FY26 International EBITDA
FY26 EBITDA Margin
1,366
2,554
$21.2m
$4.2m
25.2%
Up 8.3% vs FY25
Up 7.1% vs FY25
Up 15% vs FY25
Up 9.6% vs FY25
Down 123 bps vs FY25
Our international business continued to build local and cross-border patient pathways, supported by strong regional demand for advanced reproductive services. Kuala Lumpur hub:
Revenue +12%, EBITDA +7%—driven by IVF cycle growth, pricing and rising PGT-A demand.
Singapore:
Revenue +9% (following a January 2026 price change) and EBITDA +82%.
Johor Bahru:
Revenue +73%, EBITDA +245%, on higher IVF volumes and strong PGT-A revenue from both local demand and cross-border referrals (Singapore and beyond); well positioned to grow further when the Singapore–Johor rail link opens January 2027.
Bali:
A successful year, achieving stronger profitability and establishing a platform for future growth.
Monash IVF Group | FY26 Results Presentation
Page 15
FY26 Financial Results
Monash IVF Group | FY26 Results Presentation
Page 16
FY26 Profit & Loss Summary Revenues proved resilient and margin primed for improvement
Underlying ($m)
FY26
FY25
% change
Group revenue
269.5
271.9
(0.9%)
•
FY26 Underlying NPAT (1)(2)(3) of $16.1m, below the June 2026 updated guidance and includes the impact of the write-off of $1.4m (after tax) prepaid assets;
•
FY26 Underlying EBITDA(1)(2) Margin of 19.8%, 460 bp decline on FY25 (H1 -3.5%, H2 -5.7%);
Underlying EBITDA(1)(2)
53.4
66.3
(19.5%)
Underlying EBITDA margin
19.8%
24.4%
(4.6%)
•
H1 market share losses, H2 stabilised in a flat Domestic ARS market
Underlying EBIT(1)(2)
28.4
43.0
(34.0%)
•
IVF price increases deferred (East Coast) despite cost increases
Underlying NPAT(1)(2)(3)
16.1
27.4
(41.2%)
•
Efficiency program underway
Reported ($m) Reported EBITDA(1)
43.5
65.4
(33.5%)
EBITDA Margin (reported)
16.1%
24.1%
(7.9%)
Depreciation & amortisation
(23.3)
(22.0)
6.0%
Reported EBIT
20.2
43.4
(53.6%)
Net finance costs
(8.8)
(7.3)
20.5%
Reported Profit before tax
11.4
36.1
(68.5%)
Income tax expense
(3.1)
(10.4)
(70.6%)
Reported NPAT(3)
8.3
25.7
(67.6%)
•
Depreciation & amortisation up $1.3m due to higher Right of Use lease asset
•
Net finance costs up $1.5m, driven by higher Capex and working capital
•
Effective tax rate is 26.9%; reflects higher International profits with lower tax rates
Non-IFRS measure Refer to page 34 for reconciliation of Reported EBITDA, EBIT and NPAT to Underlying EBITDA, EBIT and NPAT NPAT including minority interest
Monash IVF Group | FY26 Results Presentation
Page17 17 Page
FY26 Revenue Analysis 280 4.6
270
$M
(9.6)
2.7
0.7
(0.9)
260 271.9
269.5
250
240
Market share, Pricing and Industry
International
Ultrasound
DSU
•
FY26 Domestic IVF revenue decline of $9.6m driven by: • H1 Market Share (1) losses • Flat Australian ARS Sector volumes • Pricing held unchanged for East Coast, some increases elsewhere International revenue up $2.7m driven by +8% increase in Stimulated cycles, strong in-bound International visitors;
•
$0.7m growth in Ultrasound revenues driven by new launch in WA and improved pricing and mix, overall volumes mildly softer;
•
Genetics and Ancillary income up $4.6m, driven by higher PGT and storage fees.
•
FY25
MBS items 13200/1
Genetics & Other
FY26
Monash IVF Group | FY26 Results Presentation
Page18 18 Page
FY26 EBITDA(1) Analysis
EBITDA (1) decline reflects concentrated, identifiable and largely non-structural margin pressure
70
(3.6)
0.9
(7.8)
60
0.4
0.6
(0.8)
(1.6)
(9.9)
$M
50 66.3
65.4
40
55.5
53.4 43.5
30 20
FY25 Reported EBITDA(1)
Non-regular items(2)
FY25 Underlying EBITDA(1)
MVF Market Net Price Share Inflation & Other Cost Base
Industry
Sub Total
International
Day Surgery
Ultrasound
•
FY26 Domestic IVF EBITDA(1) decrease driven by: • Market share (3) position • Pricing hold on east coast in 1H26 • Increased wage rates/supplier costs over 4% Cost optimisation initiatives underway focusing on optimising labour, procurement and capital expenditure
•
International: +$0.4m EBITDA(1) with in-bound international patients driving higher volumes
•
Day Surgery: -$0.8m EBITDA(1) primarily reflects case mix margin off slightly higher volumes
•
Ultrasound: -$1.6m EBITDA(1) reflects 0.94% scan volume decline, ongoing sonographer shortages and startup WA service expansion
•
-
Underlying EBITDA and Reported EBITDA are a non-IFRS measures
-
Refer to page 34 for reconciliation of Non-regular items from Reported to Underlying
-
MBS items 13200/1
FY26 Underlying EBITDA(1)
Non-regular items(2)
FY26 Reported EBITDA(1)
Monash IVF Group | FY26 Results Presentation
Page19 19 Page
FY26 Capital Position Cashflow
FY26
FY25
% change
Net operating cash flow
36.7
12.9
185%
Net operating cash flow conversion % (4)
85.0%
84.9%
Free cash flow (1)
12.9
(4.5)
(387%)
Net Debt
FY26
FY25
Total Debt
(110.0)
(99.0)
Cash
8.8
9.4
Net Debt
(101.2)
(89.6)
Leverage(2)
1.9x
1.7x
Interest cover(2)
9.1x
11.3x
Return on equity(3)
6.4%
10.9%
Return on assets(3)
3.1%
5.6%
Free cash flow excludes financing, acquisition and investment cash flows Leverage ratio above is based on Underlying EBITDA divided by Net Debt. Interest Cover excludes the impacts of AASB 16 Leases and other items prepared for covenant purposes as defined in our banking agreement. EBITDA is not an IFRS measure. Both metrics well within banking covenants.
Net Debt Movement — FY26 ($m)
Net debt increase for Capital Expenditure • $23.8m of Capital Expenditure for Brisbane, Equipment and IT systems • One-off costs included in the operating cashflow
- Return on equity and Return on Assets is Underlying NPAT for the twelve-month period to 30 June 2026 and 30 June 2025 respectively divided by closing equity
- FY26 Operating cashflow conversion excludes the impact of non-regular items ($10.4m) and FY25 excludes NiPGT settlement payments (also non-regular)
Monash IVF Group | FY26 Results Presentation
Page 20
- Market Update and Outlook
Monash IVF Group | FY26 Results Presentation
Page21 21 Page
ARS Sector Volumes softened in FY26 Australian ARS industry stimulated cycles decreased by 0.2% Number of Australian Stimulated Cycles(1) half on half
Australian Stimulated Cycles(1) bi-annual growth vs pcp 6%
1H22
4%
2H22
1H23
2H23 5.3%
1H24 5.1%
2H24
1H25
2H25
1H26
2H26
2.9%
2% 0% -0.5%
-2%
-2.1%
-4%
-1.2%
-0.2%
-6.8%
23,467
24,721
24,606
24,312
24,268
27,431
28,229
26,483
27,821
27,227
27,184
FY21
FY22
FY23
FY24
FY25
FY26
-0.2%
-6% -8%
25,189
-6.2%
•
2H26 Australian industry STIMs -0.2%, in line with 1H26 performance, compared to pcp
•
Market fluctuation Q3 -4.4% vs Q4 +3.4% with June rebounding, however reflects economic uncertainty
•
Continued state variability in FY26 (2) •
2H
Strong growth in Western Australia, with modest growth in South Australia as well as in Queensland and Victoria — MVF’s two largest state operations
New South Wales market decreased 5.4%, which was an outlier vs. the industry where all other markets saw growth ARS Sector fundamentals remain good, with volumes expected to return to growth in FY27 •
•
1H
-
Stimulated cycles are MBS items 13200/1
-
Services Australia, Medicare item statistics (MBS items 13200/1), by state, 12 months to 30 June 2026
Monash IVF Group | FY26 Results Presentation
Page22 22 Page
Structural IVF demand remains compelling Fertility patients pause rather than defer treatment
STIM cycles vs. Unemployment Rate and Interest Rate
•
IVF demand is influenced by consumer confidence and household affordability rather than any single macroeconomic indicator
•
Higher interest rates and cost-of-living pressures have coincided with softer treatment volumes as patients defer treatment
•
Historical trends suggest demand recovers as economic conditions stabilise, rather than waiting for demonstrated uplift, with deferred patients re-entering the market
Data indicates industry softness is cyclical, not structural, supporting confidence in the long-term growth outlook as economic conditions stabilise
Monash IVF Group | FY26 Results Presentation
Page23 23 Page
Demographic tailwinds support long-term demand Infertility prevalence projected to sustain demand, according to latest analysis from The Lancet Obstetrics & Gynaecology July 2026
Four global jump-points
•
Female infertility prevalence has increased steadily over the past three decades, particularly in women aged 35–49
•
Global infertility cases in 35-49 age group are projected to increase by approximately 50% to 80 million by 2036
•
These demographic trends are expected to underpin sustained long-term demand for fertility services
•
South-East Asia is expected to experience the strongest growth, driven by delayed parenthood, greater treatment awareness, improved access and rising disposable incomes
Du, Yuanyuan, Furong Wang, Wei Zhou, et al. 2026. “Epidemiological Trends, Disparities, and Developmental Correlates of Infertility in Women of Advanced Maternal Age, 1990–2023: A Comprehensive Analysis within the GBD Framework.” The Lancet Obstetrics, Gynaecology, & Women’s Health 2 (7): e597–612.
Combining projected ABS population growth and historical prevalence growth, Australian stimulated cycles should be expected to increase more than 30% over the next 15 years, with Asian growth predicted to be 40-60%
Monash IVF Group | FY26 Results Presentation
Page24 24 Page
Regulatory reform in sector welcomed by MVF MVF is engaged with governments and regulators, and contributing to industry reform
Monash IVF welcomes the regulatory reforms announced by Health Ministers and currently the subject of a national review by ACSQHC •
Australian Commission on Safety and Quality in Health Care (ACSQHC) appointed to lead implementation of a set of National ARS Standards similar to those already in use in hospitals
•
Monash IVF has already established the governance, quality and reporting capability required to adapt to the elevated regulatory framework, enabling implementation within existing infrastructure
Monash IVF is a key contributor to the industry consultation, and will engage with governments and regulators across the implementation timeline: •
Draft Standards now available for piloting from January 2027
•
All ARS providers to be transitioned to new scheme by December 2028 with dissolution of current regulator RTAC
MVF well placed for reform: •
Transparent safety and quality for all patients
•
Highest calibre clinical quality becomes a visible differentiator, reinforcing the value of MVF with established governance frameworks, data systems and demonstrated patient outcomes
•
Greater transparency, strengthening patient confidence, supporting long-term demand for high-quality providers
•
Experience and scale means MVF is perfectly placed to assist clinicians and providers across the sector
Monash IVF Group | FY26 Results Presentation
Page 25
- Nurture 2030: A New 3Y Strategy
Monash IVF Group | FY26 Results Presentation
Page26 26 Page
The new strategy builds on foundations set in our previous plan The investments made through the Vision 2026 Strategy provided the launchpad for Nurture 2030, including: •
Strategic investment in international growth
•
Investment in integrated surgical infrastructure
•
Enterprise-wide scientific leadership structure leading to world class outcomes
•
Key doctor partnerships driving regional growth strategies
•
Delivered measurable improvement in outcomes
Monash IVF Group | FY26 Results Presentation
Page27 27 Page
Purpose
Nurturing possibility for every reproductive health journey Strategic Pillars
Clinical Excellence and Safety
Connected Patient Ecosystem
IndustryLeading Talent
Science, Research and Technology
Sustainable Growth and Performance
Enablement Layer
Progressive Leadership
Data, Digital and AI
Service Domains
Fertility Care
Diagnostics
Reproductive Health
Monash IVF Group | FY26 Results Presentation
Page 28
- FY27 Plan and Priorities
Monash IVF Group | FY26 Results Presentation
Page29 29 Page
FY27 Priorities & Trading Outlook A series of operational focal points in the context of a positive trading outlook
Reignite organic growth
Connect the patient journey
• Strengthen market share, patient demand and conversion • Focus on Victoria & NSW • Restore standard pricing policy
• Embed data, digital across the patient journey • Real-time insights to improve patient experience
Unlock our network • Leverage completed capital investments • Embed productivity, cost efficiency
Grow the reproductive journey • Deepen the clinical specialty matrix • Extend patient contact, improve outcomes and increase lifetime value
Amplify medical workforce • Value growth across doctor lifecycle, • Strengthen doctor value proposition and leadership
Lead the future of reproductive care • Progress readiness for ARS reform • Advance precision pathways, research, science and innovation
Trading Outlook MVF is positioned to convert volume growth into stronger earnings through operating leverage and strategic execution •
Structural industry demand remains compelling
•
FY27 growth expected to strengthen through the year, supported by improving market conditions and disciplined execution.
•
Market share growth through doctor attraction, practice development and enhanced patient experience.
•
Structural productivity focus on cost optimisation, asset utilisation and disciplined capital allocation expected to improve operating leverage and margins.
•
MVF is well positioned to successfully implement evolving regulatory standards through established governance capability.
•
Capital expenditure to reduce by 50% on FY25
Monash IVF Group | FY26 Results Presentation
- Q&A "It is nice to know that there’s hundreds and thousands of babies around the world related to something that I helped to create.” — Professor Carl Wood, IVF pioneer, Founder Monash IVF. Australian Story, ABC, 2001
Page 30
Monash IVF Group | FY26 Results Presentation
Appendix
Page 31
Monash IVF Group | FY26 Results Presentation
Page32 32 Page
FY26 Cashflow Cashflow ($m)
FY25
% change
Reported EBITDA(1)
FY26 43.5
65.4
(33.5%)
Movement in working capital
(4.8)
(49.6)
Income taxes paid
(2.0)
Net operating cash flow (post-tax)
36.7 (23.8)
•
Working capital year on year improved
(90.3%)
•
FY26 outflow of $4.8m driven by timing of GST and higher inventory
(2.9)
(30.9%)
•
Majority of $23.8m capital expenditure comprised:
12.9
184.4%
(14.4)
64.8%
(3.0)
(100%)
Cash flow from investing activities Free Cash flow(2) Dividends paid
(23.8) 12.9 (5.4)
(17.4) (4.5) (19.9)
36.4% (385.5%) (72.8%)
Interest on borrowings
(6.5)
(4.0)
61.7%
Lease incentives received
1.8
Payments of lease liabilities
(14.2)
(12.4)
14.4%
Net proceeds of borrowings
11.0
39.0
(71.8%)
Cash flow from financing activities
(13.3)
Net cash flow movement
(0.4)
2.7 (1.9)
(600.7%) (77.5%)
Closing cash balance
8.8
9.4
(6.2%)
Capital expenditure Payments for businesses
Non-IFRS measure Free cash flow is a non-IFRS measure used by the Group as a key indicator of cash generated from operating and investing activities and is not subject to audit or review. Calculated as Net cash flow generated from operating activities less Net cash flows used in investing activities.
o
Brisbane fertility clinic and day hospital
o
Laboratory and theatre (clinical) assets
•
FY27 capital expenditure reduction of circa 50%
•
Interest payments up $2.5m, reflecting higher borrowings and brought forward timing of interest coupon on facility extension;
•
Dividends paid - $4.7m for 1.2 cps FY26 interim dividend;
•
$11.0m of net debt drawn to fund capex and working capital.
Monash IVF Group | FY26 Results Presentation
Page33 33 Page
30 June 2026 Balance Sheet Balance Sheet ($m)
30 Jun 2026
30 Jun 2025
% Change
8.8 35.3
Net working capital Non-current borrowings Goodwill & Intangibles Right of use assets Lease liabilities Plant & Equipment Contingent consideration Other assets/(liabilities)
(11.2) (4.8) (49.8) (21.6) (109.4) 295.6 81.5 (79.1) 84.2 (3.3) 5.5
9.4 32.3 (9.7) (4.4) (47.3) (19.7) (98.5) 297.2 76.4 (71.8) 69.6 (4.5) 1.7
(6.2%) 9.4% 14.9% 9.1% 5.3% 9.7% 11.0% (0.6%) 6.7% 10.1% 21.0% (27.2%) 228.5%
Net assets
253.5
250.4
1.2%
Capital Metrics
30 Jun 2026
30 Jun 2025
+/-
Net Debt1 ($m)
$101.2
$89.6
+$11.6
Leverage Ratio (Net Debt / EBITDA2)
1.9x
1.7x
+0.2x
Interest Cover (EBITDA2/ Interest)
9.1x
11.3x
(2.2x)
Net Debt to Equity Ratio3
39.9%
35.8%
+4.1%
Return on Equity
6.4%
10.9%
(4.5%)
Return on Assets
3.1%
5.6%
(2.5%)
Cash and cash equivalents Other current assets Current lease liabilities Contingent consideration Other current liabilities
- Net Debt is cash less borrowings and excludes capitalised bank fees
- EBITDA is based on normalised EBITDA excluding AASB16 Lease impact for covenant purposes as defined in the Syndicated Debt Facility Agreement. EBITDA is a non-IFRS measure
- Net debt divided by equity at the balance date
•
Net Debt increased to $101.2m; capital projects and working capital
•
Net leverage Ratio is 1.9x
•
Debt Facility increased $20m to $130m, 3-year extension secured to support growth;
•
Other Current Assets - Inventory up to mitigate supply disruption, timing of GST recoverable
•
Plant and equipment up 21% reflecting higher Capex;
•
Final dividend of 1.3 cents per share (record date: 4 September 2026; payment date: 15 October 2026)
•
Full year dividend of 2.5 cents per share (FY25 5.1 cents per share)
Monash IVF Group | FY26 Results Presentation
Page34 34 Page
FY26 Earnings Reconciliation
Statutory earnings adjusted for non-regular items to derive Underlying Results $m
EBITDA(1)
EBIT
Non-cash Interest
FY26 NPAT
FY25 NPAT
Reported Statutory
43.5
20.2
8.3
25.7
Commissioning costs
1.6 0.2
1.1 0.1
0.4
Class Action and Acquisition costs
1.6 0.2
(2.6)
SaaS Expenses and Other Related Costs
2.4
2.4
1.7
1.1
Professional Service Costs and Additional Measures
4.5
4.5
3.2
0.9
Impairment
0.8
Restructuring
1.2
1.2
0.8
0.4
Adjusted
53.4
30.1
15.3
26.5
(1.7)
2.0
0.8
0.9
53.4
28.4
2.0
16.1
27.4
AASB 16 Lease Accounting Underlying (1)
• Commissioning costs ($1.1m) related to pre-opening occupancy and other related expenditure for new facilities including Brisbane; • Legal costs including Class Action and Acquisition costs ($0.1m); • SaaS and other related costs ($1.7m) relating to the enhanced IVF patient management information system; • Professional Service costs ($3.1m) relates to legal and ancillary costs relating to incidents. Anticipated insurance recovery of up to $2.8m in FY27 - contingent asset, not recognised; • Restructuring ($0.8m) largely due to changeover of C-Suite and other members of the leadership team. • $0.8m non-cash lease expenditure and right-of-use asset depreciation under AASB 16 lease accounting is being adjusted from Reported to Underlying due to its non-cash nature; (1)
Non-IFRS measure
Monash IVF Group | FY26 Results Presentation
Page 35
Overview of Monash IVF Group Monash IVF Group is a market leader in reproductive care Domestic IVF
International IVF
Ultrasound
Genetics & Pathology
24 clinics & 4 services centres
4 clinics
18 clinics
7 Australian States / Territories
4 international cities
19 Sonologists
1 Genetics Laboratory (SA)
4 Day hospitals (SA, NSW, QLD, VIC)
3 Day hospitals (Malaysia & Singapore)
6 Australian states
5 Endocrine Laboratories (SA, VIC, NSW, WA and QLD) 11 Andrology Laboratories (SA, NT, VIC, NSW, WA and QLD)
1100 Staff and Doctors (1)
- Employee numbers represents the full-time equivalents as at August 2026 and includes recent acquisitions
1
ASX Announcement 31 August 2026
Monash IVF Group Limited (ASX: MVF) Board succession and renewal Monash IVF Group Limited (ASX:MVF) announces the next steps in the Board renewal and succession program it initiated in 2024. These include the appointment of Ms Catherine West as Chair-elect to succeed Mr Richard Davis as Chair, the appointment of Mr Gerd Schenkel as an independent NonExecutive Director, and the retirement of long-serving directors. At the Company’s 2025 Annual General Meeting, Mr Davis outlined the renewal process and announced he would stand for re-election to continue to oversee the transition – including the appointment of a new permanent CEO and new Directors – before retiring in 2026. The program has included the appointments of Ms Cathy Aston (February 2024) and Dr Dwayne Crombie (November 2025) as independent Non-Executive Directors, and of Dr Victoria Atkinson as CEO in January 2026. Mr Davis will retire from the Board on 28 October 2026 after more than 12 years as Chair, and will be succeeded by Ms West, a Director since September 2020. Dr Richard Henshaw and Mr Neil Broekhuizen will also retire after more than 12 years’ service, Dr Henshaw on 28 October 2026 and Mr Broekhuizen on 31 August 2026. Mr Schenkel will be appointed to the Board with effect from 1 September 2026 and will stand for election at the next Annual General Meeting. Further information on Ms West’s and Mr Schenkel’s experience is set out below. Following these changes, the Board will comprise Ms West as Chair, Ms Zita Peach (a Director since October 2016), Ms Aston, Dr Crombie, Mr Schenkel and Dr Atkinson. The Board is progressing a search for one further Non-Executive Director. Mr Davis said “I am pleased that Catherine has agreed to succeed me as Chair. Her experience, knowledge of Monash IVF and strong contribution to the Board position her well to lead the Company through its next phase, and I look forward to working with her to support an orderly transition. We are also delighted to welcome Gerd to the Board. His technology, digital transformation and customer experience expertise will complement the Board’s existing skills as Monash IVF continues to invest in innovation and execute its strategy. I also want to pay tribute to Richard Henshaw and Neil Broekhuizen, valued colleagues since the Company listed, and thank them for their wise counsel and commitment over many years.” Ms West said “On behalf of the Board, I thank Richard Davis for his leadership in steering Monash IVF and thank Dr Richard Henshaw and Neil Broekhuizen for their significant contribution – each having given dedicated service to the Company since its IPO in 2014.
2
I am honoured to be appointed Chair-elect, and warmly welcome Gerd and the expertise he will bring to the Board. FY26 has been a year of significant change for Monash IVF, with encouraging momentum established in the second half. We enter FY27 as a stronger organisation, with renewed operational focus and a clear strategic direction articulated in the refreshed Nurture 2030 strategy. I am looking forward to taking on the role of Chair at this important point in the Group’s journey and to working with the Board, Victoria and the rest of the management team to build on the momentum and deliver sustainable long-term value.” Mr Schenkel said “It is a privilege to join the Board of Monash IVF at an important time for the Company. Having spent my career in technology, digital and customer-focused businesses in regulated sectors, I look forward to working with the Board and management as Monash IVF strengthens its digital capability and the experience it delivers for its patients.” Authorised by the Board of Directors.
Final Director’s Interest Notice Rule 3.19A.3
Appendix 3Z Final Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.
Name of entity Monash IVF Group Limited ABN 90 169 302 309 We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of director
Neil John Broekhuizen
Date of last notice
30 April 2021
Date that director ceased to be director
31 August 2026
Part 1 – Director’s relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Number & class of securities Nil
- See chapter 19 for defined terms. 11/3/2002
Appendix 3Z Page 1
Appendix 3Z Final Director’s Interest Notice Part 2 – Director’s relevant interests in securities of which the director is not the registered holder Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Name of holder & nature of interest
Number & class of securities
Note: Provide details of the circumstances giving rise to the relevant interest
Indirect interest in Ordinary Shares held by: 1.
132,787
- 217,213
Jasper Investments Pty Ltd as trustee for the Jasper Discretionary Family Trust CAJAL SF Pty Ltd as trustee for the CAJAL Super Fund
Part 3 – Director’s interests in contracts Detail of contract
n/a
Nature of interest
n/a
Name of registered holder (if issued securities)
n/a
No. and class of securities to which n/a interest relates
- See chapter 19 for defined terms. Appendix 3Z Page 2
11/3/2002
Monash IVF Group Limited (ASX: MVF, the "Company") advises that completion of the audit of its FY2026 financial statements is taking longer than anticipated and will not be finalised in time for release of the Company's FY2026 results on 24 August 2026. The Company will therefore be postponing the release of its FY2026 results while management works closely with the Company’s auditor to complete the remaining audit procedures. The Company expects to release its FY2026 results on 31 August 2026. The Company will keep the market informed of any further developments in accordance with its continuous disclosure obligations. Authorised by the Board of Directors.
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Announcement Summary
Entity name MONASH IVF GROUP LIMITED Date of this announcement Friday July 10, 2026 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securities to be issued/transferred
ASX +security code
Security description
MVFAA
PERFORMANCE RIGHTS
Total number of +securities to be issued/transferred
Issue date
453,988
10/07/2026
Refer to next page for full details of the announcement
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
1/6
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Part 1 - Entity and announcement details
1.1 Name of entity MONASH IVF GROUP LIMITED We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities. 1.2 Registered number type
Registration number
ABN
90169302309
1.3 ASX issuer code MVF 1.4 The announcement is New announcement 1.5 Date of this announcement 10/7/2026
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
2/6
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Part 2 - Issue details
2.1 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX 2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which: has an existing ASX security code ("existing class")
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
3/6
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B
ASX +security code and description MVFAA : PERFORMANCE RIGHTS Date the +securities the subject of this notification were issued 10/7/2026 Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes
Were any of the +securities issued to +key management personnel (KMP) or an +associate? Yes Provide details of the KMP or +associates being issued +securities. Name of KMP
Name of registered holder
Number of +securities
Rebecca Redden
Rebecca Redden
60,781
Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms Performance Rights granted under the Monash IVF Group Limited Equity Incentive Plan (EIP). The EIP was approved by shareholders at the 2017 annual general meeting. https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2995-01910978-2A1044469&v=undefined Any other information the entity wishes to provide about the +securities the subject of this notification The total number of performance rights on issue is 1,158,147, being the sum of the 929,034 previously on issue plus 453,988 issued on this App3G less 224,875 (per App 3H lodged today)
Issue details
Number of +securities 453,988
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
4/6
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Part 4 - +Securities on issue
Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise: The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing. 4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX) ASX +security code and description
Total number of +securities on issue
MVF : ORDINARY FULLY PAID
389,634,840
4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX) ASX +security code and description MVFAA : PERFORMANCE RIGHTS
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Total number of +securities on issue 1,383,022
5/6
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Part 5 - Other Listing Rule requirements
5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? Yes 5.1a Select the number of the applicable exception in Listing Rule 7.2 13
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
6/6
Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity
Monash IVF Group Limited
ABN/ARBN
Financial year ended:
90 169 302 309
30 June 2026
Our corporate governance statement 1 for the period above can be found at: 2
☐
These pages of our annual report:
☒
This URL on our website: https://monashivfgroup.com.au/investor-centre/corporategovernance/
The Corporate Governance Statement is accurate and up to date as at 21 August 2026 and has been approved by the board. The annexure includes a key to where our corporate governance disclosures can be located. 3 Date:
31 August 2026
Name of authorised officer authorising lodgement:
Rebecca Dean – Company Secretary
1 “Corporate governance statement” is defined in Listing Rule 19.12 to mean the statement referred to in Listing Rule 4.10.3 which
discloses the extent to which an entity has followed the recommendations set by the ASX Corporate Governance Council during a particular reporting period. Listing Rule 4.10.3 requires an entity that is included in the official list as an ASX Listing to include in its annual report either a corporate governance statement that meets the requirements of that rule or the URL of the page on its website where such a statement is located. The corporate governance statement must disclose the extent to which the entity has followed the recommendations set by the ASX Corporate Governance Council during the reporting period. If the entity has not followed a recommendation for any part of the reporting period, its corporate governance statement must separately identify that recommendation and the period during which it was not followed and state its reasons for not following the recommendation and what (if any) alternative governance practices it adopted in lieu of the recommendation during that period. Under Listing Rule 4.7.4, if an entity chooses to include its corporate governance statement on its website rather than in its annual report, it must lodge a copy of the corporate governance statement with ASX at the same time as it lodges its annual report w ith ASX. The corporate governance statement must be current as at the effective date specified in that statement for the purposes of Listing Rule 4.10.3. Under Listing Rule 4.7.3, an entity must also lodge with ASX a completed Appendix 4G at the same time as it lodges its annual report with ASX. The Appendix 4G serves a dual purpose. It acts as a key designed to assist readers to locate the governance disclosures made by a listed entity under Listing Rule 4.10.3 and under the ASX Corporate Governance Council’s recommendations. It also acts as a verification too l for listed entities to confirm that they have met the disclosure requirements of Listing Rule 4.10.3. The Appendix 4G is not a substitute for, and is not to be confused with, the entity's corporate governance statement. They serve different purposes and an entity must produce each of them separately. 2 Tick whichever option is correct and then complete the page number(s) of the annual report, or the URL of the web page, where
your corporate governance statement can be found. You can, if you wish, delete the option which is not applicable. 3 Throughout this form, where you are given two or more options to select, you can, if you wish, delete any option which is not
applicable and just retain the option that is applicable. If you select an option that includes “OR” at the end of the selection and you delete the other options, you can also, if you wish, delete the “OR” at the end of the selection. See notes 4 and 5 below for further instructions on how to complete this form. ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 1
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations
ANNEXURE – KEY TO CORPORATE GOVERNANCE DISCLOSURES Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINCIPLE 1 – LAY SOLID FOUNDATIONS FOR MANAGEMENT AND OVERSIGHT 1.1
1.2
1.3
1.4
A listed entity should have and disclose a board charter setting out: (a) the respective roles and responsibilities of its board and management; and (b) those matters expressly reserved to the board and those delegated to management.
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed a copy of our board charter at: https://monashivfgroup.com.au/investor-centre/corporategovernance/
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should: (a) undertake appropriate checks before appointing a director or senior executive or putting someone forward for election as a director; and (b) provide security holders with all material information in its possession relevant to a decision on whether or not to elect or re-elect a director.
☒
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should have a written agreement with each director and senior executive setting out the terms of their appointment.
☒
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
The company secretary of a listed entity should be accountable directly to the board, through the chair, on all matters to do with the proper functioning of the board.
☒
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
Tick the box in this column only if you have followed the relevant recommendation in full for the whole of the period above. Where the recommendation has a disclosure obligation attached, you must insert the location where that disclosure has been made, where indicated by the line with “insert location” underneath. If the disclosure in question has been made in your corporate governance statement, you need only insert “our corporate governance statement”. If the disclosure has been made in your annual report, you should insert the page number(s) of your annual report (eg “pages 10-12 of our annual report”). If the disclosure has been made on your website, you should insert the URL of the web page where the disclosure has been made or can be accessed (eg “www.entityname.com.au/corporate governance/charters/”). 4
5
If you have followed all of the Council’s recommendations in full for the whole of the period above, you can, if you wish, delete this column from the form and re-format it.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 2
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
1.5
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed a copy of our diversity policy at: https://monashivfgroup.com.au/investor-centre/corporategovernance/ and we have disclosed the information referred to in paragraph (c) at: Section 1.5 Diversity and Inclusion Policy of our Corporate Governance Statement
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should: (a) have and disclose a diversity policy; (b) through its board or a committee of the board set measurable objectives for achieving gender diversity in the composition of its board, senior executives and workforce generally; and (c) disclose in relation to each reporting period: (1) the measurable objectives set for that period to achieve gender diversity; (2) the entity’s progress towards achieving those objectives; and (3) either: (A) the respective proportions of men and women on the board, in senior executive positions and across the whole workforce (including how the entity has defined “senior executive” for these purposes); or (B) if the entity is a “relevant employer” under the Workplace Gender Equality Act, the entity’s most recent “Gender Equality Indicators”, as defined in and published under that Act. If the entity was in the S&P / ASX 300 Index at the commencement of the reporting period, the measurable objective for achieving gender diversity in the composition of its board should be to have not less than 30% of its directors of each gender within a specified period.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 3
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
1.6
A listed entity should: (a) have and disclose a process for periodically evaluating the performance of the board, its committees and individual directors; and (b) disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed the evaluation process referred to in paragraph (a) at: Section 1.6 Director Performance Evaluation of our Corporate Governance Statement
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should: (a) have and disclose a process for evaluating the performance of its senior executives at least once every reporting period; and (b) disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed the evaluation process referred to in paragraph (a) at: Section 1.7 Senior Executive Evaluations in our Corporate Governance Statement and whether a performance evaluation was undertaken for the reporting period in accordance with that process at: Section 1.7 Senior Executive Evaluations in our Corporate Governance Statement
☐
we are an externally managed entity and this recommendation is therefore not applicable
1.7
ASX Listing Rules Appendix 4G (current at 17/7/2020)
and whether a performance evaluation was undertaken for the reporting period in accordance with that process at: Section 1.6 Director Performance Evaluation of our Corporate Governance Statement
Page 4
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINCIPLE 2 - STRUCTURE THE BOARD TO BE EFFECTIVE AND ADD VALUE 2.1
2.2
The board of a listed entity should: (a) have a nomination committee which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a nomination committee, disclose that fact and the processes it employs to address board succession issues and to ensure that the board has the appropriate balance of skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively.
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed a copy of the charter of the committee at: https://monashivfgroup.com.au/investor-centre/corporategovernance/
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should have and disclose a board skills matrix setting out the mix of skills that the board currently has or is looking to achieve in its membership.
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed our board skills matrix at: Section 2.2 “Board Skills Matrix” in our Corporate Governance Statement
☐
we are an externally managed entity and this recommendation is therefore not applicable
ASX Listing Rules Appendix 4G (current at 17/7/2020)
and the information referred to in paragraphs (4) and (5) at:
• •
For recommendation 2.1(a)(4): Section titled 2.1 Remuneration and Nomination Committee of our Corporate Governance Statement For recommendation 2.1(a)(5): Section titled “Meetings of Directors” in our Financial Report.
•
Page 5
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
2.3
A listed entity should disclose: (a) the names of the directors considered by the board to be independent directors; (b) if a director has an interest, position, affiliation or relationship of the type described in Box 2.3 but the board is of the opinion that it does not compromise the independence of the director, the nature of the interest, position or relationship in question and an explanation of why the board is of that opinion; and (c) the length of service of each director.
☒
☐
set out in our Corporate Governance Statement
A majority of the board of a listed entity should be independent directors.
☒
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
The chair of the board of a listed entity should be an independent director and, in particular, should not be the same person as the CEO of the entity.
☒
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should have a program for inducting new directors and for periodically reviewing whether there is a need for existing directors to undertake professional development to maintain the skills and knowledge needed to perform their role as directors effectively.
☒
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
2.4
2.5
2.6
ASX Listing Rules Appendix 4G (current at 17/7/2020)
and we have disclosed the names of the directors considered by the board to be independent directors at: Section 2.3, 2.4 and 2.5 Board Members, Roles and Independence of our Corporate Governance Statement and, where applicable, the information referred to in paragraph (b) at: Section 2.3, 2.4 and 2.5 Board Members, Roles and Independence of our Corporate Governance Statement and the length of service of each director at: Section 2.3, 2.4 and 2.5 Board Members, Roles and Independence of our Corporate Governance Statement
Page 6
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINCIPLE 3 – INSTIL A CULTURE OF ACTING LAWFULLY, ETHICALLY AND RESPONSIBLY 3.1
A listed entity should articulate and disclose its values.
☒
☐
set out in our Corporate Governance Statement
☐
set out in our Corporate Governance Statement
☐
set out in our Corporate Governance Statement
☐
set out in our Corporate Governance Statement
and we have disclosed our values at: Section 3.1 Organisational values of our Corporate Governance Statement 3.2
3.3
3.4
A listed entity should: (a) have and disclose a code of conduct for its directors, senior executives and employees; and (b) ensure that the board or a committee of the board is informed of any material breaches of that code.
☒
A listed entity should: (a) have and disclose a whistleblower policy; and (b) ensure that the board or a committee of the board is informed of any material incidents reported under that policy.
☒
A listed entity should: (a) have and disclose an anti-bribery and corruption policy; and (b) ensure that the board or committee of the board is informed of any material breaches of that policy.
☒
ASX Listing Rules Appendix 4G (current at 17/7/2020)
and we have disclosed our code of conduct at: https://monashivfgroup.com.au/investor-centre/corporategovernance/
and we have disclosed our whistleblower policy at: https://monashivfgroup.com.au/investor-centre/corporategovernance/
and we have disclosed our anti-bribery and corruption policy at: https://monashivfgroup.com.au/investor-centre/corporategovernance/
Page 7
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINCIPLE 4 – SAFEGUARD THE INTEGRITY OF CORPORATE REPORTS 4.1
The board of a listed entity should: (a) have an audit committee which: (1) has at least three members, all of whom are nonexecutive directors and a majority of whom are independent directors; and (2) is chaired by an independent director, who is not the chair of the board, and disclose: (3) the charter of the committee; (4) the relevant qualifications and experience of the members of the committee; and (5) in relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have an audit committee, disclose that fact and the processes it employs that independently verify and safeguard the integrity of its corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner.
☒
4.2
The board of a listed entity should, before it approves the entity’s financial statements for a financial period, receive from its CEO and CFO a declaration that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.
4.3
A listed entity should disclose its process to verify the integrity of any periodic corporate report it releases to the market that is not audited or reviewed by an external auditor.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
☐
set out in our Corporate Governance Statement
☒
☐
set out in our Corporate Governance Statement
☒
☐
set out in our Corporate Governance Statement
and we have disclosed a copy of the charter of the committee at: https://monashivfgroup.com.au/investor-centre/corporategovernance/ and the information referred to in paragraphs (4) and (5) at: •
For recommendation 4.1(a)(4): Section titled 4.1 Audit and Risk Committee of our Corporate Governance Statement • For recommendation 4.1(a)(5): Section titled “Meetings of Directors” in our Financial Report.
Page 8
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Where a box below is ticked, 4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
A listed entity should have and disclose a written policy for complying with its continuous disclosure obligations under listing rule 3.1.
☒
☐
set out in our Corporate Governance Statement
5.2
A listed entity should ensure that its board receives copies of all material market announcements promptly after they have been made.
☒
☐
set out in our Corporate Governance Statement
5.3
A listed entity that gives a new and substantive investor or analyst presentation should release a copy of the presentation materials on the ASX Market Announcements Platform ahead of the presentation.
☒
☐
set out in our Corporate Governance Statement
A listed entity should provide information about itself and its governance to investors via its website.
☒
☐
set out in our Corporate Governance Statement
6.2
A listed entity should have an investor relations program that facilitates effective two-way communication with investors.
☒
☐
set out in our Corporate Governance Statement
6.3
A listed entity should disclose how it facilitates and encourages participation at meetings of security holders.
☒
☐
set out in our Corporate Governance Statement
A listed entity should ensure that all substantive resolutions at a meeting of security holders are decided by a poll rather than by a show of hands.
☒
☐
set out in our Corporate Governance Statement
Corporate Governance Council recommendation
PRINCIPLE 5 – MAKE TIMELY AND BALANCED DISCLOSURE 5.1
and we have disclosed our continuous disclosure compliance policy at: https://monashivfgroup.com.au/investor-centre/corporategovernance/
PRINCIPLE 6 – RESPECT THE RIGHTS OF SECURITY HOLDERS 6.1
6.4
ASX Listing Rules Appendix 4G (current at 17/7/2020)
and we have disclosed information about us and our governance on our website at: https://monashivfgroup.com.au/investor-centre/corporategovernance/
and we have disclosed how we facilitate and encourage participation at meetings of security holders at: Section 6.3 and 6.4 Attendance at Company meetings of our Corporate Governance Statement
Page 9
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
6.5
☒
☐
set out in our Corporate Governance Statement
The board of a listed entity should: (a) have a committee or committees to oversee risk, each of which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a risk committee or committees that satisfy (a) above, disclose that fact and the processes it employs for overseeing the entity’s risk management framework.
☒
☐
set out in our Corporate Governance Statement
The board or a committee of the board should: (a) review the entity’s risk management framework at least annually to satisfy itself that it continues to be sound and that the entity is operating with due regard to the risk appetite set by the board; and (b) disclose, in relation to each reporting period, whether such a review has taken place.
☒
☐
set out in our Corporate Governance Statement
A listed entity should give security holders the option to receive communications from, and send communications to, the entity and its security registry electronically.
PRINCIPLE 7 – RECOGNISE AND MANAGE RISK 7.1
7.2
ASX Listing Rules Appendix 4G (current at 17/7/2020)
https://monashivfgroup.com.au/investor-centre/corporategovernance/ and the information referred to in paragraphs (4) and (5) at: •
For recommendation 7.1(a)(4): Section titled 4.1 Audit and Risk Committee of our Corporate Governance Statement • For recommendation 7.1(a)(5): Section titled “Meetings of Directors” in our Financial Report.
and we have disclosed whether a review of the entity’s risk management framework was undertaken during the reporting period at: Section 7.2 Risk Management of our Corporate Governance Statement
Page 10
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
7.3
A listed entity should disclose: (a) if it has an internal audit function, how the function is structured and what role it performs; or (b) if it does not have an internal audit function, that fact and the processes it employs for evaluating and continually improving the effectiveness of its governance, risk management and internal control processes.
☒
☐
set out in our Corporate Governance Statement
A listed entity should disclose whether it has any material exposure to environmental or social risks and, if it does, how it manages or intends to manage those risks.
☒
☐
set out in our Corporate Governance Statement
7.4
ASX Listing Rules Appendix 4G (current at 17/7/2020)
and we have disclosed the fact that we do not have an internal audit function and the processes we employ for evaluating and continually improving the effectiveness of our risk management and internal control processes at: Section 7.3 Internal Audit of our Corporate Governance Statement
and we have disclosed whether we have any material exposure to environmental or social risks at: Section 7.4 Risk exposure of our Corporate Governance Statement and, if we do, how we manage or intend to manage those risks at: Section 7.4 Risk exposure of our Corporate Governance Statement
Page 11
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Where a box below is ticked, 4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
The board of a listed entity should: (a) have a remuneration committee which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a remuneration committee, disclose that fact and the processes it employs for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive.
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed a copy of the charter of the committee at: https://monashivfgroup.com.au/investor-centre/corporategovernance/ and the information referred to in paragraphs (4) and (5) at:
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives.
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed separately our remuneration policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives at: Section 8.2 Remuneration of Executive and Non-Executive Directors of our Corporate Governance Statement
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity which has an equity-based remuneration scheme should: (a) have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme; and (b) disclose that policy or a summary of it.
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed our policy on this issue or a summary of it at: Section 8.3 Equity-Based Remuneration of our Corporate Governance Statement
☐
we do not have an equity-based remuneration scheme and this recommendation is therefore not applicable OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
Corporate Governance Council recommendation
PRINCIPLE 8 – REMUNERATE FAIRLY AND RESPONSIBLY 8.1
8.2
8.3
ASX Listing Rules Appendix 4G (current at 17/7/2020)
• •
For recommendation 8.1(a)(4): Section titled 8.1 Remuneration and Nomination Committee of our Corporate Governance Statement For recommendation 8.1(a)(5): Section titled “Meetings of Directors” in our Financial Report.
•
Page 12
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
ADDITIONAL RECOMMENDATIONS THAT APPLY ONLY IN CERTAIN CASES 9.1
9.2
9.3
A listed entity with a director who does not speak the language in which board or security holder meetings are held or key corporate documents are written should disclose the processes it has in place to ensure the director understands and can contribute to the discussions at those meetings and understands and can discharge their obligations in relation to those documents.
☐
☐
set out in our Corporate Governance Statement OR
and we have disclosed information about the processes in place at: ……………………………………………………………………… [insert location]
☒
we do not have a director in this position and this recommendation is therefore not applicable OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity established outside Australia should ensure that meetings of security holders are held at a reasonable place and time.
☐
☐
set out in our Corporate Governance Statement OR
☒
we are established in Australia and this recommendation is therefore not applicable OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
☐
set out in our Corporate Governance Statement OR
☒
we are established in Australia and not an externally managed listed entity and this recommendation is therefore not applicable
☐
we are an externally managed entity that does not hold an AGM and this recommendation is therefore not applicable
☐
set out in our Corporate Governance Statement
A listed entity established outside Australia, and an externally managed listed entity that has an AGM, should ensure that its external auditor attends its AGM and is available to answer questions from security holders relevant to the audit.
☐
ADDITIONAL DISCLOSURES APPLICABLE TO EXTERNALLY MANAGED LISTED ENTITIES
Alternative to Recommendation 1.1 for externally managed listed entities: The responsible entity of an externally managed listed entity should disclose: (a) the arrangements between the responsible entity and the listed entity for managing the affairs of the listed entity; and (b) the role and responsibility of the board of the responsible entity for overseeing those arrangements.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
☐ and we have disclosed the information referred to in paragraphs (a) and (b) at: …………………………………………………………………………….. [insert location]
Page 13
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
☐
☐
Alternative to Recommendations 8.1, 8.2 and 8.3 for externally managed listed entities: An externally managed listed entity should clearly disclose the terms governing the remuneration of the manager.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
set out in our Corporate Governance Statement
and we have disclosed the terms governing our remuneration as manager of the entity at: …………………………………………………………………………….. [insert location]
Page 14
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Monash IVF Group Limited
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.